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Abstract 
Proteasome inhibitors are a class of drugs that have been largely successful in 
the treatment of cancer patients, particularly those with the plasma cell malignancy, 
multiple myeloma.  The most successful of these drugs, bortezomib (Bz), has paved the 
way for the development of next-generation proteasome inhibitors.  Although Bz has 
significantly contributed to improved outcomes in myeloma patients, acquired resistance 
to Bz is imminent.  Furthermore, a portion of patients never initially respond to the drug.  
Therefore, the goal of these studies was to further characterize Bz resistance with the 
aim to better predict secondary therapies that may be used successfully with Bz to 
recapture drug sensitivity. 
In the first study, we describe the creation of an in vitro malignant mouse plasma 
cell system from which we create isogenic pairs of Bz-sensitive and -resistant cell lines.  
We further characterize the transcriptional responses of these cell line pairs to identify 
both conserved and unique expression signatures.  Using the expression signatures that 
are unique to each pair of cell lines, we identify secondary therapies that may be useful 
for treatment of the Bz-refractory cell line using an in silico database called Connectivity 
Map (CMAP).  This analysis predicted a unique response to histone deacetylase 
inhibitors, a class of drugs that are currently being tested for efficacy in myeloma, in only 
one mouse cell line pair.  Indeed, we find that the predicted Bz-resistant cell line has 
increased sensitivity to this class of drugs (including the drug panobinostat).  When 
these cells were transferred back into syngeneic recipient mice, panobinostat treatment 
could successfully extend the life of Bz-resistant animals suggesting that the Bz-resistant 
phenotype may select also for increased sensitivity to other drugs that may be identified 
through in silico approaches.  
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In the second study, we follow up these observations by investigating other 
CMAP prediction patterns, such as those that are conserved across all cell line pairs.  A 
second prediction of one class of these CMAP-predicted drugs using high-throughput 
drug screening of the cell lines revealed that a combination of these approaches may be 
highly successful for accurate prediction of secondary therapies.  Based on these 
predictions, we further investigate the efficacy of topoisomerase inhibitors in combination 
with Bz for the treatment of Bz-resistant cell lines. 
In the third study, we provide further immunophenotypic characterization of the 
Bz-sensitive and -resistant mouse cell lines revealing not only cell surface markers that 
are associated with “acquired” and “innate” Bz resistance but perhaps a mechanism of 
resistance.  Although Bz-sensitive mouse cells display a classic myeloma phenotype, 
homing to the bone marrow in vivo and expressing classic plasma cell markers, Bz-
resistant mouse cells present as extramedullary disease and express a more B cell-like 
immunophenotype.  We identify that differences in migration may be linked to the 
differential expression of the bone marrow homing protein, CXCR4.  Lower expression of 
this gene in a Bz human clinical trial was also associated with inferior survival.  
Immunophenotypic characterization of these cell populations further revealed that forced 
differentiation of the Bz-resistant population could restore Bz-sensitivity. 
The final study investigates the acquisition of Bz-resistance in a B cell 
malignancy, Burkitt lymphoma, that is currently undergoing Bz clinical trials.  In this 
particular malignancy, a DNA mutator, AID, is known to be expressed that may 
contribute to other types of drug resistance.  Here, we identify that this is unlikely a 
mechanism for developing resistance to Bz.  Furthermore, we provide evidence that AID 
activity is reduced in Bz-resistant clones and, in fact, that high AID expression may be 
selectively eliminated during Bz selection.  
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CHAPTER 1 
INTRODUCTION 
Normal lymphocyte development is a tightly regulated process that is necessary 
for the creation and maintenance of a healthy immune system.  A class of white blood 
cells, the lymphocyte, is classified as one of three main cell types: natural killer cells 
(NK) cells, thymus (T) cells or bursa-derived (B) cells.  While all three cell types are 
essential for a healthy immune system and the subsequent clearing of antigen infections 
from the body, only B cells interact directly with antigen targets through a B cell receptor 
(BCR) complex that stimulates the production of antigen-specific antibodies (1).  These 
functions require incredible antigen specificity; however, creating this diversity comes at 
the price of compromised genomic integrity over the course of B cell development that 
may contribute to neoplastic transformation (2). 
B cell development 
All lymphocytes originate from a small, self-renewing, multi-potent stem cell 
progenitor population called hematopoietic stem cells (HSCs) which, in human adults, 
reside in bone marrow compartments that, after adolescence, are limited to the femurs, 
pelvis, sternum and other long bones (3).  HSCs are characterized as CD34+CD59+ 
CD90+CD38loCD117+ but most importantly lack lineage-specific markers (4).  HSCs 
perform 2 main functions: 1) maintaining the stem cell pool and 2) creating large 
amounts of daughter cell progeny that can differentiate into multiple lineages.  The fate 
of a HSC daughter cell depends on its lineage bias (toward lymphoid or myeloid cells).  
The common lymphoid progenitor (a.k.a. pre-pro B cells), along with expressing HSC 
markers also express c-kit, IL-7Rα, CD45R/B220, CD11b/Mac-1, GR1, Ter119, and Flt3 
but specifically lack CD19 whose expression is restricted to later B cell stages (5-7).  
Following B lineage commitment, these cells progress through a linear differentiation 
process to define and perfect their antigen specificity in order to become valuable 
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Figure 1. Stages of B cell differentiation. Linear differentiation of B cells from 
hematopoietic stem cells (HSCs) through plasma cells including cell-surface markers at 
each stage and organ localization.  Highlighted in blue are stages at which malignant 
transformations are predicted to occur.  CLP = common lymphoid progenitor; MALT = 
mucosal-associated lymphoid tissues; SLPC = short-lived plasma cell; GC = germinal 
center; ALL= acute lymphoblastic leukemia; CLL = chronic lymphocytic leukemia; MCL = 
mantle cell lymphoma; MZL = mantle zone lymphoma; FL = follicular lymphoma; BL = 
Burkitt lymphoma; NHL = non-Hodgkin lymphoma; DLBCL = diffuse large B cell 
lymphoma; SHM = somatic hypermutation; CSR = class switch recombination; LPL = 
lymphoplasmacytic lymphoma (Waldenström macroglobulinemia); MGUS = monoclonal 
gammopathy of undetermined significance; MM = multiple myeloma. 
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effectors of the immune system as mixed B, T, and NK cells only (8). 
Creating the B-cell receptor (BCR) complex 
Still residing within the bone marrow due to the expression of CD19, CD45R and 
CD43 on the developing B cell (9), pro B cells begin the first step toward antigen 
specificity by rearranging the “variable” (V), “diversity” (D), and “joining” (J) regions of the 
heavy chain locus.  Beginning at one of the two immunoglobulin heavy chain (IgH) loci, 
lymphocyte-specific recombination activating genes (RAG) 1 and 2 proteins recognize 
and stimulate recombination at recombination signal sequences (RSS) which flank the 
V, D, and J  gene segments (10). One DH and one JH segment are combined through 
excision of the excess DNA between these two regions and repair by non-homologous 
end-joining machinery (11).  This can occur with or without full commitment to B-cell 
lineage.  Late pro B cell stage follows shortly after where the newly-created (D)J 
segment is recombined with one VH segment (12).  However, this final step can only 
occur in committed B cells (10, 13) and is marked by Pax5 expression (5) which is 
thought to contribute to successful V to (D)J recombination at the level of histone 
modification (14).   
Successful V(D)J arrangement on one allele results in the expression of μ 
polypeptide which is important for forward B cell development.  Unsuccessful V(D)J 
arrangement can result in a second attempt by the cell for a successful rearrangement at 
the IgH locus on the other chromosome homolog (15).  A successful V(D)J 
recombination transitions the developing B cell to the large pre-B cell stage.  At this time, 
heavy chain μ expression is primarily localized within the cytoplasm and, perhaps to a 
small degree, on the cell surface accompanied by a surrogate light chain (λ5 or VpreB) 
as a pre-BCR (pBCR) complex (10, 16).  This signals the cell to halt further VH (D)J 
recombination through a process called allelic exclusion, and to proliferate.  This 
ensures that only one μ heavy chain is expressed per B cell resulting in single antigen 
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specificity; this regulatory event likely involves chromatin remodeling (17) to render the 
second IgH locus inaccessible to further recombination by RAG proteins (1) which are 
themselves downregulated at the level of transcription following successful 
recombination (18).   
With a successful μ heavy chain in production, the cell moves to the next stage of 
development, the small pre-B cell stage.  At this stage, the developing BCR gains further 
antigen specificity by recombining either the κ or the λ light chain (LC) locus.  Light chain 
rearrangement occurs at either the κ or the λ locus through a recombination process 
similar to heavy chain rearrangement.  The recombination machinery can move to the 
second locus if there is a failure to successfully recombine at the first.  The successful 
recombination of one LC locus results in the expression of IgM on the cell surface and is 
a milestone of development indicating that the cell has reached the immature B cell 
stage.  Together with the accessory proteins Igα and Igβ, this is termed the BCR 
complex.  Immature B cells then undergo a selection process to eliminate cells with self-
antigen specificity or that are unable to survive independent of bone marrow support 
(19).  Cells that fail these tests may re-activate RAG-1/2 for BCR editing where 
rearrangement of a second, un-recombined locus may create a successful BCR that can 
be expressed and allow the cell to survive selection (19, 20).   
V(D)J recombination is an imperfect process and can sometimes lead to aberrant 
expression of oncogenes and transformation when translocations relocate these genes 
to the heavy or light chain loci placing them under the control of immunoglobulin 
regulatory elements.  For example, two translocations t(11;14) linking cyclin D1 and IGH 
in mantle cell lymphoma (MCL) and t(14:18) linking BCL2 and IGH in follicular lymphoma 
(FL) have recombination structures that are consistent with RAG recombination and are 
observed prior to the activated B cell stage (21-23). 
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A mature immune reaction: an Achilles’ heel for transformation?  
As immature B cells lose CD43 expression and leave the bone marrow, they 
transition to mature (naïve) B cells surviving in the periphery while expressing both IgM 
and IgD on their cell surfaces.  Some mature B cells localize to mucosal-associated 
lymphoid tissues (MALT) where they commit to expression of IgA.  However, many 
mature B cells will migrate to follicles in the spleen or lymph nodes and enter circulation 
of the peripheral tissues as follicular B cells.  Furthermore, some mature B cells will 
remain within splenic follicles settling in the marginal zones found at the border of the 
white pulp of the spleen becoming resting, marginal zone B cells.  Marginal zone B cells 
do not re-enter circulation but instead may be involved in quick immune responses by 
becoming short-lived plasma cells as described below (1).   
T cell-independent activation of marginal zone and circulating follicular B cells 
following exposure to an antigen, can stimulate these cells to proliferate and differentiate 
into short-lived plasma cells (SLPCs) (24).  SLPCs are part of the early immune 
response that secrete mostly low affinity IgM and are short-lived (1).  SLPCs are likely 
formed in the marginal zone and lack expression of BCL-6 but do express the PC 
“master regulator”, BLIMP-1(1, 25).  T-cell dependent antigen-activation can also trigger 
a more robust and long-term immune response within follicular B cells.  This interaction 
causes the B cell to proliferate and undergo further antigen specification through a 
germinal center (GC) reaction (24).  Although the GC reaction is necessary for the long-
term immune response, the processes that occur at the GC make cells especially 
vulnerable to malignant transformation as discussed in detail below.   
The germinal center and beyond 
Follicular B cells that have been activated for a GC reaction migrate to lymph 
node follicles where they form large germinal centers of proliferation and BCR 
diversification (15).  At this stage, cells upregulate the expression of BCL-6 and STAT3 
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which act to repress the plasma cell markers, BLIMP1 and IRF4, delaying terminal 
differentiation (1, 26).  A large burst of proliferation caused by the upregulation of cell 
cycle genes but not cell growth genes (27) decreases cell doubling time to seven hours 
(28).  This is accompanied by the expression of the DNA-damaging enzyme activation-
induced cytidine deaminase (AID) which creates single-base point mutations within the V 
region of the heavy chain defining a process called somatic hypermutation (SHM).  This 
process results in a large, diverse pool of BCR complexes which are further selected by 
a process call affinity maturation for those cells with the greatest specificity for the 
antigen.  Following specification, AID also contributes to a process of isotype switching 
from IgM to IgG or IgA termed class-switch recombination (CSR) (16).  Those cells that 
survive selection are primarily destined to become highly antigen-specific long-lived PCs 
that produce and secrete large amounts of switched isotype Abs that will contribute to 
clearing the antigen infection (29).   
A minor population of cells that survive the germinal center reaction will become 
long-lived memory B cells which can function to quickly clear the body in cases of 
repeated antigen exposure (24, 30).  Importantly, normal memory B cells lack large-
scale Ig secretory capabilities.  Memory cells are thought to exist as two subtypes: 
B220+ cells which are highly proliferative and B220- pre-plasma memory B cells which 
are less proliferative but may serve as a transitional cell type that can quickly become a 
mature plasma cell (PC) following a second infection (31); however, the proposed 
transition from a proliferative GC B cells to a B220+ memory to a B220- memory B cell to 
a secreting, non-proliferative, fully differentiated PC is still not well understood.   
 Those cells that are destined for terminal PC differentiation are thought to exit the 
GC reaction in an intermediate or plasmablastic cell stage that may intersect with the 
memory cell phenotype (31).  At this stage, cells are still rapidly dividing due to the 
lingering GC transcriptional program, but increasing expression of PC genes begins to 
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increase the cell size and expand the antibody secretion machinery (32).  A full transition 
to the PC transcriptional program results in terminally differentiated, non-dividing cells 
that make and secrete antigen-specific antibodies and migrate back to the BM 
compartment where the secretion of growth factors and stimulatory cytokines like 
interleukin 6 (IL-6) from the stromal microenvironment act to sustain these properties for 
months to years (33-35). 
 The transition from a GC B cell to a PC is a process that is largely regulated by a 
small number of transcription factors that are often used to delineate these distinct 
stages of B cell development (Figure 2).  The proliferative capacity required of GC B 
cells is primarily driven by the expression of BCL-6 and PAX-5 at this stage.  Part of their 
role in driving cell cycle progression is through the repression of genes like XBP-1 and 
BLIMP-1 that are necessary for terminal differentiation.  As cells leave the GC reaction 
becoming plasmablasts, there is an increase in the expression of IRF4 and NF-κB 
which, besides increasing the Ig secretory capabilities of these intermediate cells, also 
positively regulate BLIMP-1 expression (32, 36).  BLIMP-1, termed the “master 
regulator” of PC differentiation, is the transcription factor that is ultimately responsible for 
executing the terminal differentiation program during normal PC development. 
BLIMP-1 is sufficient for induction of plasmacytic differentiation (37) acting 
through multiple processes.  First, by the direct repression of PAX-5 transcription, CSR 
is halted as is BCR signaling and the expression of the B cell transcriptional program 
(38).  Secondly, by repressing c-MYC, cell proliferation is arrested (24, 39-42).  Thirdly, 
the expression of BLIMP-1 allows developing PCs to leave the lymph nodes and home 
back to the bone marrow through the repression of follicular homing signals (43).  The 
culmination of these events allows the developing PCs to switch from membrane-bound 
to secreted Ig which is required for the sustained immune response (41). 
The inhibition of PAX-5 by BLIMP-1 is a particularly important regulatory step in 
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Figure 2. Transcription factor regulation network controlling the transition from 
GC B cells to PCs.  A schematic of the key transcription factors known to regulate the 
transition from a proliferating germinal center (GC) B cell to an intermediate/ 
plasmablastic cell stage where antibody secretion increases through to the terminally 
differentiated plasma cell (PC) stage.
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PC development because it allows X box binding protein-1 (XBP-1) to be expressed 
which is required for PC formation and maintenance (38, 44, 45).  Due to the high 
antibody load at the PC stage, restructuring of the cell’s energy usage and secretory 
ability must occur, which in many ways is similar to an unfolded protein response (UPR) 
(46).  XBP-1 is a gene involved in the mammalian UPR (46) and is, therefore, involved in 
later stages of PC differentiation with BLIMP-1.  However, to what extent XBP-1 is 
involved in cellular remodeling during terminal differentiation is not fully understood (1, 
47, 48).  Ultimately, the expression of BLIMP-1 and XBP1 and the repression of BCL-6 
and PAX-5 are required for normal PC maintenance (49, 50). 
The danger zone   
The highly-active DNA damage machinery present at the GC reaction, as well as 
the complexity involved in the transcriptional shift from GC B cells to PCs is thought to 
act as a promoter of malignant transformation.  In many cases, genomic evidence of 
V(D)J recombination and the GC reaction (SHM or CSR) serve as markers for the 
staging of B cell malignancies such as FL, Burkitt lymphoma (BL), diffuse large B-cell 
lymphomas (DLBCL), Waldenström’s macroglobulinemia (LPL), monoclonal 
gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and MCL.  
Gene expression profiling and, in some cases, presence of ongoing SHM has showing 
that FL, BL, and some DLBCLs are likely derived from GC B cells (51-53) whereas LPL, 
MGUS and MM are all thought to be derived from post-GC cells as variability at the Ig 
locus remains constant throughout the course of the disease (54-56).  MCL, while having 
undergone V(D)J recombination, lacks evidence of SHM and CSR placing its cell of 
origin prior to the GC reaction (57). What differs between these malignant B cells and 
their normal cells of origin is their ability to 1) proliferate, 2) evade programmed cell 
death, and 3) avoid terminal differentiation, which suggests that the malignant stage of 
differentiation is not fixed or linear as in a normal B cell.  
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In many cases, characteristics of the cell of origin may contribute to aberrations 
that hallmark cancer diagnosis and progression such as upregulation of oncogenes and 
downregulation of tumor suppressor genes.  For example, the presence of t(8;14/2/22) 
lesions in endemic BL results in translocations between C-MYC and the IGH, κ LC, or λ 
LC loci, respectively, which may be attributed to off-target activity of the SHM machinery 
(58-63).  CSR, which also targets the IGH locus, is thought to likely be responsible for 
most of the translocations involving this locus in MM and sporadic BL (64, 65).  In 
addition, key players in the GC to PC transition are often hijacked for their oncogenic 
properties.  This has been well-illustrated through events that have been identified in 
lymphoma.  C-MYC often expressed in BL, is an oncogenes that promotes cell growth 
and clonal expansion (66) as does NF-κB which is activated in DLBCL, marginal zone 
lymphoma (MZL), and Hodgkins lymphoma (HL).  In addition, activation of anti-apoptotic 
genes like BCL2 in FL and DLBCL allow cells to escape death.  Finally, translocations 
that result in BCL-6 in non-Hodgkins lymphoma (NHL) and PAX-5 in LPL allow 
proliferation to continue by inhibiting plasmacytic differentiation (2). 
Multiple myeloma: a history at the bedside 
Of these B cell-derived malignancies, perhaps none is more devastating than 
MM which is the second most common hematologic malignancy in the United States, 
accounting for approximately 20% of deaths from blood and bone marrow cancer each 
year (67).  The earliest reports of MM date as far back as the 1840’s and were 
characterized by the pathological detection of large, oval cells with prominent nucleoli in 
the bone marrow of patients suffering from “soft bones” (68).  These observations were 
followed closely by the description of abnormal urinary proteins in these same patients 
termed Bence Jones proteins, named for the physician who discovered them (69).  It 
was not until 1900 that these characteristics were found to embody the malignancy now 
termed “multiple myeloma” (70).  The further characterization of these Bence Jones 
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proteins paved the way to our current understanding of the role that abnormal Ig 
secretion plays in the pathophysiology of the disease (71) and led to the development of 
detection methods for identifying monoclonal antibodies (paraproteins) in the serum of 
patients.  Using protein electrophoresis, increased paraprotein load could now be 
identified through the detection of a “church-spire” that we today term the “M-spike” (72).  
From this work, pioneers in the field were able to distinguish polyclonal from monoclonal 
disease leading to the discovery of MGUS, LPL, and amyloid light-chain (AL)-
amyloidosis (73). 
 Currently, MM is characterized in the clinic by clonal PC expansion in the bone 
marrow (BM) with excessive serum paraproteins/Ig.  The disease can be further 
characterized by the presence of osteolytic bone disease, hypercalcemia, 
immunodeficiency, anemia, renal failure, and peripheral neuropathy (74).  A combination 
of increased osteoclast activity and decreased osteoblast activity causes the bone 
resorption seen in up to 60% of MM patients (75-77).  This bone resportion contributes 
greatly to the hypercalcemia seen in patients as much of the calcium from the bones is 
released into the extracellular fluid (78).  The increased serum Ig levels contribute 
directly to the renal impairment observed in these patients as the light chain can bind 
Tamm-Horsfall protein within the distal tubule of the kidneys leading to obstructions (79).   
 In many ways MM is considered a spectrum disorder preceded by a pre-
condition call MGUS (80).  MGUS is thought to be present in 1% of adults over the age 
of 25 years and likely progresses to MM at a rate of 0.5-3% per year (81, 82).  MGUS is 
characterized by low disease burden and an absence of organ involvement which 
means that many patients likely go undiagnosed until progression to MM occurs (83).  
Progression to the earliest stage of MM, smoldering MM (SMM), is accompanied by 
increased serum paraprotein and/or increased clonal PC in the bone marrow but this is 
not accompanied by organ dysfunction (84).  The rate of progression from SMM to 
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intramedullary MM is 10% in the first 5 years following diagnosis (85); however, the 
majority of patients progress in 2-3 years (86).  Diagnosis of intramedullary MM is 
followed by extramedullary disease and finally plasma cell leukemia at end stages.   
Newer technologies have allowed clinicians to analyze bone marrow aspirates 
from MM patients at different stages of disease to study PC morphology and clonality 
and to FISH for common MM mutations and translocations (87, 88).  Gene expression 
profiling is sometimes performed for ongoing clinical studies to further identify genetic 
variant within patient samples (89).  Because MM staging relies heavily on paraprotein 
production and organ involvement, the extent of bone disease is often monitored by 
computed tomography (CT), magnetic resonance imaging (MRI), fluorodeoxyglucose 
positron emission tomography (FDG)-PET or dual-energy X-ray absorptiometry (90, 91).  
Depending on the institution, a combination of these data may be used to predict patient 
outcomes and select chemotherapeutic agents.  
Classification of MM by genetic abnormalities      
 MM patients are also often also classified based on the genetic lesions present at 
diagnosis which are detected in as many as 90% of patients (92).  A combinations of 
ploidy status and the translocations present at diagnosis can be used to classify disease 
and predict outcome (93).  These lesions are generally divided into two group, 
hyperdiploids and non-hyperdiploids.  Hyperdiploids, which include trisomies, generally 
affect the odd-numbered chromosomes 3, 5, 7, 9, 11, 15, 19, and 21 whereas the non-
hyperdiploids include those karyotypes that are hypodiploid, near-diploid, pseudodiploid, 
or near-tetraploid (e.g. fewer than 48 or more than 74 chromosomes) (94-96).  Ploidy 
status is thought to be fixed at transformation and does not generally change throughout 
the course of the disease (97).  Hyperdiploidy is considered a better prognosis than non-
hyperdiploidy (89, 98); however, a subset of patients within the hyperdiploid population 
with 1q gains and/or losses of chromosome 13 have been shown to have a worse 
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prognosis than even non-hyperdiploid patients (99).  Using gene expression profiling, 
Shaughnessy et al. identified a 70 gene signature that could predict poor prognosis is 
MM patients.  Interestingly, 30% of the genes identified by this approach were located on 
chromosome 1 either downregulated on 1p or upregulated on 1q further validating the 
importance of chromosomal changes on chromosome 1 in MM patient outcomes (100).   
Several decades of work has allowed researchers and physicians to classify 
common genetic lesions into those that are likely involved in primary disease or 
progression.  Analysis of common translocation events in both MGUS and MM have 
identified that recombination between Ig elements (65, 101) and genes such as cyclin 
D1 (102), cyclin D3 (103), MMSET/FGFR3 (104, 105), and MAF (106, 107) are likely 
involved in early pathogenesis and perhaps the transition from MGUS to MM.  Cyclin D1 
has particularly been implicated in early stages of the disease as it is found to be highly 
expressed at the level of gene expression in both hyper and non-hyperdiploid groups 
(108).  Although these primary lesions appear to be mutually exclusive, 5% of MGUS 
and 25% of advances MM cases possess two translocations (109).  Secondary lesions 
appear to target oncogenes activation (RAS, C-MYC) and tumor suppressor silencing 
(i.e. phosphatase and tensin homolog (PTEN), p16INK4a, and TP53) resulting in 
advanced disease (110) .  For reasons unknown, translocations are more common in 
non-hyperdiploid patients (101) with the except of chromosome 13 monosomy, 
chromosome 17p loss (including the TP53 locus), chromosome 1p loss,  and 1q gains 
which have all been associated with poor prognostic outcome (89, 96, 99, 111, 112) 
(Table 1).   
Additional genetic events likely contribute to the transformation of post-GC 
MGUS cells into MM.  For example, the Wnt pathway may be targeted during 
transformation (113, 114) as evidenced by the aberrant expression of frizzled-related 
protein (FRZB) (115) and Dickkopf-related protein 1 (DKK1) (an inhibitor of Wnt/β- 
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Table 1. Common translocations in MM associated with outcome. 
Gene 1 Gene 2 Frequency Prognosisa 
IGH (14q32) CCND1 (11q13) 15-20%b Best 
IGH (14q32) CCND3 (6p21) 5%c Standard 
IGH (14q32) MMSET/FGFR3 (4p16.3) 15%d Poor 
IGH (14q32) MAF (16q23) 5-10%e Poor 
IGH (14q32) MAFB (20q11) 5%f Poor 
 
aAs reported by Laubach, et al. (112) and Fonseca, et al. (92). 
bAs reported by Gabrea, et al. (102). 
cAs reported by Shaughnessy, et al. (103). 
dAs reported by Chesi, et al. (104). 
eAs reported by Chesi, et al. (106). 
fAs reported by Hurt, et al. (107). 
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catenin) in MM cells which may contribute to the destructive nature of MM cells toward 
neighboring bone (116).  Epigenetic and microRNA modifiers may also contribute to 
transformation (117-120).  Mutations in tumor suppressors like TP53, PTEN, the cyclin-
dependent kinase inhibitors CDKN2A and CDKN2C (110), tumor necrosis factor (TNF), 
receptor-associated factor 3 (TRAF3), and cylindromatosis (CYLD) (121) and the RAS 
oncogenes family (110, 122) may also be targeted in MM cells.  The aberrant expression 
of normal B cell transcription factors like XBP1 (45, 123), MYC (110, 124, 125) and IRF4 
(126, 127) also likely play a role in MM pathogenesis.  However, as illustrated here, MM 
disease is largely heterogeneous, and further characterization of these genes may 
reveal new drug targets for some but perhaps not all patients. 
Therapy: classical meets next-generation 
The standard of care for MM patients since the 1960’s has been and continues to 
include alkylating agents  and corticosteroids in cocktail which has been shown to 
reduce disease burden but not cure patients (128-130).  Over the years, this cocktail 
regimen has come to include additional treatment options such as newer drugs (131) 
and autologous (autoSCT) (132) or allogeneic stem cell transplantation (alloSCT) from a 
close relative (i.e. a sibling) (133, 134).  Patients who are eligible for either autoSCT or 
alloSCT undergo aggressive chemotherapy with vincristine, doxorubicin, and 
dexamethasone (135) prior to transplant and followed by high-dose treatment with stem 
cell support.   
Patients who are ineligible for SCT due to age or comorbidities often undergo 
chemotherapy to reduce the tumor burden and preserve or improve organ health.  This 
is followed by a treatment-free period until relapse occurs which is often characterized 
as a spike in serum and/or urine M-protein levels.  A new cocktail treatment regimen will 
ensue until the disease can again be controlled.  However, most patients acquire 
reduced sensitivity to drugs over time meaning that the time between treatment-free 
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periods is reduced over the course of the disease until continuous treatment is required 
at end stages of the disease (112).   
The greatest advances in treating MM have been made over the last two 
decades with the discovery of next-generation drugs (IMiDSs and proteasome inhibitors) 
that, in combination with classical agents (corticosteroids, alkylating agents, 
anthracyclines, mitotic inhibitors), have drastically improved the outcomes for patients 
(136).  One such drug, the IMiD thalidomide, has made a valiant return in MM after being 
abandoned for its teratogenic effects in the early 1960’s.  Thalidomide, as well as its 
derivatives lenalidomide and pomalidomide, negatively impacts MM cell growth by 
limiting growth cytokine and blood vessel production in the bone marrow and by 
promoting MM cell death by inhibiting E3 ubiquitin ligase complexes (137, 138) (Figure 
3).  IMiDs have been shown to be especially effective in combination therapies for both 
newly-diagnosed and relapsed patients (139, 140).   
Proteasome inhibitors (PIs) have also vastly improved patient outcomes in MM 
led primarily by bortezomib/VELCADE® (Bz) (Millennium Pharmaceuticals).  Bz targets 
chymotrypsin-like proteasome activity through reversible binding of the PSMB5 subunit 
of the 20S proteasome core (141) (Figure 3).  Early work with this compound showed 
that Bz induces apoptosis by inhibiting NF-κB signaling, disrupting IL-6 induced signaling 
pathways, and cleaving DNA repair enzymes (142, 143).  The earliest drug trials showed 
its efficacy in mouse models (144) and relapsed and refractory MM patients (145).  Bz is 
currently used in cocktail for newly-diagnosed MM and has proven very effective; 
however, potential side effects such as peripheral neuropathy, thrombocytopenia, and 
shingles can negatively contribute to patient quality of life and make the use of this drug 
in some patients impossible (146-149).  Further descriptions of the cellular 
consequences of Bz treatment will be provided in each chapter of this thesis.   
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Figure 3. Pathway targets of MM drugs.  A diagram of the MM cell highlighting those 
unique characteristics that may be targeted by therapeutic agents.  Also shown are 
supporting cell types and structures that contribute to MM cell viability (i.e. osteoclasts, 
bone marrow stromal cells (BMSCs), and blood vessels which may also be targeted for 
MM cell killing.  The secretion of cytokines by the MM cell including VEGF contribute to 
the recruitment of supporting vasculature, a process thought to be inhibited by IMiD 
compounds.  The reciprocal growth stimulation between the MM cell and neighboring 
osteoclasts may be targeted by bisphosphonates which inhibit osteoclasts and decrease 
bone disease in MM patients.  Pathways that contribute to cellular homeostasis within 
MM cells are often targeted by chemotherapeutic agents (e.g. proteasomal degradation, 
cell growth, replication, and stress response).  Newer agents may also target MM cells 
more specifically using monoclonal antibodies (mAb) toward proteins uniquely 
expressed on the surface of MM cells.  HDAC = histone deacetylase inhibitor; Topo = 
topoisomerase inhibitor; HSP = heat shock protein.
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Recent FDA approval of the PI carfilzomib/KYPROLIS® (Cz) (Figure 3) has 
shown that irreversible inhibition of the proteasome may also be useful in treating MM;  
therefore, novel PIs are currently being developed including MLN2238 and ONX0912.  
Interestingly, genetic lesions that were once associated with poor prognosis on classical 
treatments, such as loss of chromosome 13 and constitutive activation of FGFR3 by 
Lys650Glu mutation, have been met with great success on Bz treatment (150, 151).  In 
fact, some of this work has suggested new classes of drugs that might be developed for 
the treatment of MM.  One example of this is the development of endoplasmic reticulum 
(ER) stress response pathway agonists that enhance the activation of this pathway 
resulting in increased Bz sensitivity (152-154).  Heat shock protein 90 (HSP90) is a 
chaperone protein family that is involved in many pathways required for homeostasis by 
interacting with proteins such as AKT, TP53, MEK and STAT3.  Inhibition of HSP90 
using NVP-HSP90 has been shown to kill human myeloma cell lines (HMCLs) and may 
synergize with azacytidine and Bz (155).  In addition, the inhibition of HSP90 by IPI-504 
or GRP78/BiP knockdown was able to kill Bz-resistant MCL cell lines in vitro and in vivo 
because the HSP90/BiP association was lost (156).  Additional drugs, such as the 
calcium channel blocker, verapamil, plus Bz have also shown synergistic killing by 
upregulation of ER stress (157).  Clinical trials are currently underway for the use of the 
HSP90 inhibitor tanespimycin in combination with Bz (158) (Figure 3).   
Additional studies of the Bz mode of action have also shown that inhibition of 
histone deacetylase inhibitors (HDACs) is an effective synergist strategy for enhanced 
Bz killing.  Panobinostat (a.k.a. LBH589) has been shown to be a potent killer of drug 
resistant (classical treatment) MM cells and is synergistic with Bz (159, 160).  This 
synergy is thought to occur through the inhibition of cell cycle progression and anti-
apoptotic factors (e.g. BCL-2 and BCL-X (161)) and the upregulation of p21, p53 and 
p57 killing cells through intrinsic cell death pathway activation.  An additional HDAC 
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inhibitor, vorinostat (SAHA), has also shown promise in combination with Bz in early 
clinical trials (162) with a 42% response rate in refractory MM (163) (Figure 3).  
Interestingly, Bz has been shown to down-regulate the mRNA expression of class I 
HDACs (HDAC1, HDAC2, HDAC3) in HMCLs and primary MM cells resulting in histone 
hyperacetylation via caspase-8-dependent degradation of Sp1 protein (a potent HDAC 
transactivator) while HDAC1 overexpression conferred Bz resistance in MM cells 
suggesting a mechanism for synergy (162).  Yet, no matter the treatment regimen, still 
MM remains an incurable disease.   
Causes of bortezomib resistance in MM patients 
How and why cancer patients become resistant to treatment is not well 
understood.  This problem is particularly pertinent to the use of Bz in MM patients.  
Although over 50% of patient may respond favorably to initial Bz treatment, all patients 
will eventually relapse from Bz therapy, and still a small percentage of patients never 
initially respond presenting with primary Bz refractory disease (164).  The basis of these 
“acquired” and “innate” Bz resistant phenotypes are not well understood.  However, 
studies that have utilized multiple model systems have provided evidence as to three 
main mechanisms through which Bz-refractory disease occurs: microenvironment 
protection, drug active site mutations, and pathways mutations that increase cell viability.   
Perhaps the most widely-accepted cause of differences in MM cell sensitivity to 
chemotherapeutic agents is due to cell-cell interactions with the bone marrow 
microenvironment (165-168) (Figure 4).  Like normal plasma cells, MM cells thrive in the 
bone marrow compartment due to a nearly endless supply of extracellular matrix 
proteins (i.e. fibronectin, collagen, laminin and osteoponotin) and supporting cell types 
(i.e. HSCs, progenitor and precursor cells , immune cells, erythroid cells, bone marrow 
stromal cells (BMSCs), endothelial cells, adipocytes, osteoclasts and osteoblasts).  
These cells produce and secrete growth cytokines like interleukin 6 (IL-6), insulin-like 
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growth factor 1 (IGF-1), B cell-activating factor, fibroblast growth factor (FGF), SC-
derived factor 1α (SDF-1α), tumor necrosis factor α (TNF-α), transformation growth 
factor β (TGF-β), and vascular endothelial growth factor (VEGF) (169).  In addition to 
supporting normal PC survival, these growth factors are also required for BM 
osteoclastogenesis  (170) and angiogenesis (171), both of which are negatively 
impacted by MM cell growth (172, 173).  Physical interactions between MM and 
supporting cell types, particularly BMSCs through cell-surface molecules like CD40, 
CXCR4, and P-selectin glycoprotein ligand-1 (PSGL-1) increase the secretion of these 
cytokines by BMSCs which, in turn, stimulate the phosphatidylinositol-3 kinase 
(PI3K)/AKT, RAS/RAF/MAPK kinase (MEK)/extracellular signal-regulated kinase (ERK), 
and Janus kinase 2  (JAK)/signal transducers and activators of transcription 3 (STAT3) 
downstream survival by decreasing drug sensitivity, enhancing cell migration and 
antibody secretion, upregulating cell cycle regulatory proteins, and increasing 
telomerase activity (169, 174-177) (Figure 4). 
Because normal PCs also utilize these same interactions with BMSCs for survival, there 
has been some discussion about whether those BMSCs that support MM cell survival 
are themselves somewhat transformed to better support malignant PC growth and 
hence have been termed by some as MM-BMSCs.  In vitro studies of MM-BMSCs have 
shown that they express much higher levels of IL-6 and VEGF than their healthy BMSC 
counterparts; they also may modulate the expression of microRNA within MM cells that 
may be involved in drug sensitivity (178-180).  Interestingly, Bz resistance has been 
associated with MM cell secretion of growth cytokines (181, 182) suggesting that MM 
cells can mimic the bone marrow milieu for enhanced survival (Figure 4).  Furthermore, 
constitutively activating mutations within growth cytokine signaling pathways, such as 
those for IL-6, within MM cells have been identified that confer resistance to classical 
drugs.  These changes that allow MM cells to thrive away from the bone marrow  
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Figure 4. Effects of MM cell interactions with the bone marrow microenvironment.  
Illustration of the MM cell interaction with the bone marrow microenvironment including 
bone marrow stromal cells (BMSCs), osteoblasts, and osteoclasts which stimulate the 
production of growth cytokines from BMSCs and MM cells.   
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compartment may further explain how extramedullary masses arise in end-stage 
patients (166).  
Although differences in Bz sensitivity due to BMSC interactions is considered by 
some as controversial, several studies have shown that disruption of this interaction may 
be a useful therapeutic approach for targeting MM cell growth (183).  Indeed, studies 
have shown that antibody inhibition of the CD40/CD40L interaction (184) and chemical 
inhibition of the CXCR4/SDF-1α axis disrupt MM/BMSC binding and may even sensitize 
cells to Bz treatment (185).  However, mutations resulting in the loss of adhesion 
proteins and increased migratory capabilities have been associated with reduced PI 
sensitivity (186).  In addition, there have been several reports on MM patients where Bz 
resistance was associated with the development of extramedullary masses (187, 188).  
Interestingly, MM cells with ectopic cyclin D1 expression but not t(11;14) which depend 
on BMSC support for survival are underrepresented in extramedullary stages of disease 
(189).  Together, these data suggest that there is a dependence on the bone marrow 
milieu for survival in early but not advanced stages of the disease and that this might be 
further informed by the presence of certain genetic alterations.      
The most common mechanism for acquired Bz resistance in in vitro model 
systems is attributed to mutations at the drug active site within the protein, PSMB5.  
PSMB5 is a β subunit of 20S catalytic core responsible for chymotrypsin-like proteasome 
activity (190).  Many human cell line models have been dose-escalated with Bz over 
time to create resistance that has been attributed to PSMB5 mutations.  Most of these 
mutations have been identified within the PSMB5 binding pocket resulting in Met56Ile, 
Cys63Phe, Ala49Thr, Met45Val and Cys52Phe, or Ala49Val changes.  One study 
reported an additional propeptide region mutation resulting in an Arg24Cys change.  
These mutations were often associated with increases in PSMB5 transcript and protein 
as well as proteasome chymotrypsin-like activity.  In some cases, these mutations were 
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also associated with increases in immunoproteasome activity which was associated with 
cross-resistance to other next-generation PIs.  In many of these cases, synthetic knock-
down of PSMB5 expression or chemical inhibition of α proteasomal subunits restored Bz 
sensitivity (191-203).  However, what is perhaps most intriguing about these studies is 
that although non-synonymous coding PSMB5 variants have been identified in Bz-
refractory MM patients, none of these have been associated with survival or differences 
in proteasome activity.  Furthermore, none of the mutations that have been identified in 
Bz-resistant cells in vitro have been identified in Bz-refractory MM patient samples (191, 
204-206). 
In addition to contributions from the bone marrow microenvironment and drug 
active site mutations, there remains a large body of literature that attributes Bz 
resistance to cellular changes that overall promote malignant cell viability in the face of 
extreme cellular stress (i.e. the inability to degrade excess and/or misfolded proteins).  
One such example of this is through inhibition of NOXA upregulation following Bz 
treatment.  NOXA is a pro-apoptotic gene that acts though the BAK/BAX axis to promote 
cell death.  Downregulation of NOXA expression as well as other factors in this pathway 
(i.e. RAD) as well as loss of wild-type TP53 activity have been implicated in Bz 
resistance (159, 160, 207-209).  Overexpression of anti-apoptotic genes, such as BCL-2, 
MCL-1, and BAG3, has also been associated with reduced Bz sensitivity (210-213). 
Besides changes in cell death, onocogenic activation has also been suggested 
by many as a mechanism for MM cells to avoid Bz-induced cell death.  Constitutive 
activation of NOTCH, PI3K/AKT/mTOR, Hedgehog, NF-κB, MEK/ERK and/or 
JAK/STAT3  signaling pathways has been observed in multiple model systems of Bz-
resistance (214-222) (223).  The overexpression of the receptor tyrosine kinase c-MET 
in Bz-resistant HMCLs led to upregulation of cell proliferation (224) and survival.  This 
finding is particularly interesting given the normal metastatic function of c-MET, the 
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upregulation of which may explain the development of extramedullary disease at Bz 
relapse (187, 188). 
Finally, reduced cellular stress has also come to the forefront of the Bz-
resistance literature.  Reducing oxidative stress by increasing the baseline expression of 
stress response proteins (i.e. HSPA2, GRP78/BiP, NRF2, HSP27, HSP70, HSP90) may 
help Bz-resistant cells maintain homeostasis even in the presence of Bz (225-231).  The 
activation of alternative pathways, like autophagy, in Bz-resistant cell may help shunt 
unfolded and/or misfolded proteins toward degradation, allowing intracellular stress to 
remain low in these cells (186, 232-234).  Also, increased expression of drug efflux 
pumps like P-glycoprotein/multidrug resistance 1 (MDR1) may contribute to reduced Bz 
sensitivity by keeping intracellular levels of Bz low (193). 
Mouse modeling of MM 
Because patient samples are relatively rare, a number of mouse model systems 
have been utilized to identify the genetic variants that are associated with disease 
progression, severity, and drug resistance.  These models can generally be divided into 
mouse myeloma-like models and xenograft models.  Each model possesses certain 
advantages and disadvantages for studying different components of the disease. 
The earliest mouse MM model utilized BALB/cAn and BALB/cJ strain mice which 
were susceptible to plasmacytomas when injected with the inflammatory agent, pristane 
(235).  The formation of these localized tumors could be further expedited by co-injection 
with retroviruses (236).  Although these tumors do secrete Ig, greater than 95% possess 
IgH/Myc translocations which are not that common in the MM patient population.   
However, this model has proven useful for studying BL where this translocation is most 
common (237).   
Although IGH/MYC translocations are not that common in MM (occurring in only 
approximately 3% of the patient population (238)), the deregulation of MYC is found in 
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53-85% of patients (239-241).  One commonly used mouse model, the Vk*myc C57Bl6/J 
mouse, spontaneously develop a post-GC MGUS-like condition with PC expansion in 
the bone marrow.  In this model, c-Myc activation occurs by SHM of the myc locus by 
AID.  A low percentage of Vk*myc mice progress to a MM-like disease at advanced 
ages.  This presents with a monoclonal M-spike, low proliferative index, anemia, and 
decreased bone density.  Importantly, Vk*myc mice are responsive to drugs commonly 
used to treat MM (125).   
Another transgenic model, developed in our laboratory, utilizes the dual 
overexpression of the oncogene, c-Myc, and the anti-apoptotic gene, Bcl-xL, by hijacking 
regulatory components of the Ig machinery.  The double transgenic progeny succumb to 
disease quickly with complete penetrance.  In addition to an in vivo phenotype that 
closely recapitulates the human disease, as shown in this thesis, stable cell lines can be 
created from these animals that can be manipulated and adoptively transferred back into 
syngeneic recipients resulting in the same disease phenotype (124, 242).  This is 
currently the only mouse model from which stable cell lines can be created which may 
be highly advantageous for certain approaches.   
 An additional transgenic mouse model expresses the spliced, active form of the 
PC gene XBP-1 controlled by the Ig VH promoter and Em enhancer elements.  This 
pEμXBP-1s model is prone to MM development which presents as elevated IgM and 
IgG, PC expansion in the BM, the development of plasmacytic tumors resembling MGUS 
or MM, and bone lesions; however, this occurs at advanced ages in only a small percent 
of the patient population (123). 
Interestingly, some strains of mice, like C57BL, spontaneously develop murine 
MGUS-like disease that will progress to MM at elderly ages; the C57BL/KaLwRij stain 
develops idiopathic paraproteinemia at the highest frequency and has since been 
termed the 5T mouse model.  At 2 years of age, 50% of these mice develop MGUS and 
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0.5% develop MM (243).  Cells from these animals can be serially transferred into 
recipient C57BL/KaLwRij mice resulting in secondary plasma cell disease and death 
(244).  This adoptive transfer process has been used to create three additional related 
models: 5T2MM, 5T33MM, and 5THL (245).   These models possess similar cell-surface 
marker expression but have different rates of growth and homing properties in vivo (246, 
247).  This mouse model has contributed greatly to understanding of the 
pathophysiology and cell biology of MM (248-259) and particularly to the discovery of 
bisphosphonate drugs for the treatment of bone disease in MM patients (260-268).   
The Vk*myc, Bcl-XL/Myc, pEμXBP-1s, and 5T mouse models have proven 
especially useful given that the bone marrow microenvironment plays a key role in cell 
growth, proliferation and drug sensitivity in MM (269).  Perhaps the biggest advantage is 
the ability to study the disease in an immunocompetant host species (237).  However, 
the problem remains that no single model provides the spectrum of heterogeneity that is 
present in the patient population (270, 271).  While Vk*myc, pEμXBP-1s and 5T mice 
represent MGUS and can progress to MM, this is a very latent disease that transforms at 
a low frequency making large-scale studies using these models cost-prohibitive.  In 
contrast, the Bcl-XL/Myc model may represent aggressive disease.  While this may be 
useful for studying refractory disease which is often aggressive, it does not necessarily 
inform disease progression. 
For these reasons, some researchers favor xenograft models where MM patient 
cells can be injected into immunocompromised mice (SCID, NOD/SCID, or SCID-beige) 
creating palpable plasmacytoma that can be measured for easy quantification of growth 
over time (272).  Higher levels of engraftment may be reached in this model by the 
addition of matrigel with the tumor cells to temporarily mimic a microenvironment (144).  
This cancer model system has been utilized for pre-clinical anti-MM drug development 
successfully for a variety of drug classes (144, 273-287).  Several drugs commonly used 
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to treat MM patients, including Bz (144) and thalidomide (273), were first tested in this 
model system.  However, for drugs that are considerably affected by MM-BMSC 
interactions (i.e. dexamethasone, alkylating agents, anthracyclines), this model system 
may not be suitable (177, 269).  The absence of bone disease in these models means 
that an end point of death is not useful.  Because of this, over-estimates of the efficacy 
of new drugs, especially those that may be affected by the MM-BMSC interaction, may 
be predicted by this model that will not translate to the clinic. 
These limitations led to modifications of this methodology to include fetal bone 
fragments at the tumor cell injection site, a system now called the SCID-hu model.  
Implantation of these bone fragments provide a human bone marrow-like 
microenvironment instead of direct BM injection into mouse BM as the 
microenvironments may be different enough to limit human MM cell growth (288).  
Human MM cells show bone engraftment, marrow infiltration, and classic MM symptoms 
including an M-spike in the serum and LC renal involvement in these mice.  Importantly, 
this model provides a much higher rate of engraftment for primary MM samples than 
traditional subcutaneous xenograft models, perhaps as high as 80% (289).  Pre-clinical 
testing of many MM drugs has been performed in this model system (290-297).  
Because of the bone involvement phenotype (298), this system has also been used 
extensively to study bone resportion common to MM patients (172, 291).  The lack of 
palpable tumor in this xenograft system means that other markers such as Ig or soluble 
IL-6 receptor must be used to quantify disease burden (288, 296, 299).  Yet, death 
remains a useless endpoint in these mice as the human MM cells cannot infiltrate and 
cause extramedullary disease in the endogenous mouse tissues (237).  The use of fetal 
bone has been highly controversial, and there is not a clear understanding of the 
differences (if any) of MM growth in fetal versus adult bone marrow; however, we do 
know that infants and children have never been diagnosed with MM.  A more-recent 
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modification of this model uses rabbit bone marrow inserted into SCID mice (SCID-rab).  
This approach is much less controversial but has not been used as extensively although 
it does show promise (300). 
Besides primary patients samples, established and well-described HMCLs are 
often used in the xenograft model systems for drug discovery (301-308).  There are 
approximately 40 cell lines created from end-stage MM patients that were established 
over 20 years ago (309, 310).  When injected into immunodeficient mice, these cells 
lines home primarily to the bone marrow but have also been shown capable of infiltrating 
lymph nodes and soft tissues similar to what is seen in extramedullary disease in MM 
patients (110, 269, 301, 302, 311-313).  However, many studies have reported drug 
efficacy using these cell lines which cannot be recapitulated in MM clinical trials.  
Perhaps this is due to the fact that they cell lines represent only a small portion of the 
disease population.  For example, the majority of these cell lines have TP53 mutations 
and lack hyperdiploidy which are relatively rare events in the MM patient population 
(310, 314-316).  Even so, many elegant studies have utilized these cell lines for in vitro 
approaches (e.g. RNAi screens) that have revealed druggable targets for translational 
studies aimed toward identifying drugs that will synergize with Bz (317). 
Clonal evolution and the myeloma cancer stem cell 
 Although the last two decades have brought marked improvements in MM patient 
treatment and understanding of drug resistance primarily through the use of model 
systems, MM remains an incurable disease suggesting that no treatments currently on 
the market are able to deplete the myeloma cancer stem cell (CSC) population.  The 
development of drugs that target this population has been a challenge as this cell type is 
not well-defined.  The first description of a potential MM CSC population came from 
mouse studies of serially propagated pristane-induced mouse plasmacytoma tumors 
which showed that only a small percentage of the tumor cells were capable of 
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clonogenic growth both in vitro and in vivo while the bulk of the tumor cells were 
quiescent (318, 319). These clonotypic B cell were also observed in MM patient 
samples, albeit at a frequency of 0.2-0.8% from total B cells, and had clonogenic growth 
properties when tested in vitro (320-327); however, further characterization of these cell 
populations was necessary in order to distinguish it from the bulk tumor. 
The most well-defined marker of MM cells is CD138, a surface transmembrane 
heparin sulfate-bearing proteoglycan.  CD138 binds type I collagen inducing the 
expression of matrix metalloproteinase 1 (MMP-1) and aids MM progression by 
promoting bone resorption and tumor invasion.  Increased soluble CD138 promotes MM 
tumor growth in vivo and is considered a marker of poor prognosis (328, 329).  In fact, 
targeting MM cells using CD138-specific antibodies has been described as a potentially 
successful approach for killing MM cells in vivo (330).  Interestingly, CD138 status has 
come to the forefront of MM CSC literature based on studies performed by Matsui et al.  
They observed that small fractions of CD138- cells isolated from both MM cell lines as 
well as patients had greater clonogenic potential than their CD138+ counterparts when 
transferred into NOD/SCID mice (331).  CD138- cells also expressed CD19, CD20, 
CD22 and CD45 and higher levels of Ki67, a proliferation marker, as well as surface Ig 
with restricted LC expression (either κ or λ) (331) which was the same as the greater 
MM cell population (332).  Further characterization of the CD138- population showed 
that clonally-related memory B cells which are CD19+CD27+ found in the peripheral 
blood of MM patients could also produce disease in primary NOD/SCID animals as well 
as secondary recipients and could contribute CD138+ cells to the host BM (327, 333, 
334).   In vitro colony-forming assays as well as in vivo transfer experiments showed that 
CD138-/CD34- cells could give rise to CD138+ cells suggesting that transformation is a 
post-GC event that gives rise to a B cell-like CSC which can then give rise to the bulk 
CD138+ cell population that is detected in MM patients at diagnosis (331).  Rituximab, 
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humanized monoclonal CD20 antibody originally developed originally for B-cell NHLs, 
was especially effective in inhibiting the growth of the CD138- population which was 
generally cross-resistant to all other MM therapies (331, 333).  Hedgehog (Hh) signaling 
has been implicated as a player in MM CSCs and is a known player in stem cell self-
renewal.  Hence, this may be a druggable target for eliminating CSCs in MM patient 
populations.  The Hh signaling pathway is significantly upregulated in CD138- cells; 
inhibition of this pathway using the drug cyclopamine killed these cells, induced terminal 
differentiation and inhibited clonogenic growth; however, the expression of Hh in vivo 
may be dependent on stromal interactions (335, 336).  These data suggest that although 
the bulk of the MM tumor cells may not be affected by these particular drugs, drugs that 
target cancer stem cells may be important moving forward in combination therapies to 
achieve eradication of all MM cells.  
Defining the MM CSC population has revealed that these cells may be more B 
cell-like than was previously thought which does make sense given that B cells possess 
the ability to proliferate and are not restricted to the bone marrow compartment (337-
340). Clonally-related mature B cell-like cells have been identified in peripheral blood 
and BM of MM patients (323, 341-345).  Characterization of this clonogenic MM cell 
population has shown that these cells do in fact express markers of B cells rather than 
terminally differentiated PCs.  These clonogenic B cells have many similar 
characteristics to normal adult stem cells including higher expression of detoxifying 
enzymes and membrane-bound drug transporters (346), persisting through drug 
treatment and increase during relapse in MM patients (347-350).  Interestingly, 
increased numbers of peripheral blood malignant circulating PCs have been associated 
with negative outcome due to relapsed or refractory disease in MM patients (351). 
Significant decreases in CD138 in patients with relapsed/progressive disease have also 
been observed compared to drug naïve patients (352) leading many to ask whether the 
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expression of a B cell program, while being associated with the MM CSC phenotype, 
may also be associated with Bz refractory disease.  The intersection of these two 
themes could mean that MM CSCs are resistant to Bz treatment which is thought to be 
true (333), but it could also mean that MM cells are capable of reverting to a CSC-like 
phenotype to survive Bz treatment.   
 In studies of CD138 status associated with outcomes, Gu et al. found that 
patients with low CD138 had a worse overall survival than patients with high CD138.  
These studies described two MM cell lines derived from the same patient, one with high 
and the other with low CD138 expression.  The cell line with low CD138 expressed high 
levels of the B cell transcription factors BCL-6 and PAX-5 while the CD138 high cells 
expressed the PC regulators IRF4, BLIMP-1, and XBP1 suggesting that the CD138 cells 
were less PC-like (Figure 2).  Importantly, forced PC differentiation of the CD138 low 
cells increased their sensitivity to Bz (353).  Complimentary work in MCL has shown that 
the expression of BLIMP-1 is required for Bz sensitivity in MCL cell lines and primary 
tumor cells (354).  Another cell line model of Bz resistance shows that the MM CSC 
marker CD20 is upregulated in Bz-resistance increasing sensitivity to rituximab (192).  
These lines of evidence point toward a loss of PC maturation markers and a gain in B 
cell identity in Bz-refractory disease.  Whether these B cell types are selected for or 
induced by the drug is still unknown.   
Investigation of the MM CSC and Bz resistant populations may be leading to 
smarter treatment strategies but it has also changed the way that physicians and 
researchers are thinking about clonal evolution.  Classically, MM has been thought of as 
a linear cancer progression from MGUS through to plasma cell leukemia.    More recent, 
large-scale cytogenetic and genome sequencing studies of MM patients through the 
course of disease progression has provided evidence that myelomas may be 
categorized into three categories: 1) genetically stable, 2) linearly evolving, or 3) 
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heterogeneous clonal mixtures which may contribute greatly to drug sensitivity and 
outcomes (355, 356).  The earliest evidence of heterogeneous clonal mixtures in 
disease was reported as a switch in a patient after treatment from hyperdiploid to a near-
tetraploid abnormal clone (357).  This population may represent as high as 42% of the 
population (355) and shows that in fact clones may wax and wane with different 
therapeutic regimens (356).  Perhaps not surprisingly, this heterogeneous phenotype 
was associated with high-risk myeloma as it was genetically unstable (355), but these 
studies warrant further characterization of emerging clones following relapse 
underscoring the desperate need for better personalized medicine approaches in MM.  
Although many mechanisms of Bz resistance have been described, PIs are still 
considered a front-line treatment for patients with MM (358).  The success of Bz 
treatment in MM patients has now led to investments by many research groups to 
determine whether Bz can be utilized in other types of cancer, particularly solid tumors 
(359-370).  With this potential expansion in the use of Bz, understanding of the evolution 
of refractory disease and synergist drug combinations to combat Bz-resistance are vital. 
Statement of thesis 
This thesis will combine in vitro, in silico, and in vivo approaches to further 
characterize Bz resistance within the MM cancer cell population.  The first study 
describes the establishment of in vitro MM-like mouse cell lines which is the model 
system that we favor for studying Bz-refractory disease in MM.  We further investigate 
both the conserved and unique transcriptional signatures of Bz-sensitive and -resistant 
cell lines in vitro which may provide predictive power for the in silico selection of 
secondary therapies using a database called Connectivity Map.  The second study 
further investigates the predictive power of combining in silico predictions with high-
throughput compound screening for secondary drug predictions of compounds that may 
synergize effectively with PIs.  The third study involves further immunophenotypic 
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characterization of the Bz-sensitive and -resistant mouse cells lines in order to identify 
unique cell surface markers that might be used diagnostically or targeted successfully by 
secondary therapy to regain Bz sensitivity.  The final study investigates BL, a 
malignancy that is currently undergoing Bz clinical trials, to determine what role ongoing 
SHM might play in acquiring Bz resistance.  These studies provide a more thorough 
characterization of the Bz-resistant phenotype and together describe new approaches 
that may be successfully implemented in the future for the treatment of patients with 
refractory MM. 
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CHAPTER 2 
DEVELOPMENT OF AN IN VITRO MOUSE PLASMA CELL TUMOR SYSTEM 
 Prior to my joining the Van Ness laboratory in 2009, a number of mouse model 
systems of multiple myeloma (MM) had been established and well-described (as 
illustrated in Chapter 1).  However, the characterization of pharmacogenomic 
mechanisms for cancer drugs has traditionally been explored using cell line models 
which are not limited by cell number, as is the case with primary tumor samples.  
Although a number of human myeloma cell lines (HMCLs) were available, we did not 
feel that these were particularly representative of current MM disease phenotypes due to 
the caveats described above.  Therefore, the first aim of the studies described in this 
thesis was to establish a robust malignant plasma cell (PC) culture system.  
 For this system, we chose to utilize the Bcl-XL/Myc double transgenic mouse 
model of MM developed previously in our laboratory and described in Chapter 1.  Not 
only do these mice express a fully-penetrant MM-like phenotype, but the PCs that can 
be isolated from moribund animals possess karyotypic and gene expression signatures 
that align with the human disease (124, 242, 371).  Furthermore, malignant cells from 
these animals can be isolated and established to create stable cell lines that do not 
require Epstein-Barr virus (EBV)-transformation for immortalization.  This is an 
advantage that is distinct to our mouse model which we believe is particularly powerful 
for pharmacogenomic applications that require repeated in vitro studies. 
Isolating malignant mouse plasma cell lines 
 In order to create a library of malignant mouse PC lines, we participated in a 
large-scale double transgenic breeding scheme that was performed to test the pre-
clinical efficacy of a next-generation proteasome inhibitor (PI).  In this study, 90 age-
matched double transgenic mice were created and divided among three treatment arms 
to receive vehicle, bortezomib (Bz), or MLN2238 beginning at nine weeks of age for six 
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consecutive weeks (372).  When mice in the vehicle or Bz treatment groups became 
moribund, they were sacrificed and dissected.  Multiple tissues including bilateral femurs 
and tibias, spleen, liver, lymph nodes and tumor masses were shipped to our laboratory 
from each mouse overnight in culture medium.  We established single-cell suspensions 
from each individual tissue and waited for stable malignant clones to emerge over the 
course of approximately six months as has been previously described (124).  The growth 
of PCs in these cultures was aided by the addition of the cytokine, IL-6 which has been 
shown to stimulate MM cell growth (373).  This produced a panel of close to 200 cell 
suspensions from which approximately 60 independent cell lines emerged. 
Characterizing candidate mouse cell lines 
 Of the cell lines that emerged, a small percentage appeared to be dependent on 
transformed stromal cells that also emerged with the malignant PCs from the mouse 
tissues resulting in mixed cell cultures (data not shown).  In addition, although the 
majority of the cell lines represented clonal populations (data not shown), many 
consisted of cells with a mixture of both B cell and PC-like morphologies (Figure 1).  
Interestingly, a small number of mice gave rise to independently-derived cell lines from 
different tissues (i.e. one cell line from the bone marrow and one from the spleen) that 
were also clonal (Figure 2, Supplemental Materials and Methods) suggesting that a 
malignant clone had emerged in the bone marrow and spread to the soft tissues at end-
stage disease.  We did not identify any clear cases of animals with biclonal disease from 
the obtained stable cell lines; however, this result may not have been surprising given 
that 100% of double transgenic mice develop PC disease.  We further performed GEP 
on a number of our most-aggressive cell lines and identified that the gene expression 
pattern among independently-derived cell lines was largely similar.  Not surprisingly, the 
cell lines that clustered most tightly were those that were derived from the same mouse 
(but different tissues) (data not shown).  We describe many of these results in Chapter 3.  
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Importantly, these GEPs did not appear to drift when tested six months and up to a year 
later (data not shown). 
 In the following studies, we utilize these malignant mouse PC lines for the 
pharmacogenomic characterization of drug resistance, which is a major problem within 
the MM patient community, and for the prediction and validation of secondary therapies. 
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Figure 1. Cell morphologies of mouse cell lines by pathologic staining. 
A representative formalin-fixed and paraffin embedded hematoxylin and eosin stained 
malignant mouse PC line (60X magnification) where black arrows indicate PC 
morphology, red arrows indicate B cell morphology, and the blue arrow indicates a 
binucleated cell morphology. 
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Figure 2. Stable malignant mouse plasma cell lines are clonal. 
A PCR-based assay (see Supplemental Materials and Methods) for mouse D(J) 
rearrangement shows by gel electrophoresis that independently-derived cell lines from 
different tissues from the same moribund animal are likely clonal (595BM = bone 
marrow-derived, 595SP = splenic-derived).  A well-described mouse pristane-induced 
plasmacytoma cell line (MPC11) was used as a positive control as was GAPDH.  JH 
bands indicate the presence of either the JH2 or JH4 joining segments in each cell line.  
The presence of a single band indicates clonality. 
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Supplemental Materials and Methods 
Clonality assay.  Cell culture clonality was determined using a PCR-based assay for 
heavy chain (D)J rearrangements where the forward primer binds a conserved (D) 
region sequence and the reverse primer bind the constant region adjacent to the final J 
segment. Rearrangement was determined by endpoint PCR using the GeneAmp PCR 
System 9700 (Applied Biosystems, Carlsbad, CA) and GoTaq Green DNA polymerase 
(Promega) using 35 cycles of 94C for 30 sec, 58C for 30 sec and 72 C for 2 min. The 
following primers used: (D)J, 5’-CTGCAACCGGTG 
TACATTCCSAGGTSMARCTGSAGSAGTCWGG-3’ (5’ primer), 5’-
TGCGAAGTCGACCCTGAGGAGACGGTGACTGAGG-3’ (3’ primer).  PCR products 
were resolved on a 1.5% agarose gel (BioExpress, Kaysville, UT), visualized using the 
ChemiDocTM XRS+ Imager (Bio-Rad, Hercules, CA). 
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ABSTRACT 
 Multiple myeloma (MM) is a hematologic malignancy characterized by the 
proliferation of neoplastic plasma cells in the bone marrow.  While the first-to-market 
proteasome inhibitor bortezomib/VELCADE® has been successfully used to treat 
myeloma patients, drug resistance remains an emerging problem.  In this study, we 
identify signatures of bortezomib sensitivity and resistance by gene expression profiling 
(GEP) using pairs of bortezomib-sensitive and -resistant cell lines created from the Bcl-
XL/Myc double transgenic mouse model of MM.  Notably, these bortezomib-resistant cell 
lines show cross-resistance to the next-generation proteasome inhibitors, MLN2238 and 
carfilzomib/KAPROLIS® but not to other anti-myeloma drugs.  We further characterized 
the response to bortezomib using the Connectivity Map database revealing a differential 
response between these cell lines to histone deacetylase (HDAC) inhibitors.  
Furthermore, in vivo experiments using the HDAC inhibitor panobinostat confirmed that 
the predicted responder showed increased sensitivity to HDAC inhibitors in the 
bortezomib-resistant line.  These findings demonstrate that GEP may be used to 
document bortezomib resistance in myeloma cells and predict individual sensitivity to 
other drugs classes.  Finally, these data reveal complex heterogeneity within MM and 
suggest that resistance to one drug class reprograms resistant clones for increased 
sensitivity to a distinct class of drugs.   This study represents an important next step in 
translating pharmacogenomic profiling and may be useful for understanding 
personalized pharmacotherapy of MM patients. 
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INTRODUCTION 
Multiple myeloma (MM) is a hematopoietic neoplasm characterized by the 
proliferation of malignant plasma cells (PCs) in the bone marrow (374).  Each year about 
22,000 new cases arise in the U.S., accounting for approximately 2% of all cancer 
deaths (67).  Standard treatments for MM patients utilize combination chemotherapies 
(i.e. alkylating agents and corticosteroids) along with autologous stem cell transplants.  
However, in the past decade a number of novel classes of agents have been developed 
for the treatment of MM, including the proteasome inhibitor (PI), bortezomib 
(Bz)/VELCADE® (Millennium Pharmaceuticals, Inc.) which is approved for the treatment 
of MM and relapsed mantle cell lymphoma (375).  Despite the initial success of Bz 
therapy, MM remains incurable due in part to the emergence of Bz-resistant cells in the 
majority of patients (376, 377).   
The primary target of Bz, the proteasome, is part of the highly regulated ubiquitin-
proteasome system (UPS) necessary for intracellular proteolysis.  The UPS plays a 
critical role in cellular homeostasis, cell cycle progression and DNA repair (378, 379).  
The constitutive proteasome, a primary UPS player, is composed of the catalytic 20S 
core barrel and 19S regulatory caps (together called the 26S proteasome).  Bz is a 
boronic acid dipeptide that is highly selective for inhibition of the chymotryptic activity of 
the 26S proteasome via reversible binding of its target, PSMB5, a subunit of the 20S 
catalytic core (144, 380).  Bz treatment has been shown to inhibit the transcriptional 
activity of NF-κB as well as trigger the unfolded protein response (UPR), leading to cell 
stress and apoptosis (45, 190, 381).  With the advent of next-generation PIs, it has 
become imperative that the Bz response and signatures that are associated with Bz-
resistance be further defined in order to identify those patients that 1) will most benefit 
from PI treatment, 2) will show signs of emerging resistance, and 3) will benefit from 
selective secondary therapies.   
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Double-transgenic Bcl-XL/Myc mice develop plasma cell tumors (mean onset of 
135 days) with full (100%) penetrance that possess many of the karyotypic, phenotypic, 
and gene expression features of human MM (124, 242).  Furthermore, malignant PCs 
can be isolated from these animals, expanded, modified in vitro, and subsequently 
transferred back into syngeneic mice for drug treatment in the presence of an active 
immune system which includes a complete bone marrow microenvironment (124, 242).  
We have chosen to utilize this system to model Bz response in order to better 
understand acquired Bz-resistance within malignant PCs for potential application to the 
human MM patient population.  While therapeutic response in human MM is likely 
dependent on a combination of tumor genetic variation and inherited population 
variation, the mouse model provides a common strain background, allowing us to focus 
on tumor variation and tumor evolution that lead to drug-resistance.  
In this study, we have used gene expression profiling (GEP) in the mouse model 
system to identify Bz-responsive genes in vitro.  In order to identify signatures of Bz-
resistance, we created Bz-resistant mouse cell lines and examined their response to Bz 
compared to sensitive controls by GEP, revealing signatures of Bz-resistance over the 
course of Bz treatment.  Finally, we used the Connectivity Map (CMAP) database to 
further identify individual differences in Bz resistance in our representative Bz-sensitive 
and -resistant lines which identified a unique response to histone deacetylase (HDAC) 
inhibitors, a class of drugs currently in early clinical trials for the treatment of MM (382-
388). 
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MATERIALS and METHODS 
Mouse and human plasma cell lines.  The mouse cell lines 595, 589 and 638 were 
isolated from three individual Bcl-XL/Myc double transgenic mice and cultured in CST 
media as previously described (124) and cultured for greater than 40 passages prior to 
any experimentation after which no changes in rate of growth, clonal drift, response to 
drug or gene expression were observed.  The human myeloma cell lines MM1.S and 
U266 (obtained from ATCC) were maintained in HMCL media: RPMI 1640 (Lonza) 
supplemented with 15% fetal bovine serum (Cellgro), 50 μmol/L beta-mercaptoethanol 
(Sigma-Aldrich), 50 units/ml of penicillin and streptomycin (Hyclone), and 2 mmol/L L-
glutamine (Life Technologies).  Cell lines were not authenticated.   
Drugs and treatment conditions.  Bortezomib (Bz) (Millennium Pharmaceuticals) was 
dissolved in serum-free RPMI-1640 (Lonza) and stored at -80C.  MLN2238 (Millennium 
Pharmaceuticals), MG-132 (American Peptide Company), trichostatin A (Cell Signaling 
Technology), and vorinostat (SAHA) (LC Laboratories) were dissolved in dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich), melphalan (Sigma-Aldrich) was dissolved in EtOH, 
and panobinostat (LC Laboratories) was dissolved in ddH20; all drugs were stored at -
20C. 
   Bortezomib resistant (BzR) cells were generated by dose escalation of Bz over 6 
months by once weekly treatment with Bz starting at 16 nM; the Bz concentration was 
doubled every 3 weeks until a final growth concentration of 64 nM was reached.  
Cultures were removed from Bz for 14 days or 6 months prior to analysis and cultured in 
a manner consistent with the parental lines.   
Cell viability assay.  Cells were seeded at a concentration of 4x105 cells per mL.  After 
24 hours the cells were treated with the indicated concentrations of drug for 48 hours.   
Cell viability was measured by CellTiter-Glo® Luminescent cell viability assay according 
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to manufacturer’s instructions (Promega) using the Synergy 2 Microplate Reader 
(Biotek).  Values were normalized to untreated controls and IC50 values were estimated 
by calculating the nonlinear regression using the sigmoidal dose-response equation 
(variable slope) in GraphPad (Prism).    In some experiments, cell growth was calculated 
by trypan blue (Life Technologies) exclusion with a hemocytometer. 
Preparation of RNA for gene expression profiling.  The mouse cell lines 595 BzS, 
595 BzR, 638 BzS and 638 BzR, removed from Bz selection for 14 days, were plated at 
a density of 4 x 105 cells per mL in CST media with mIL-6.  In addition, 595 BzS (595.2), 
595 BzR (BzR 595.2), 589 BzS and 589 BzR, removed from Bz selection for 6 months, 
were plated at a density of 4 x 105 cells per mL in CST media with mIL-6.   After 24-hour 
incubation, 66 nM Bz was added to each well, and the cells were collected at 0, 2, 8, 16 
and 24 hours after treatment.  Similarly, MM1.S and U266 were plated 24 hours prior to 
33 nM Bz treatment and cells were collected at 0, 16 and 24 hours.  Cells were lysed, 
and total RNA was extracted using QIAshredder and RNeasy RNA purification columns 
(Qiagen).  RNA concentration and integrity were analyzed using the Nanodrop-8000 
(Thermo Scientific) and 2100 Bioanalyzer (Agilent Technologies).  cDNA was prepared 
and labeled with the Illumina TotalPrep- 96 RNA Amplification Kit (Life Technologies).  
Samples were hybridized to the Illumina MouseWG-6 v2.0 Expression BeadChip 
according to manufacturer protocols and read on the Illumina iScan (Illumina).  
Microarray data have been made available at the Gene Expression Omnibus (GEO) web 
site (accession no. GSE41930). 
Normalization of gene expression data.  Fluorescence values obtained from the 
Illumina detection system without background subtraction and without normalization 
were analyzed for quality control as previously described (389).   Quantile normalization 
was applied to the data that passed quality control using GeneData Analyst Software 
(Genedata Inc.).   Following normalization, multiple probes were averaged to obtain a 
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single value for each gene. Statistical analyses and relative normalization was carried 
out as described within the draft using GeneData Analyst Software.   
Enrichment analyses.  Gene set enrichment analysis software (GSEA, Broad Institute, 
www.broadinstitute.org/gsea/) was used to test for enrichment between the differentially 
expressed genes in mouse and the MM patient gene set (390).  Specifically, the 24hr 
time point after Bz treatment was compared to the 0hr time point for all Bz-sensitive 
mouse cell lines and the resulting differential expression values were evaluated for 
enrichment for the Shaughnessy, et al. gene set (390), using default GSEA parameters.  
In addition, variant transcripts were analyzed using Ingenuity Pathway Analysis (IPA) 
(Ingenuity Systems, www.ingenuity.com) to identify canonical pathways that were 
enriched in each set of genes.  The significance of each association was determined by 
the Fisher exact test. 
CMAP drug prediction.  Genes were assigned a binary distinction of “up” or “down” 
respectively by selecting genes with at least 2-fold higher or lower expression in the BzS 
cell lines relative to the derived BzR lines at the 24hr time point (post Bz treatment).  
These “up” and “down” sets were queried against the Connectivity Map (CMAP) 
database (391, 392).  The given connectivity score estimates the similarity between the 
input and database expression signatures.  A positive score indicates that the input 
signature is similar to, and a negative score indicates that the input signature is opposite 
to what would be expected by the predicted compound.  Predicted compounds were 
ranked in ascending order of p-value and viable compounds were chosen based on 
significance of correlation with the input signature (p < 0.05). 
Quantitative PCR analysis.  1 μg of total RNA was reverse transcribed using the 
Transcriptor First Strand cDNA Synthesis Kit (Roche) with anchored-oligo(dT)18 primers. 
Quantitative RT-PCR of cDNA was performed in triplicate on the LightCycler 480 
(Roche) using LightCycler 480 Probes Master (Roche) with a pre-amplification 
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incubation of 95C for 10 minutes, followed by 45 cycles of 95C for 10 sec and 55C for 
30 sec (single acquisition).  The following primers were used: Ddit3, 5’-
GCGACAGAGCCAGAATAACA-3’ (left), 5’-GATGCACTTCCTTCTGGAACA-3’ (right).  
The Universal ProbeLibrary Mouse GAPD Gene Assay (Roche) was used as the 
reference gene.  Data were analyzed using the LightCycler 480 software (Roche), and 
relative fold changes in cDNA levels were calculated with the Gapd reference gene as 
normalization using the 2− ΔΔCt method (393).  All data were normalized to total RNA 
extracts from the mouse B cell lymphoma cell line, CH12 (a gift from Dr. Matthew 
Scharff, Albert Einstein College of Medicine, NY).  This cell line was not authenticated.  
CH12 cells were maintained in RPMI 1640 (Lonza) supplemented with 10% fetal bovine 
serum (Cellgro), 50 μmol/L beta-mercaptoethanol (Sigma-Aldrich), 50 units/ml of 
penicillin and streptomycin (Hyclone), and 2 mmol/L L-glutamine (Life Technologies).  
Statistical significance was determined using a Student’s t-test.  
Animal care, tumor injection and drug treatment.  FVBN/Bl6 recipient mice were 
generated as previously described (124, 242).  Mice were maintained in a controlled 
environment receiving food and water ad libitum.  Fresh, ficolled (Ficoll-Paque™ PLUS, 
GE Healthcare) 595 BzS and BzR cells (1 × 106) suspended in 100 μL of serum-free 
RPMI-1640 media were injected into 6 mice per group (3 groups per cell line) via the 
lateral tail vein of age-matched recipient mice.  Mice were weighed and treated by 
intraperitoneal injection twice per week starting 5 days after cell transfer with vehicle (5% 
dextrose in water), Bz (1.2 mg/kg dissolved in 0.9% saline), or panobinostat (10 mg/kg 
suspended in vehicle) until moribund.  Kaplan-Meier curves were generated using 
GraphPad (Prism).  Statistical significance was determined using a Student’s t-test.  
Tumor cell homing was monitored by positron emission tomography (PET) imaging (see 
Supplemental Methods).  All mouse veterinary care, colony maintenance, and PET 
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imaging experiments were carried out in accordance with University of Iowa Institutional 
Animal Care and Use Committee guidelines and approvals. 
FDG-PET imaging.  MicroPET studies were conducted at The University of Iowa Small 
Animal Imaging Core.  Non-fasted mice (n=2 per treatment group) were anesthetized 
with 2.8% (v/v) isoflurane and body weight was recorded.  Blood glucose (95.4 +/- 15.7 
mg/dl) was measured prior to injection of 18F-FDG using a Freestyle glucometer (Abbott 
Labs, Naperville, Il).  A subcutaneous injection of 0.1 ml 0.9% sterile normal saline was 
given to ensure adequate hydration.  18F-FDG (8.4 MBq ± 0.9) or 18F-FLT (8.5 MBq ± 
0.5) was injected via the lateral tail vein.  The mice were allowed to wake and placed in 
individual warmed cages for the 60 min. uptake period.  Anesthetized mice (2.8% 
isoflurane) were then placed prone in a heated multimodality imaging chamber (M2M 
imaging Corp) and positioned in the gantry of the INVEON PET/CT/SPECT 
multimodality animal imaging system (Siemens, Knoxville, TN).  Listmode PET mages 
were acquired for 15 minutes and in the same workflow a microCT image was acquired 
for attenuation correction purposes.  All decay corrected PET images were 
reconstructed using OSEM3D/OP-MAP with scatter correction.  Visualization and SUV 
analysis of datasets were performed using Siemens Inveon Research Workplace 
software version 3.0 and PMOD version 3.3 (PMOD Technologies Ltd, Zurich 
Switzerland). 
Histology.  Tissues (femur, liver, spleen, kidney) were dissected from euthanized, 
moribund mice and fixed in 10% formalin.  Gross examination was performed by M.A.L 
and H.A.F.S. – sections of each tissue were placed in cassettes for routine histologic 
processing.  Bones were decalcified in EDTA prior to processing.  After processing, 
samples were paraffin-embedded and sectioned.  Sections were stained with 
hematoxylin and eosin and scored for evaluation of plasma cell neoplasm by a board-
certified hematopathologist (author – M.A.L). 
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RESULTS 
Bcl-XL/Myc transgenic mouse plasma cell tumor lines show similar significant 
shifts in gene expression upon bortezomib treatment as human myeloma 
 In this study, three representative clonal cell lines isolated from the Bcl-XL/Myc 
double transgenic mouse model of plasma cell malignancy were utilized (124, 242) to 
identify transcriptional responses to bortezomib in Bz-sensitive and -resistant cells in 
vitro.  The 595, 589 and 638 plasma cell lines derived from individual mice showed IC50 
values within a 22-32 nanomolar range to Bz by cell viability assay following 48 hours of 
drug treatment (Supplemental Figure S1A).  Consistent with previous reports (142), Bz 
treatment of these cell lines resulted in programmed cell death as evidenced by caspase 
3 cleavage and annexin V-positive/propidium iodide-negative staining by flow cytometry 
(data not shown).  This cytotoxic profile was similar to two representative, well-described 
Bz-sensitive human myeloma cell lines (HMCLs), MM1.S and U266 (310, 394, 395) 
(Supplemental Figure S1B).  Taken together, these data suggest that, like in human MM, 
the treatment of these mouse cell lines in vitro with Bz induces a cytotoxic response. 
 We next asked whether the transcriptional profile induced over time by exposure 
to Bz was similar across both species.  The three Bz-sensitive (BzS) mouse lines (595 
shown in duplicate as 595.2) were treated with a sublethal 66 nM dose of Bz over a time 
course of 24 hours and analyzed using gene expression profiling (GEP).  This dose was 
chosen because it resulted in less than 20% death at 24 hours (Supplemental Figure 
S1C) but greater than 50% death at 48 hours (data not shown) suggesting that it was an 
optimal concentration for collecting kinetic data within a 24-hour timeframe.  In addition, 
the HMCLs, U266 and MM1.S, were also treated with a sublethal 33 nM dose 
(Supplemental Figure S1D) of Bz (equitoxic to the dose used on the mouse cell lines) 
and analyzed by time course GEP.  The variant transcripts identified from these human 
(genes=1421, variance > 0.1) and mouse (genes=1021, variance > 0.1) time course 
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data shared 132 genes in common, 58% of which also shared a common, kinetic pattern 
of response to Bz across all cell lines analyzed across both species (Figure 1B, 
Supplemental Table S1). 
This transcriptional response was further validated using GEP data from a 
recently published human MMTT3 drug trial by Shaughnessy, et al. where RNA was 
collected from newly-diagnosed MM patients prior to and following a single, 48 hour test 
dose of Bz (390).  Gene set enrichment analysis (GSEA) of the mouse in vitro 
transcriptional response to Bz (24hr vs. 0hr) showed remarkable enrichment (NOM p-
value < 0.05, FDR < 25%) for the Shaughnessy, et al. 80 gene model.  This 80 gene 
model included those genes that were 1) most changed among all patients by the Bz 
treatment at 48 hours and 2) were associated with progression free survival (PFS) of 
which 46 genes were unique and shared a gene symbol with mouse (Supplemental 
Figure S2A) (390).  29 genes were shown to significantly contribute to the enrichment 
between the mouse in vitro and the human in vivo data (Supplemental Figure S2B) 
many of which are known components of the proteasome ubiquitination pathway (390) 
which was found to be enriched in this dataset by Ingenuity Pathway Analysis (IPA).  In 
addition, the kinetic GEP response in both the human and mouse cell lines was enriched 
for downstream targets of the transcription factor NFE2L2 (NRF2) (p < 1 x 10-10, z-score 
> 4, IPA) a transcription factor known to be involved in the oxidative stress response to 
proteasome inhibition (396).  Taken together, these data demonstrate a robust 
transcriptional response to Bz that is conserved not only between mouse and human PC 
malignancies but also within isolated tumor cells in vitro and tumor cells in their native 
microenvironment in human patients.  
Generation of clonally-related bortezomib sensitive and resistant cell line pairs 
 Because the mouse model provides a drug-naïve system with a common strain 
background and the ability to transfer cells back into syngeneic animals with a 
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competent immune system, we chose to further profile the transcriptional response 
associated with Bz-resistance within the tumor cell using this model system.  The three 
BzS mouse cell lines characterized above, were dose-escalated with Bz over 6 months 
to obtain resistant (BzR), clonally-related (data not shown), daughter cell lines with a 2-
fold to 5-fold increase in IC50 in response to Bz (Figure 2A, Table 1).  Doubling rates for 
the pairs of cell lines were similar (data not shown) suggesting that the increased IC50 in 
BzR lines is not due to an increase in cell growth.  To determine whether these BzR 
mouse cell lines were capable of maintaining their Bz-resistance over time, the cells 
were removed from drug selection, and Bz cell viability assays were performed after one 
year.  The BzR lines maintained their resistant phenotype showing virtually identical IC50 
values (data not shown).   
 Others have reported that Bz-resistance is often associated with increases in 
chymotrypsin-like proteasome activity (194, 195, 397).  Indeed, we find that two 
representative BzR cell lines have significantly increased chymotrypsin-like activity while 
trypsin- and caspase-like activity is decreased (Supplemental Figure S3A-B) compared 
to their BzS counterparts.  This observation directly correlated with a similar increase in 
PSMB5 protein expression by Western blotting in the BzR cells (data not shown) in the 
absence of Psmb5 mutations by sequencing (data not shown) suggesting that higher 
baseline proteasome activity (via increased PSMB5 protein expression), not Psmb5 
inactivating mutations, likely contribute to the resistance observed in these BzR lines.  In 
addition, these BzR lines showed cross-resistance to the boronic acid next-generation 
proteasome inhibitor, MLN2238, as well as the epoxyketone next-generation 
proteasome inhibitor, carfilzomib/KYPROLIS®.   While the 595 BzR line also showed 
cross-resistance to the classical aldehyde proteasome inhibitor, MG-132, this line 
showed increased sensitivity to the MM drug, melphalan whereas the 589 BzR line 
maintained sensitivity to these compounds (MG-132, melphalan) (Table 1, Figure 1A).  
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Neither the BzS nor the BzR lines responded to drugs known to be ineffective as single 
agents against MM: vincristine, hydroxyurea and fludarabine (data not shown). These 
data suggest that not only is the resistance observed in the BzR lines specific to Bz and 
its next-generation derivative (MLN2238) and sustained over time but that the resistant 
phenotype may be overcome with other drugs. 
Bz-resistance is associated with changes in transcription that are predictive of 
patient outcomes  
 We were particularly interested in determining the transcriptional differences in 
gene expression between these BzS and BzR cells lines and, thus, examined time 
courses of response by GEP following the same, sublethal Bz treatment in BzR lines 
(Supplemental Figure S1E) as used on their BzS counterparts (Figure 1).  To globally 
visualize these expression patterns, we analyzed the BzR transcriptional response to Bz 
as we had the BzS cell lines described above.   
Firstly, a pair wise comparison of the BzS and BzR baseline gene expression in 
the absence of Bz treatment was performed revealing a 51-gene expression signature 
that statistically distinguished (fold change > 2, p < 0.05, Student’s t-test) sensitive and 
resistant lines (Supplemental Figure S3C).  Of these 51 mouse genes, 23 had human 
homologs.  To test the predictive power of this 23-gene model, we queried the gene 
expression signatures of 210 patients from the MMTT3 human drug trial (390).  
Unsupervised clustering of these patients based on the 23-gene model identified 2 
groups whose progression-free and overall survival were significantly different (log rank 
test) (Figure 2B).  These results suggest that our in vitro mouse model of Bz-resistance 
has predictive value in human MM drug trials which include Bz. 
 To further define the differences in the transcriptional response to Bz in BzS and 
BzR cell lines, we performed a combined analysis of the BzS and BzR Bz transcriptional 
profiles identifying 219 genes that changed significantly in both the sensitive or the 
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resistant group in response to drug  (p < 0.001, |fold change| > 2, pairwise two group t-
test) (Supplemental Table S2).  Examination of heatmap clusters showed that the 
majority of the response to Bz in the sensitive cell lines was conserved in the resistant 
cell lines (Figure 2C, Supplemental Table S2),  illustrating a common programmed 
transcriptional response of cell lines to Bz regardless of their overall sensitivity 
(measured by IC50) to the compound.  However, 29 genes were differentially responsive 
to Bz in vitro between BzS and BzR lines (p < 0.001, |fold change| > 2) (Figure 2D).  
Among these were the upregulation of a cluster of NRF-2 mediated oxidative stress 
response genes: Hspb1, Dnajb1, Hspa1a, Hspa1b, and Ddit3 (a.k.a. CCAAT/Enhancer-
Binding Protein Homologous Protein (CHOP)) (396) which has been observed in other 
Bz sensitive human cell lines (381, 396), suggesting that these may serve as a signature 
of Bz-mediated cell death which is unique to BzS compared to derived BzR cells.  
Using CMAP to identify drugs with high correlation to Bz-associated death by GEP 
Biomarkers that are associated with emerging resistance to Bz and yet may 
define sensitivity to alternative therapies, remain ill-defined (358).  Although we do see a 
common gene signature of response to Bz and have identified similar biomarkers across 
Bz-resistant cell lines compared to their sensitive counterparts, we have also observed 
differences in response to secondary therapies across Bz-resistant cell lines (Table 1).  
Indeed, not all Bz-refractory MM patients respond similarly to secondary therapies.  
Given these differences we aimed to use the individual cell line GEP data described 
above to identify non-PI drugs that could target BzR cell populations using Connectivity 
Map (CMAP, Broad Institute) (391).  The CMAP database contains treatment-induced 
transcriptional signatures from 1,309 bioactive compounds in 4 human cancer cell lines.  
An input signature can be used to query the database for correlated drug signatures.  To 
create these input signatures, gene set enrichment analysis was used to identify in 
individual paired mouse GEPs those genes that were most different in BzS versus BzR 
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lines following drug treatment (24hr vs. 0hr data comparison, |fold change| > 2).  These 
genes were then used to query CMAP to identify drugs that induced expression 
signatures that were similar (positive correlation) or dissimilar (negative correlation) to 
the differential expression response of each BzS lines relative to its BzR line when 
treated with Bz.  We hypothesized that such drugs, particularly those with positive 
correlations to the differential response, may have the potential to kill the BzR lines.   
The CMAP query produced a number of compounds with signatures that were 
predicted as significantly correlated (positive) or anti-correlated (negative) with the 
BzS/BzR differential response (Table 2, Supplemental Table S3).  Broadly, drugs 
promoting inhibition of the proteasome-ubiquitin pathway, NF-κB, HSP90, protein 
synthesis and microtubules showed positive correlation, while drugs that inhibit the cell 
cycle showed negative correlation with the differential responses in all pairs (Table 2, 
Supplemental Table S3).  These predictions were not surprising given the known modes 
of action for Bz (398).   Interestingly, several HDAC inhibitors (HDACis), were 
significantly positively correlated with the differential Bz response in one of the three 
pairs of cell lines, 595 (p < 2 x 10-5) (Table 2, Supplemental Table S3), but were not 
predicted in the other two highlighting some heterogeneity among these cell line pairs.  
In fact, this was the only drug family with consistent drug predictions for each drug 
across the three cell lines queried (Supplemental Table S3).  Since HDACis have been 
reported as having synergistic effects when combined with other MM treatments (398) 
and are currently in clinical trials for refractory MM (399), we chose to evaluate this result 
further.  We hypothesized that the 595 pair of lines would respond differently to HDACi 
treatment than the other pairs of lines based on the CMAP results. 
 Based on the HDACi prediction, three HDAC inhibitors were chosen to test two 
representative pairs of BzS and BzR mouse lines (595 and 589) for in vitro sensitivity.  
The 595 BzR line showed enhanced sensitivity to the HDACis trichostatin A (TSA) and 
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vorinostat (SAHA) (Figure 3A & B, upper panels), which were chosen from the CMAP 
predicted drug list (Supplemental Table S3), as well as panobinostat (Figure 3C, upper 
panel).  This was a cytotoxic response as evidenced by CHOP induction (381, 398, 400) 
(Supplemental Figure S4A).  In contrast, the 589 BzR line (not predicted for enhanced 
sensitivity to HDACis by CMAP) showed cross-resistance to all three HDACi compounds 
compared to the BzS line (Figure 3A-C, lower panels).  This panobinostat-sensitive 
phenotype has been observed in an additional BzR mouse cell line (Bz IC50s: 34 nM 
(BzS) and 63 nM (BzR); panobinostat IC50s: 37 nM (BzS) and 22 nM (BzR)) and 
indicates that CMAP may have the ability to identify differences in secondary drug 
response in these cell line models.   
A subset of Bz-resistant mouse cell lines have greater in vivo sensitivity to HDAC 
inhibitors 
It is well-documented that the myeloma response to some chemotherapeutic 
agents is dependent not only on the stromal microenvironment of the bone marrow (401) 
but on a complete immune system (402) highlighting the utility of our immunocompetent 
mouse model system.  To determine whether the differential in vitro drug responses 
were maintained in vivo, the 595 BzS and BzR cell lines were adoptively transferred 
back into syngeneic recipients.  The untreated BzS mouse phenotype appeared to be 
significantly less severe compared to BzR mice which reached moribundity quickly at a 
median time of 16 days (p = 0.033).   
To better compare the disease burden in these animals, both FDG- and FLT-
positron emission tomography (PET) imaging were used.  FDG-PET imaging of 
representative animals from each group showed that the BzS cells home to the bone 
marrow whereas the BzR cells are dispersed in moribund animals with fewer 
characteristic “hot spots” in the long bones (Figure 4A).  Representative 
histopathological analyses of bone marrows and soft tissues from these animals showed 
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that the malignant PCs were present in the marrows of both animals but were notably 
absent or minimal in the soft tissues of BzS mice (Supplemental Figure S4B).  Those 
BzS and BzR cells that did home to the bone marrow had similar metabolic activity 
(FDG-PET); however, BzS cells had significantly higher rates of proliferation (FLT-PET) 
in vivo even though the BzS and BzR growth rates were similar in vitro (Figure 4B).  
Treatment of BzS and BzR mice with Bz in vivo (n=6 mice per group) showed that BzS 
mice received a significantly greater survival advantage with Bz treatment than their BzR 
counterparts (Figure 4C) whose survival did not differ from BzR vehicle-treated mice 
(data not shown) in agreement with our in vitro data (Figure 2A).  This was directly 
correlated with significantly decreased tumor burden (FDG-PET) in BzS mice treated 
with Bz compared to vehicle (Figure 4D).  These results indicate that myeloma cell 
homing may play a role in Bz sensitivity and that the immunophenotype associated with 
extramedullary homing may be associated with Bz resistance in vivo.     
To specifically determine whether 595 BzR mice receive a survival advantage 
from panobinostat treatment as predicted in vitro, mice were injected with BzR cells and 
treated with either vehicle (n=5) or panobinostat (n=6), and the time to death for each 
group was compared.  Consistent with our in vitro findings (Figure 2A & 3C), 
panobinostat treatment significantly increased the overall survival of BzR mice (Figure 
4E) and decreased the tumor burden (Figure 4F) in these animals.  These in vivo results 
not only confirm our in vitro findings but further suggest that there may be a greater 
benefit from HDAC inhibitor therapy as a salvage therapy in some refractory myelomas. 
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DISCUSSION 
 In this study, we defined the malignant PC response to Bz and characterized 
signatures of Bz-sensitivity and -resistance by GEP using cell lines derived from the Bcl-
XL/Myc double transgenic mouse model.  Although a number of Bz treatment studies 
using HMCLs, primary patient samples, and non-myeloma primary patient samples have 
been reported (390, 394, 403-405), they did not provide a kinetic analysis of Bz-sensitive 
and -resistant cells exposed to Bz over time nor did they explore individual differences in 
Bz-resistance that may contribute to secondary drug efficacy.  In addition, the availability 
of published Bz data has allowed us to validate the Bcl-XL/Myc cell lines’ response to 
drugs in vitro further illustrating their utility as a preclinical tool for asking 
pharmacogenomic questions. 
 Malignant PCs isolated in cell culture from these animals were generally 
sensitive (nanomolar concentrations) to Bz.  In addition, we found evidence of a robust, 
conserved and likely complex response to Bz in our mouse cell lines consistent with 
recent reports (390, 396, 403).  This response was highly conserved in well-
characterized HMCLs and in human patient clinical trial samples.  Perhaps the most 
striking trend was the coordinated upregulation of the majority of the constitutive 
proteasomal subunits in response to Bz treatment in both Bz-sensitive and -resistant cell 
lines which has been previously described (390, 396, 403) further validating our model 
system.   
 The transcriptional response to Bz that we observed in all cells regardless of their 
sensitivity to the drug included the induction of the gene Psmd4 which is part of the 19S 
proteasomal cap complex that selectively targets and binds ubiquitinated substrates for 
degradation by the 20S proteasome and whose amplification has been associated with 
high-risk myeloma (390).  We did not identify higher baseline Psmd4 expression in our 
Bz-resistant cell lines; nor did we identify increases in copy number at the mouse Psmd4 
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locus by array comparative genomic hybridization (mouse 3qF2.1 syntenic to human 
1q21) (data not shown).  Therefore, although 1q21 amplification has been associated 
with a high-risk MM phenotype in patients, our data would suggest variations in Bz 
response may be more complex than Psmd4 expression levels alone.  Interestingly, we 
do observe differences in baseline expression of Eno1 and Cxcr4 in BzR compared to 
BzS cell lines, both of which have been associated with a poor prognostic outcome in 
MM patients (100, 406).  We believe that these data further highlight the utility of this 
system and underscore the need for companion analyses to validate these potential 
biomarkers using clinical samples which we are currently developing. 
 We found it particularly interesting that HDACis were predicted by CMAP in this 
study because Bz is known to downregulate the expression of class I HDACs (162), and 
HDACis have been shown to decrease the 20S chymotryptic activity of the proteasome 
(407), both mediating cell death through the induction of CHOP and NOXA (408).  In 
addition, HDAC6 has been shown to be a key regulator of aggresome activity, an 
alternative pathway for protein degradation in the absence of proteasome activity (409).  
Bz response is correlated to the HDAC inhibitor response in only one of the three pairs 
of mouse cell lines suggesting that 1) we might further identify a small, very specific 
gene signature that is associated with an HDAC inhibitor response in vitro in these 
mouse cell lines and that 2) not all drug resistant myelomas will respond similarly to 
HDACis highlighting some heterogeneity within our in vitro system that is also likely 
present in the Bz-refractory patient population.  Although there is a conserved 
transcriptional response to Bz between these 2 pairs of Bz-sensitive and -resistant cell 
lines, they respond very differently to HDACi compounds suggesting that a more-
favorable response might be achieved with HDACis such as panobinostat or vorinostat 
as a secondary therapy in some, but not all relapsing myelomas.   Indeed, we have 
identified those genes that uniquely predicted the HDACi response in the 595 cell lines 
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(Supplemental Table S4).  Interestingly, these genes were enriched for biosynthetic and 
metabolic pathways (IPA) which we are currently investigating in Bz-resistant disease.  
We did not include a dual treatment (Bz and panobinostat) arm in our in vivo study; 
however, dual treatment of the cell lines in vitro indicates that there is synergy between 
these two compounds (data not shown) which has been shown in another mouse model 
of MM (410).  The mechanism of this synergy may be further informed by these studies.   
 Although CMAP produced additional predictions to other classes of drugs, the 
true predictive power of this approach remains unclear.  For example, alkylating agents 
were predicted by CMAP but did not include melphalan for which we have observed 
differential response between our Bz-resistant cell lines.  In fact, HDACis were the only 
drug family that had a consistent prediction pattern across all three cell line pairs for all 
drugs predicted.  This suggests that perhaps the most viable secondary drug candidates 
will be those with consistent predictions.  It remains to be seen if there are similar 
predictions of response in subsets of patients receiving Bz/panobinostat combination 
therapy; however, our data suggest that refinement of this model may be effective for 
predicting these cases in advance.  
 With the initial success of combination Bz and HDACi treatments for refractory 
patients in the clinic (163) and our indication of differential response to HDACis in vitro 
and in vivo, our model system provides additional opportunities to characterize 
sensitivity and resistance to HDACis in vitro and in vivo.  It is apparent that the approach 
taken in this study identifies a novel use for gene expression profiling in the repurposing 
of drugs as secondary therapies in myeloma.  The prediction of HDACis as a secondary 
therapy here suggests that a panobinostat response profile of emerging resistance might 
be further elucidated that could provide preclinical support for personalized medicine 
approaches in MM. 
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Table 1.  Drug IC50
a table for Bz-sensitive (BzS) and Bz-resistant (BzR) mouse  
 
lines.  
 
 
Drug 
595
BzS 
595 
BzR 
Fold 
Δb 
589
BzS 
589
BzR 
Fold 
Δb 
638 
BzS 
638 
BzR 
Fold 
Δb 
Bortezomib, nM 23 112 4.9 22 96 4.4 36 102 2.8 
MLN2238, nM 28 154 5.5 39 180 4.6 N/A N/A N/A 
Carfilzomib, nM 28 71 2.5 41 77 1.9 N/A N/A N/A 
MG-132, nM 42 95 2.3 80 85 1.1 N/A N/A N/A 
Melphalan, μM 240 50 0.2 80 100 1.3 N/A N/A N/A 
 
aIC50 calculations were determined by a sigmoidal dose-response equation in triplicate 
over multiple experiments.  
bFold change (Δ) is representative of the BzR line normalized to its BzS control.
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Table 2.  Families of drugs with expression patterns significantly correlated to the 
Bz response in mouse lines using CMAP.   
 
Drug Family Predictiona 
 595sp
b 638bm 589bm 
Proteasome inhibitors and UPS modulators + + + 
NF-κB inhibitors  + + + 
Alkylating Agents + + + 
HSP90 inhibitors + + + 
Protein synthesis inhibitors + + + 
Microtubule inhibitors + + + 
CDK/TopoI/TopoII/Cell cycle inhibitors – – – 
HDAC inhibitors + np np 
 
 
aSignificant predictions (p < 0.05) were made for each of the mouse line pairs 
individually.  A positive prediction indicates that the drug family induces a similar 
expression signature to the BzS signature. A negative prediction indicates that the drug 
family induces an opposite expression signature to the BzS signature.  An “np” indicates 
that no drug prediction was made.   
b595 is a combination of the 595 and 595.2 datasets. 
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Figure 1. Identification of Bz-responsive genes by gene expression profiling.  A) 
Chemical structures of the proteasome inhibitors bortezomib (Bz), MLN2238, and 
carfilzomib (Cz) and the alkylating agent, melphalan.  B) Heat map of Bz-responsive 
genes common to mouse and human plasma cell malignancy in vitro using 3 BzS mouse 
lines (595 in duplicate as 595.2) treated with 66 nM Bz and 2 HMCLs treated with 33 nM 
Bz. Mouse cells were collected at 0, 2, 8, 16 and 24 hours and human cells at 0, 16 and 
24 hours after Bz treatment.  Columns represent time points and rows represent genes.  
Columns are ordered firstly by cell line and secondly by ascending time; genes are 
ordered by hierarchical cluster analysis.  Color indicates fold change which was 
determined for each gene by comparing the average of the 16 and 24 hour time points to 
the 0 hour time point in each time course.  A full gene list has been provided in 
Supplemental Table S1. 
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Figure 2.  Kinetic similarities and differences in Bz response in BzS and BzR 
mouse lines.  A) Kill curve analysis of 3 representative pairs of Bz-sensitive and -
resistant mouse cell lines (595, left panel; 589, middle panel; 638, right panel).  Cell 
viability data were collected over a range of 0-128 nM Bz.  Open squares represent Bz-
sensitive (BzS) lines and filled squares represent Bz-resistant (BzR) lines.  All data 
points shown were normalized to untreated controls.  Error bars, which are shown but 
are smaller than the data symbols, represent the standard deviation of triplicate reads 
over each experiment.  B) Kaplan-Meier curves showing significant differences in event-
free (EFS, left) and overall (OS, right) survival in patients from the MMTT3 drug trial 
clustered based on the expression of the genes that most distinguished mouse BzS and 
BzR cell lines (Supplemental Figure S3C).  Heat maps of C) Bz-responsive genes 
across the 3 BzS mouse lines and their BzR counterparts (595 in duplicate) treated with 
66 nM Bz and collected at 0, 2, 8, 16 and 24 hours after treatment highlighting D) those 
genes whose responses are most significantly different between BzS and BzR lines.  
Columns represent time points and rows represent the genes.  Columns are ordered 
firstly by sensitivity and secondly by sample; genes are ordered by hierarchical cluster 
analysis.  Colors indicate fold change which was determined for each gene by 
comparing the average of the 16 and 24 hour time points to the 0 hour time.  A full gene 
list for part B has been provided in Supplemental Table S2. 
 72 
 
 
 
 
 
 
 
 
 
 
 
 73 
 
Figure 3.  Mouse cell lines respond differently to HDAC inhibitors.  A-C) Kill curve 
analysis of 2 representative pairs of BzS and BzR mouse cell lines (595, top panels; 
589, bottom panels).  Cell viability data were collected over a range of A) 0-100 nM 
trichostatin A, B) 0-4 µM vorinostat, or C) 0-128 nM panobinostat.  Open squares 
represent BzS lines and filled squares represent BzR lines.  All data points shown were 
normalized to untreated controls.  Error bars, which are shown but are smaller than the 
data symbols, represent the standard deviation of triplicate reads over each experiment.  
Drug structures are shown below corresponding kill curves. 
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Figure 4.  Bz-resistant cells respond favorably to panobinostat in vivo.  A) 
Representative FDG-PET imaging of untreated 595 BzS and BzR cell-injected FVBN/Bl6 
syngeneic mice (one mouse shown from each group).  Red arrows indicate tumor 
“hotspots”.  B) Quantification of FDG- (blue) and FLT-PET (red) imaging of untreated 
BzS and BzR mice (n=2 per group (4 tissue sites scored from each), * p < 0.05).  C) 
Kaplan-Meier curve of BzS (black) and BzR (red) cell-injected mice treated with Bz.  
Statistical significance was determined using a one-tailed Student’s t-test.  D) 
Quantification of FDG-PET-imaged BzS mice treated with either vehicle (left, white bar) 
or Bz (right, gray bar) (n=2 per group (4 tissue sites scored from each), *** p < 0.0005).  
E) Kaplan-Meier curve of BzR cell-injected mice treated with vehicle (n=5, black) or 
panobinostat (n=6, blue) until death.  Statistical significance of both Kaplan-Meier curves 
was determined using a one-tailed Student’s t-test.  F) Quantification of FDG-PET-
imaged BzR mice treated with either vehicle (left, white bar) or panobinostat (right, gray 
bar) (n=2 per group (4 tissue sites scored from each), * p < 0.05). Statistical significance 
of all PET imaging was determined using a two-tailed, nonparametric Mann-Whitney test 
(95% CI).     
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Supplemental Figure S1.  Mouse and human plasma cell lines respond to Bz in 
vitro.  Kill curve analysis of A) 3 representative Bz-sensitive mouse cell lines (595, 589 
and 638, left panel) and B) 2 human myeloma cell lines (U266 and MM1.S, right panel).  
Cell viability data were collected 48 hours post-treatment over a range of 0-128 nM Bz.  
All data points shown were normalized to untreated controls.  Error bars, which are 
shown but are smaller than the data symbols, represent the standard deviation of 
triplicate reads over each experiment.  Viable cell percentages in C) 2 representative 
BzS mouse cell lines following 24 hours of 66 nM bortezomib treatment, D) 2 
representative, HMCLs following 24 hours of 33 nM bortezomib treatment, and E) 2 
representative BzR mouse cell lines following 24 hours of 66 nM bortezomib treatment.  
Viable percentages are indicated (filled bars) relative to an untreated control (open bars) 
by trypan blue exclusion using a hemacytometer in triplicate. 
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Supplemental Figure S2.  Gene Set Enrichment Analysis (GSEA) shows 
enrichment between mouse in vitro and human in vivo data.  A) Enrichment plot 
comparing the transcriptional response of the BzS cell lines in vitro with 66 nM Bz (24hr 
vs. 0hr) to the Shaughnessy, et al. 80 gene model patient data.  The dashed line 
represents the enrichment score, and the filled arrow represents the leading edge genes 
contributing to this enrichment.  B) Heatmap illustrating the kinetic response of the 29 
leading edge genes over the course of 24 hour 66 nM Bz treatment in 3 BzS cell lines 
(595 in duplicate shown as 595.2).  Mouse cells were collected at 0, 2, 8, 16 and 24 
hours.  Columns represent time points and rows represent genes.  Columns are ordered 
firstly by cell line and secondly by ascending time; genes are ordered by hierarchical 
cluster analysis.  Color indicates fold change which was determined for each gene and 
time point by comparing to the 0 hour time point. 
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Supplemental Figure S3.  Baseline differences in BzS and BzR cells in the 
absence of drug.  Proteasome activity assay of A) 595 and B) 589 BzS and BzR mouse 
cell lines in the absence of Bz.  Open bars represent BzS lines and filled bars represent 
BzR lines for chymotrypsin-, trypsin- and caspase-like assays.  All data points shown 
were normalized to their representative BzS line.  Error bars represent the standard 
deviation of triplicate reads over each experiment, and statistical significance was 
determined using a two-tailed Student’s t-test (** p < 0.005; *** p < 0.0005).  C) Heat 
map of the 51 genes that differ significantly (p < 0.05, |fold change| > 2) in BzR cell lines 
(right) normalized to their BzS counterparts (left) in the absence of drug selection.  
Columns represent cell lines; rows represent the genes which are ordered by 
hierarchical cluster analysis.  Genes in bold where those with a human homolog.   
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Supplemental Figure S4.  The analysis of BzS and BzR properties in vitro and in 
vivo.  Quantitative RT-PCR of Ddit (CHOP) expression prior to (“-”) or following (“+”) 66 
nM Bz (top panel) or 55 nM panobinostat (bottom panel) treatment for 24 hours.  Open 
bars represent BzS lines and filled bars represent BzR lines.  All data points shown were 
normalized to an untreated control mouse B cell lymphoma cell line, CH12 (not shown).  
Error bars represent the standard deviation of triplicate reads over each experiment, and 
statistical significance was determined using a two-tailed Student’s t-test (* p < 0.05; ** p 
< 0.005; *** p < 0.0005).  B) Representative hematoxylin and eosin stained bone marrow 
(50X with oil), liver (20X), spleen (50X with oil) and kidney (20X) sections from moribund 
595 BzS (top panels) and BzR (bottom panels) cell-injected animals receiving vehicle 
treatment showing the presence or absence of malignant plasma cell infiltrates.  
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Supplemental Table S1. Significant Bz-responsive genes common to human and  
 
mouse corresponding to Figure 1B.  
 
Gene Symbol 
CD9 
SLC7A7 
ANKRD37 
FOS 
LDLR 
AHNAK 
IFI27 
HVCN1 
SELPLG 
ACSS1 
DBI 
FAIM3 
ITGB5 
SIDT2 
PON2 
EBPL 
MKI67 
NUP210 
CCND1 
KLF13 
PAFAH1B3 
GALK1 
LDHA 
CYSLTR1 
DHCR7 
CD47 
ICAM2 
ATP2A3 
OXCT1 
CST3 
CYBASC3 
GLT25D1 
SLC35B2 
GUSB 
TFRC 
SLC5A6 
TMEM109 
SLC19A1 
STT3A 
SLC29A1 
UNC93B1 
CD52 
COQ2 
IDH2 
RASSF4 
MFNG 
EVL 
CALM2 
STMN1 
PRPS2 
PLAC8 
MAT2A 
PDXP 
SFRS7 
SRM 
CXCR4 
TAP1 
TLR7 
TMEM51 
ALDH18A1 
CSTB 
STARD5 
TUBB2B 
DDIT4 
JUN 
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P4HA2 
BLVRB 
BSCL2 
MAFG 
ATF4 
HSP90AA1 
HSPA8 
DNAJB1 
HSPA1B 
GADD45A 
DEDD2 
DDIT3 
BAG3 
ZFAND2A 
DNAJB2 
RNF181 
GABARAPL1 
TBC1D15 
PSMC4 
ATF5 
IER3 
NPLOC4 
ADRM1 
PSMC3 
PSMD4 
SQSTM1 
GCLM 
PSMD1 
PSMC5 
STK40 
TTC1 
YPEL5 
HSPA1A 
MLLT11 
MVP 
HSPB1 
UCHL1 
ATF3 
CEBPB 
TSC22D3 
SARS 
TRIB3 
CYB5R1 
SESN2 
STIP1 
EIF4EBP1 
SNX10 
GADD45G 
KLF6 
VIM 
PSAT1 
PSMD14 
ST13 
SGK1 
VPS37B 
EMP3 
CBR3 
KLF2 
SLC2A3 
SLC38A2 
RHBDL2 
S100A10 
NDRG1 
PIK3IP1 
DUSP1 
TOB1 
STC2 
 
 
 
 
 87 
 
 
Supplemental Table S2. Significant Bz-responsive genes corresponding to Figure  
 
2C.  
 
Gene Symbol 
Maged1 
Nploc4 
Mlkl 
Vcp 
Zwint 
Gclm 
Psmd12 
Tax1bp1 
Wdr1 
Ier3 
Pdlim7 
Bach1 
Sod1 
Psmc2 
Atp6v1h 
Psmd4 
Hspb6 
2500002L14Rik 
Mad2l1bp 
Oraov1 
Ttc1 
8430410K20Rik 
scl0002315.1_12 
Ufd1l 
Whdc1 
Ccdc77 
Dnajb2 
Slc25a38 
Gch1 
Mocs1 
Rnf181 
2310004I24Rik 
2310004N11Rik 
Nars 
Napb 
Cdr2 
Dnajb1 
Stip1 
Hspa8 
Chordc1 
Hsp105 
Rnu6 
Prmt2 
4930504E06Rik 
Mvp 
Tbc1d15 
2310005E10Rik 
LOC100047261 
Mns1 
Dedd2 
Zyx 
Bag3 
Gadd45a 
C130022K22Rik 
Hspa1a 
Hspa1b 
Cebpb 
1500012F01Rik 
2410006H16Rik 
Stx5a 
Ddit3 
Ypel5 
Zfand3 
Gtpbp2 
LOC100045005 
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4932441N08Rik 
Angptl6 
Soat2 
1110038B12Rik 
E430031D18Rik 
LOC100041797 
2310005L22Rik 
2810026P18Rik 
Csprs 
Mib2 
Slc6a9 
4930431B09Rik 
Rassf1 
Atf3 
Myd116 
Lpxn 
Ypel3 
Tubb6 
Hsp90aa1 
LOC100048105 
Ubg 
Fos 
mtDNA_ND2 
mtDNA_ND4L 
mt-Nd4l 
LOC381365 
Idh2 
LOC100044779 
LOC207685 
Plac8 
LOC245892 
LOC329750 
Bhlhb8 
Dbp 
Pdk1 
Ak3l1 
Fam162a 
IGLC2_J00595_Ig_la
mbda_constant_2_14 
Bcl11a 
LOC386520 
Psg23 
Slc15a3 
Retsat 
3110056O03Rik 
Car12 
H2-DMa 
Crlf1 
Ltbp4 
Cercam 
Gm2a 
Cyp51 
Nrm 
Cnp 
Selpl 
Selplg 
Atp2a3 
Pld4 
Elovl6 
9130415E20Rik 
Cd47 
Scd1 
Prodh 
Scd2 
Cd22 
Plxnb2 
Abcd1 
Cd93 
Fcrla 
Oxct1 
Kcnn4 
Napsa 
Hvcn1 
Ptprcap 
Ifi30 
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LOC100047579 
Cd72 
Ahnak 
Cst3 
LOC669658 
Tnni2 
Ly6e 
LOC100047815 
Ng23 
1700052O22Rik 
LOC100044948 
Ifi27 
Slc35b2 
1110001J03Rik 
Grcc10 
Clec2d 
Tmem109 
Camkv 
Glt25d1 
Gusb 
Tfrc 
Slpi 
Mpeg1 
Phtf2 
Cybasc3 
LOC100045882 
Gcs1 
Slc5a6 
H2-Aa 
Nola3 
Coq2 
Gcat 
Vpreb3 
9630015D15Rik 
Eno3 
2210411K11Rik 
Arhgdig 
Cd3g 
Nudt19 
Aars 
Chac1 
Trib3 
Atf5 
Nupr1 
Hspb1 
Cd151 
Impact 
Uchl1 
Mllt11 
Casp1 
Psmc4 
Psmc5 
EG432448 
Psmd1 
Psmc3 
Adrm1 
Trafd1 
Zfand2a 
Rit1 
Gabarapl1 
Sqstm1 
Ankrd37 
Mist1 
LOC100044439 
B930041F14Rik 
H2afx 
Rsph1 
1600014C23Rik 
Hist1h2bf 
Rgs16 
Hist2h2aa1 
Hist2h2aa2 
2310039H08Rik 
Macrod1 
Slc7a3 
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BC028528 
LOC630729 
Atf4 
Glipr1 
Stk40 
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Supplemental Table S3. Individual drug predictions by CMAP analysis. 
 
   Correlation
c 
Drug Familya Drug Degreeb 595 638 589 
Proteasome inhibitors 
and UPS modulators 
disulfiram ++ + + + 
 MG-262 +++ np + + 
 mometasone ++ np + + 
NFκB inhibitors  15-delta prostaglandin J2 ++ + + + 
 thiostrepton ++ + + np 
 parthenolide ++ + + np 
 withaferin A ++ + + + 
HSP90 inhibitors geldanamycin ++ + + np 
 alvespimycin ++ + np + 
 monorden + + np + 
 tanespimycin + + np np 
Protein synthesis 
inhibitors 
puromycin +++ + + + 
 anisomycin +++ np + + 
 emetine ++ np + + 
 cephaeline +++ np + + 
 cicloheximide ++ + + + 
CDK/TopoI/TopoII/Cell 
cycle inhibitors 
doxorubicin – – – np - - 
 resveratrol ++ + np np 
 camptothecin – – – np - np 
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 ellipticine – – np - np 
 etoposide – – np - np 
 mitoxantrone – – np - np 
 harmine – – np np - 
 luteolin – – np np - 
 staurosporine – np np - 
Sodium/calcium 
modulators and calcium 
channel blockers 
tetrandrine + + + + 
 gossypol ++ + + + 
 econazole ++ + + np 
 perhexiline ++ + + np 
 clomifene ++ + + np 
 bepridil ++ + + np 
 felodipine + np + + 
 nitrendipine – – - np np 
 cyproheptadine ++ + np np 
Na+/K+ - ATPase 
membrane pump 
inhibitors 
helveticoside ++ np + + 
 lanatoside C ++ np + + 
 digoxin ++ np + + 
 digitoxigenin ++ np + + 
 digoxigenin + np np + 
 strophanthidin + np np + 
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 ouabain + np np + 
Antihistamines and 
Anticholinergics 
terfenadine +++ + + + 
 astemizole ++ + + np 
 proadifen ++ + np + 
 spiperone ++ np + + 
 atropine – – np np - 
 mefloquine ++ + np + 
 clemastine ++ np + np 
Microtubule inhibitors mebendazole  ++ + + np 
 nocodazole ++ + np + 
 fenbendazole ++ + + np 
Alkylating agents semustine ++ + + + 
 lomustine ++ + + np 
PI3K inhibitors LY-294002 ++ + np np 
HDAC inhibitors trichostatin A ++ + np np 
 vorinostat ++ + np np 
 rifabutin ++ + np np 
 scriptaid ++ + np np 
 valproic acid ++ + np np 
Antipsychotics thioridazine ++ + + np 
 prochlorperazine ++ + + np 
 pimozide ++ + + np 
 fluphenazine ++ + + np 
 Metergoline ++ + np np 
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 chlorcyclizine + + + np 
 trifluoperazine ++ + + np 
 metixene ++ np np + 
 cloperastine ++ + np np 
 perphenazine ++ + np np 
 thioproperazine ++ + np np 
Antidepressants desipramine ++ + + np 
 doxepin ++ + np np 
 norcyclobenzaprine ++ + np np 
 imipramine ++ + np np 
Antivirals mycophenolic acid – – np - - 
 methotrexate – np - np 
 
aDrugs families determined from previous literature (411). 
bIndicates the degree to which a drug is positively or negatively correlated (by correlation 
score output from CMAP) calculated as the average correlation score across the 3 lines 
where: |0-0.33| = +/-; |0.34-0.66| = ++/--; |0.67-1| = +++/---. 
cOutput given by CMAP indicating the relatedness of the input profile to the database 
profile where “–“ is a strong opposite response and “+” is a strong similar response by 
gene expression profiling.  “np” indicates that no prediction was made for this drug in this 
cell line.  Prediction are significant with a p < 0.05. 
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Supplemental Table 4. Genes driving HDACi predictionsa by CMAP in mouse cell 
lines.
Genes Symbol 
ANP32A 
NCBP2 
PWP1 
CTCF 
CTPS 
CAD 
TMPO 
COIL 
RCC1 
IFRD2 
COQ7 
MCM7 
SUV39H1 
TTC27 
MRTO4 
PEX14 
MBD3 
DCTD 
USP1 
UMPS 
DTYMK 
STC2 
PDCD2 
GEMIN4 
PPP1R8 
UCK2 
LMNB2 
USP16 
NIP7 
POLR3B 
TSEN2 
SETD6 
IPP 
PPAN 
PSAP 
CKB 
ENO2 
EMP1 
MVP 
TAP1 
TRAFD1 
GMPR 
RAB11FIP5 
LMNA 
GNS 
GM2A 
RNASE4 
SLC2A14 /// 
SLC2A3 
NAGK 
ABCA7 
PLEKHO2 
STK17B 
  
aGenes shown were common to the trichostatin A and vorinostat predictions uniquely in 
the 595 cell line made available through the CMAP portal.
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ABSTRACT 
Bortezomib/VELCADE® (Bz) is a proteasome inhibitor that has been used successfully 
in the treatment of multiple myeloma (MM) patients.  However, acquired resistance to Bz 
is an emerging problem.  Thus, there is a need for novel therapeutic combinations that 
enhance Bz sensitivity or re-sensitize Bz resistant MM cells to Bz. The Connectivity Map 
(CMAP; Broad Institute) database contains treatment-induced transcriptional signatures 
from 1,309 bioactive compounds in 4 human cancer cell lines.  An input signature can be 
used to query the database for correlated drug signatures, a technique that has been 
used previously to identify drugs that combat chemoresistance in cancer.  In this study 
we used in silico bioinformatics screening as well as a high-throughput drug screening 
assay system to compare pairs of isogenic Bz sensitive and resistant mouse cell lines 
derived from the iMycCα/Bcl-xL mouse model of plasma cell malignancy, to identify 
compounds that combat Bz resistance.  The intersection of these two approaches 
provided evidence that topoisomerase inhibitors may in fact target Bz-resistant MM cells 
and re-sensitize them to Bz.  Indeed, we found that multiple topoisomerase inhibitors 
were significantly more active against Bz-resistant than Bz-sensitive cells as single 
agents and restored sensitivity to Bz when combined with Bz as a cocktail regimen. This 
work demonstrates the potential synergy of these approaches for identifying novel 
therapeutic combinations that may overcome Bz resistance in MM.  Furthermore, it 
identifies topoisomerase inhibitors, drugs that are already approved for clinical use, as 
agents that may have utility in combating Bz resistance in refractory MM patients. 
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INTRODUCTION 
  Bortezomib/VELCADE® (Bz) is a proteasome inhibitor (PI) that has been used 
successfully in the treatment of the malignant plasma cell malignancy, multiple myeloma 
(MM).  Despite the recent success of Bz therapy, MM is still incurable due in part to the 
emergence of Bz-resistant cells in the majority of patients, which likely contributes to the 
fact that only 41% of patients survive past 5 years (67).  Bz is often used in combination 
with other drugs to target and kill malignant plasma cells in patients (412); however, the 
pool of therapeutic options available for cocktail regimens remains limited.  Thus, there 
is a need for novel therapeutic combinations that enhance Bz sensitivity and/or target 
Bz-resistant MM cells to maximize the efficacy of the combination therapy approach.  
  The Connectivity Map (CMAP; Broad Institute) database provides an in silico 
platform for drug discovery (391, 413) that has been previously used to identify cancer 
salvage therapies (392).  This database contains treatment-induced transcriptional 
signatures from 1,309 bioactive compounds in 4 human cancer cell lines.  An input 
signature can be used to query the database for correlated or anti-correlated drug 
signatures.  A correlated (+) connectivity score indicates pathways that are likely 
targeted by the drug of interest used to create the input signature, whereas an anti-
correlated (-) score could have two interpretations: 1) this could indicate simply that this 
pathway is inversely regulated by the drug of interest or 2) this could be interpreted as a 
difference in pathway regulation between two disease states if a paired transcriptional 
analysis was used to crease the input signature.  Although early studies explored 
primarily the predictive value of correlated signatures (392, 414), a recent push has been 
made to decipher the value of anti-correlated drug predictions (415, 416). 
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  Recent analysis of the differential transcriptional response in isogenic pairs of Bz-
sensitive and derived Bz-resistant mouse cell lines showed that treatment of the Bz-
sensitive line correlated with genes expression profiles (GEPs) of drugs that target the 
proteasome, NF-κB, HSP90 and microtubules, as indicated by positive connectivity 
scores using the CMAP approach (Chapter 3, Table 2).  Defining the mechanism of 
action for a drug is a well-described function of this in silico approach (417) and here 
displays a proof-of-principle.  However eight compounds, all classified as topoisomerase 
(Topo) I and/or II inhibitors, were negatively correlated to the same input signatures by 
CMAP analysis (Chapter 3, Supplemental Table 3) (418).  Because the input signature, 
in this case, was a comparison of the response to Bz in Bz-sensitive versus resistant 
cells lines, the negative connectivity score here could be interpreted as 1) an 
upregulation of Topos by Bz treatment in Bz sensitive lines, which has been previously 
reported (419) or 2) as an inhibition of Topos in Bz resistant cells upon Bz treatment.  
  In this study we investigate whether Topo inhibitors, as negatively predicted 
drugs by the CMAP approach, may be viable candidates for secondary therapy in Bz-
resistant MM.  By merging in silico CMAP data with a high throughput drug screening 
(HTS) assay system, we identify that Topo inhibitors may synergize with Bz for greater 
killing of Bz-resistant cells.  In addition, a new compound was identified through the high-
throughput drug screening approach that is highly effective at killing Bz-resistant cells.  
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MATERIALS AND METHODS 
Mouse and human plasma cell lines.  The mouse cell line pairs 595 and 589 were 
cultured in CST media as previously described (418).  The human myeloma cell lines 
MM1.S and U266 (obtained from ATCC) and their BzR counterparts were maintained in 
HMCL media: RPMI 1640 (Lonza) supplemented with 15% fetal bovine serum (Cellgro), 
50 μmol/L beta-mercaptoethanol (Sigma-Aldrich), 50 units/ml of penicillin and 
streptomycin (Hyclone), and 2 mmol/L L-glutamine (Life Technologies). 
Drugs and treatment conditions.  Bortezomib (Bz) (Millennium Pharmaceuticals) was 
dissolved in serum-free RPMI-1640 (Lonza) and stored at -80C.  MLN2238 (Millennium 
Pharmaceuticals), carfilzomib (Onyx Pharmaceuticals), camptothecin (CPT), CPT-11, 
topotecan and teniposide (all from Selleck Chemicals) were dissolved in dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich); all drugs were stored at -20C. 
  Bortezomib resistant (BzR) MM1.S and U266 cells were generated by dose 
escalation of Bz over 4 months by once weekly treatment with Bz starting at 5 nM; the 
Bz concentration was increased by 5 nM every 2 weeks for the MM1.S line and every 4 
weeks for the U266 line. 
Cell viability assay.  Cells were seeded at a concentration of 4x105 cells per mL.  After 
24 hours the cells were treated with the indicated concentrations of drug(s) for 48 hours.   
Cell viability was measured by CellTiter-Glo® Luminescent cell viability assay according 
to manufacturer’s instructions (Promega) using the Synergy 2 Microplate Reader 
(Biotek).  Values were normalized to untreated controls and IC50 values were estimated 
by calculating the nonlinear regression using the sigmoidal dose-response equation 
(variable slope) in GraphPad (Prism).  Drug synergy was determined by calculating the 
combination index (CI) value for each drug combination using Chou-Talalay 
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methodology which has been previously described (420).  The dose reduction index 
(DRI) was calculated using Compusyn software (ComboSyn, Inc.).     
Flow cytometric analysis.  To detect intracellular cleaved caspase 3, BzS and BzR 
cells were treated with either 0-100 nM Bz or media for 48 Bz.  The cells were then fixed 
using the Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosciences), blocked in 
buffer containing 30% FBS, 0.1% Saponin and 20 mM HEPES, and stained using an 
anti-caspase 3 antibody (BD Pharmingen).  Samples were analyzed using an EPICS 
Elite (Beckman Coulter) and are presented as relative to the media-treated controls. 
High-throughput drug screening assay.  Screening was conducted using the NCI 
Diversity Set II small molecule chemical library of ~1500 compounds that were selected 
for their broad structural diversity and drug-like properties.  One pair (595) of isogenic 
BzS and BzR mouse cell lines was used to query this library.  Cells were seeded at a 
density of 3x104 cells per well of a 96-well plate.  Compounds were screened at 5 μM 
final concentration for a duration of 48 hours, after which cell viability was measured 
using CellTiter-Glo® Luminescent cell viability assay according to manufacturer’s 
instructions (Promega).  Three groups were incorporated into the screening: (1) BzS 
cells were treated with single-agent Diversity Set compounds to identify compounds with 
general anti-MM activity; (2) BzR cells were treated with single-agent Diversity Set 
compounds to identify compounds with greater activity in BzR cells than in the BzS cells; 
(3) BzR cells were treated with a combination of Diversity Set compounds in the 
presence of 25 nM Bz to identify compounds that re-sensitize resistant cells to Bz.  Bz 
was added to one of the blank wells as an internal standard on each plate.  For analysis, 
the luminescent signal from the untreated 4 corner wells of each plate were averaged 
and set as 100%. All other viability scores were reported relative to these controls. 
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Positive hits were verified in follow-up cell viability assays that were performed using 
triplicate wells.  The false positive rate for the screening was ~25%. 
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RESULTS 
  Based on previously reported CMAP data (418), we queried an isogenic pair of 
mouse Bz-sensitive (BzS) and -resistant (BzR) cell lines against the NCI Diversity Set II 
small molecule library (421) to identify drugs with overlapping sensitivity profiles using 
both in silico and screening approaches.  We hypothesized that common drug “hits” 
would be highly effective in combination with Bz for the treatment of Bz refractory 
disease.  The BzS cells were tested against the single-agent drug library and the BzR 
cell lines were tested under two conditions, 1) against the single-agent library and 2) 
against the library in the presence of 25 nM Bz (the concentration at which only 
approximately 10% of these cells are killed after 48 hours of exposure as evidence by 
caspase-3 cleavage (Figure 1)). 
  Drug library screening provided multiple compounds of interest that had varied 
patterns of efficacy.  While some drugs showed equal sensitivity across all tests 
suggesting no synergy with Bz, still others showed only synergy with Bz or even 
antagonism despite superb single-agent activity in BzS and BzR cell lines.  However, we 
were most interested in those drugs that showed increased sensitivity in the BzR cell 
lines and synergy with Bz (Figure 2A).  Interestingly, three of the top four drug library 
candidate drugs for potential BzR salvage were Topo inhibitors.  Camptothecin (CPT) 
and teniposide both displayed patterns of increased sensitivity in the BzR cell line and 
synergy in combination with Bz (Figure 2B).  Given that CMAP also predicted Topo 
inhibitors through anti-correlated gene expression signatures in this mouse model 
system of Bz-resistance (Chapter 3, Supplemental Table 3) (418), we chose to evaluate 
Topo inhibitors for efficacy in refractory MM further. 
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  Two representative and previously-described pairs of BzS and BzR isogenic 
mouse cell lines (Chapter 3) (418) were used to determine IC50 values for each of four 
clinically-relevant Topo inhibitors: CPT, CPT-11, topotecan, and teniposide.  Three of the 
four Topo inhibitors tested had consistently greater single-agent efficacy in the BzR cell 
lines than their BzS counterparts (Table 1) even though the rates of growth between cell 
line pairs were similar (data not shown).  Only CPT-11 did not share this pattern having 
greater efficacy in the 595 but not the 589 BzR cell line (Table 1).  Two agent kill curves 
were then performed to identify the most synergist combinations of Topo inhibitors and 
proteasome inhibitors.   
  For each drug duo (PI + Topo inhibitor) five concentrations of each drug were 
used.  Each concentration combination was plated in a separate cell culture well creating 
a 25-well grid which included the range of single-agent wells for each drug and all two-
agent combinations.  Cell viability for each well was determined after 48 hours of drug 
treatment, and these data were used to calculate the faction of affected (Fa) cells at 
each single-agent and combination treatment.  To assess drug synergy, Chou-Talalay 
plots (420) were created using these Fa values for each PI (Bz, carfilzomib or MLN2238) 
combined with each of the four Topo inhibitors (CPT, CPT-11, Topotecan, or teniposide).  
This analysis provides a metric of drug synergy termed the combination index (CI) score 
where a CI of < 1 is considered synergistic and a CI > 1 is considered antagonistic (420).  
Interestingly, although the BzR cell lines display general cross-resistance to the next-
generation PIs, MLN228 and carfilzomib/KYPROLIS®, all three PIs showed synergy with 
the Topo II inhibitor, teniposide in these cell lines (Figure 2C).  This is illustrated by CI 
values that are less than 1 through much of each dataset (Figure 2C). 
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  Using these CI values together with the single-agent data, we were further able 
to extrapolate whether, due to synergy, the dosage of PIs may be reduced in the 
presence of teniposide for optimal killing.  This dose reduction index (DRI) is calculated 
using the fixed IC50 concentration of the PI inhibitors (Bz, carfilzomib, or MLN2238) over 
the range of teniposide concentrations (422).  We find, in some cases, that PI IC50 
concentrations (Table 2) may be reduced as much as 95% in the presence of teniposide 
to achieve an Fa=0.5 (i.e. 50% death) (Table 2).  Validation of this dose reduction index 
(DRI) for the most synergist combination concentrations are currently underway as are 
the companion drug synergy studies using Bz-sensitive and derived Bz-resistant human 
myeloma cell lines.  Activity assays will also be required to further define the 
mechanism(s) behind this synergy.  Finally, in vivo experiments will be used to validate 
this response and explore the translational applicability of this approach. 
 In addition to well-described drugs, the Diversity Set II drug library also contains 
multiple compounds whose functions are currently unknown.  Interestingly, one of these 
compounds showed modest yet significant single agent activity in the mouse Bz-
resistant cell line and potent synergy when combined with Bz.  These results were 
confirmed using additional Bz-resistant mouse (589) and human (MM1.S and U266) cell 
line pairs.  We have named this compound Velcade Re-sensitizing Compound 2 (VRC2). 
Importantly, IC50 values for VRC2 in normal mouse and human fibroblasts were 100-fold 
higher than those observed in malignant human and mouse plasma cells (data not 
shown), suggesting that this drug may have a low toxicity profile in vivo. We are currently 
evaluating the activity of VRC2 in animal models of MM, alone and in combination with 
Bz.  We are also utilizing kinetic gene expression profiling and yeast screening assays to 
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establish the precise mechanism of action for VRC2.  However, these preliminary data 
suggest that VRC2 may have clinical relevance in Bz-refractory MM. 
 
 108 
 
DISCUSSION 
 In this study, we used complimentary in silico and high-throughput drug 
screening methods to identify drug families that may be effective in target Bz-refractory 
MM cells.    The intersection of these approaches revealed that Topo inhibitors might be 
useful for this purpose.  Not only did many Topo inhibitors display increased single-agent 
sensitivity in Bz-resistant cell lines compared to their Bz-sensitive counterparts, but this 
activity appears to be synergist with Bz modes of action.  Indeed, Congdon et al. 
reported that treatment of a human MM cell line with Bz results in increased Topo 
expression and double-strand DNA breaks, which led to increased sensitivity to a Topo 
inhibitor (419).  Therefore, a thorough assessment of the baseline DNA-damage, Topo 
activity, and Topo expression in Bz-sensitive and -resistant cell lines may be required to 
elucidate the mechanism behind our observed PI and teniposide synergy further.   
Interestingly, a number of Topo inhibitors are already used in the clinic for the 
treatment of cancer (423).  These drugs fall generally into two categories, Topo I or Topo 
II inhibitors, depending on their protein target.  Although the function of topoisomerases 
is to relieve DNA supercoiling during replication and transcription, the mechanism by 
which this occurs between Topo classes varies.  Human Topo I (TOP1) binds and 
generates single-stranded breaks in the DNA allowing the cleaved strand to rotate 
around the opposite strand and recruits repair proteins to re-ligate the backbone (424).  
The Topo II complex (TOP2A/B) performs a similar function but through the creation of 
double-strand breaks in the DNA (425).  Topo inhibitors function by inhibiting the 
disassociation of the Topo proteins from the DNA strand after supercoiling is relieved.  
Hindrance from the Topo protein stops ligation from occurring resulting in unresolved 
DNA breaks that trigger apoptosis (419). TOP1 inhibitors include camptothecin (CPT) 
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and its derivatives CPT-11 and topotecan, whereas teniposide inhibits TOP2A/B.  
Furthermore, a number of approved MM drugs, (i.e. etoposide and doxorubicin) have 
Topo II inhibiting properties (426).  The use of newer Topo inhibitors has been proposed 
for refractory MM, however, this was prior to the approval and widespread use of Bz 
(427, 428).  Notably, these data suggest that newer Topo inhibitors may be especially 
effective for the treatment of Bz refractory MM.    
One potential caveat of utilizing Topo inhibitors may be the presence of 
UGT1A1*28 variants which are present in as high as 37.5% of some patient populations 
(429).  The UGT1A1*28 variant has been associated with changes in the metabolism of 
CPT-11 and adverse events related to treatment (i.e. bone marrow toxicity) of patients 
(429).  UGT1A1 genotyping is currently available and recommended by the FDA for 
CPT-11 use, however, testing has yet to be fully implemented in the clinic (430). 
  Finally, these studies illustrate the utility of combined approaches for drug 
discovery to combat refractory MM.  Interestingly, we have identified both well-described 
(Topo inhibitors) and novel compounds of interest (VRC2) to this effect.  Furthermore, 
the availability of additional libraries including the FDA-Approved Oncology Drug Library 
(from the NCI Developmental Therapeutics Program) means that drug repurposing may 
be utilized successfully by this methodology.  Given the severe side effects (i.e. 
peripheral neuropathy) that can be associated with Bz treatment (431), the identification 
of drugs that can significantly reduce the concentrations of Bz required for the same 
effect may have tremendous clinical utility.  In this case, we used these combined 
approaches to identify drugs that are capable of re-sensitizing Bz-resistant cells to Bz in 
vitro, outlining a potentially useful pre-clinical pipeline for the treatment of refractory 
disease. 
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Table 1. Single-agent IC50  comparison of Bz-sensitive and -resistant mouse cell  
 
lines. 
 
 
Drug 
 
595BzS 
 
595BzR 
Log (fold 
change)a 
 
589BzS 
 
589BzR 
Log (fold 
change)a 
Bortezomib, nM 23 112 2.3 22 96 2.1 
MLN2238, nM 28 154 2.5 39 180 2.2 
Carfilzomib, nM 28 71 1.3 41 77 0.9 
Camptothecin 
(CPT), μM 
> 15 0.8 -4.3 0.7 0.6 -0.2 
CPT-11, μM 44 35 -0.3 33 20 -0.7 
Topotecan, μM > 15 0.8 -4.3 0.8 0.6 -0.3 
Teniposide, μM 3 0.6 -2.3 0.2 0.05 -1.7 
 
 
aIC50 value of the BzR relative to the BzS cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 111 
 
Table 2.  Drug reduction index for decreasing PI concentrations. 
 
Drug combination Cell line % Reductiona 
Cz + Teniposide 589 BzS N/A 
 589 BzR 92 
 595 BzS N/A 
 595 BzR 42 
MLN2238 + Teniposide 589 BzS 45 
 589 BzR 75 
 595 BzS 71 
 595 BzR 95 
 
aPercent reduction in PI concentration that can be used to obtain the same IC50 in 
combination with teniposide compared to the PI alone. 
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Figure 1.  Cell death by Bz is associated with caspase 3 cleavage. 
Flow cytometric analysis of BzS (gray bars) and BzR (black bars) cells treated with a 
range of 0-100 nM Bz for 48 hours stained with a cleaved caspase 3 antibody.  All 
treatment data shown were normalized to untreated controls. 
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Figure 2.  Drug screening identifies topoisomerase inhibitors as candidate drugs 
for Bz synergy. 
High-throughput drug screening independently identifies topoisomerase inhibitors as 
potentially effective secondary therapies in Bz-resistant mouse lines. A) The NCI 
Diversity Set II of approximately 1,800 small molecules was screened using one pair 
(595) of isogenic BzS (grey bars) and BzR (black bars) mouse cell lines.  The library was 
screened for single-agent activity (5 μM concentrations used).  In addition to screening 
for single-agent sensitivity, the BzR line was screened with the same compounds in the 
presence of 50 nM Bz (red bars) for synergistic combinations.  Of the top drug hits, two 
were Topo inhibitors, camptothecin (CPT) and teniposide.  Cell viability was measured in 
triplicate and is shown as a percent of the control.  C) Chou-Talalay (420) combination 
index (CI) plots for two independent mouse BzR cell lines (595 on the left, 589 on the 
right) for the combination of the Topo inhibitor, teniposide, with either Bz (top), 
carfilzomib (middle) or MLN2238 (bottom).  Cell viability was measured in triplicate at 
each drug combination following 48 hours of treatment in vitro.  The fraction of affected 
cell (Fa) is indicated on the X-axis and the log(CI) on the Y-axis. Combination index 
values (CI) < 1 are considered synergist combinations. 
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ABSTRACT 
Multiple myeloma (MM), the second most common hematopoietic malignancy, remains 
an incurable plasma cell (PC) neoplasm.  While the proteasome inhibitor, bortezomib 
(Bz) has increased patient survival, resistance represents a major treatment obstacle as 
most patients ultimately relapse becoming refractory to additional therapy.  Current tests 
fail to detect emerging resistance; by the time patients acquire resistance, tumor burden 
is substantial.  To establish immunophenotypic signatures that predict Bz sensitivity, we 
utilized Bz-sensitive and   -resistant cell lines derived from tumors of the Bcl-XL/Myc 
mouse model of PC malignancy.  We identified the reduced expression of 3 markers 
(CD93, CD69 and CXCR4) in “acquired” (Bz-selected) resistant cells.  Using this genetic 
signature, we isolated a subpopulation of cells from a drug-naïve, Bz-sensitive culture 
that immunophenotypically resemble “acquired” Bz resistant cells yet display “innate” 
resistance to the drug.  Of these markers, CXCR4 expression was most predictive of 
outcome in patients, as reduced CXCR4 expression was significantly associated with 
poorer survival in Bz-treated MM patients.  Although these genes were identified as 
biomarkers, they may indicate a mechanism for Bz-resistance through the loss of PC 
maturation markers which may be induced and/or selected by Bz.  Most importantly, 
induction of PC differentiation in both “acquired” and “innate” resistant cells restored Bz 
sensitivity suggesting a novel therapeutic approach for targeting Bz refractory MM.   
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INTRODUCTION 
   Multiple myeloma (MM) is a plasma cell (PC) malignancy representing the 
second most common hematopoietic cancer.  Unlike normal PCs, which are fully 
differentiated, malignant PCs retain their self-renewing capabilities and, in myeloma 
patients, accumulate in the bone marrow resulting in a fatal malignancy (432, 433).  
Over the last decade, remarkable advances have been made in the treatment of MM 
that have improved patient survival, including bone marrow transplant and the discovery 
of novel chemotherapeutic agents including proteasome inhibitors.  Proteasome 
inhibitors block the ability of the proteasomal complex to degrade overabundant, 
misfolded or damaged polyubiquitinated proteins (434, 435).  The large-scale production 
of antibodies by PCs requires the systematic degradation of excess peptides to maintain 
cellular homeostasis making the proteasome complex a successful chemotherapeutic 
target for MM (377).  
   Bortezomib (Bz)/VELCADE® (Millennium Pharmaceuticals, Inc.) was the first 
clinically approved, specific inhibitor of the proteasome and is a member of a growing 
family of proteasome inhibitors including next-generation compounds such as MLN2238 
(Millennium Pharmaceuticals, Inc.) and the recently FDA-approved carfilzomib (Onyx 
Pharmaceuticals) (377).  Bz reversibly inhibits the PSMB5 subunit of the proteasome, 
primarily targeting its chymotrypsin-like activity (436).  Bz has been widely used to treat 
MM in combination with agents such as melphalan, dexamethasone, thalidomide and 
other newer IMiD-derivatives such as lenalidomide (377). 
   MM patients treated with Bz alone or in combination with other agents achieve 
high response rates (437).  Despite this initial success, the majority of patients 
eventually relapse; some maintaining sensitivity to further Bz therapy, while others 
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develop refractory disease due to “acquired” drug resistance. Furthermore, some 
patients never respond to Bz having primary refractory disease and, therefore, 
displaying “innate” resistance to the drug (438).  However, the similarities and 
differences between innate and acquired Bz resistance remain ill-defined. Currently, 
there are no reliable diagnostic predictors to determine whether a patient will respond to 
Bz treatment.  By the time MM patients are classified as drug resistant, their tumor 
burden is often substantial and the prognosis is poor.  Therefore, diagnostic tests that 
could predict Bz sensitivity or resistance prior to treatment are critically needed.   
   Our previous studies, which utilized in vitro cell lines created from the Bcl-XL/Myc 
mouse model of plasma cell malignancy, highlighted by gene expression profiling a 
number of genes that may distinguish Bz-sensitive from -resistant cells in vitro (418).  
The goal of this study was to identify and validate those immunophenotypic markers that 
best distinguish Bz-sensitive from -resistant cells to establish signatures that predict Bz 
sensitivity as preclinical support for the development of a future diagnostic test for MM 
patients.  We utilized these previously described Bz-sensitive (BzS) and Bz-resistant 
(BzR) mouse cells lines (418) derived from tumors of this Bcl-XL/Myc double transgenic 
mouse model (124, 242).  We employ this model because PC tumor lines isolated from 
these mice closely resemble human MM based on GEP, chromosomal abnormalities 
and progression of disease in the bone marrow (124, 242, 372, 418).  Here we identify 
the loss of plasma cell maturation markers as a component of an immunophenotype that 
is associated with both innate and acquired Bz resistance.  This is a highly regulated 
network that may prove vulnerable in the case of Bz resistance. 
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MATERIALS AND METHODS 
Mouse tumor cell lines and treatment conditions.  Mouse cell lines 595BzS, 595BzR, 
589BzS and 589BzR were cultured in murine PC media containing RPMI 1640 (Lonza, 
Allendale, NJ), 15% fetal bovine serum (FBS) (Cellgro, Mediatech, Manassas, VA), 25 
mmol/L HEPES (Lonza), 1mmol/L sodium pyruvate, 50 μmol/L beta-mercaptoethanol 
(Sigma-Aldrich, St. Louis, MO), 50 units/ml of penicillin and streptomycin (Thermo Fisher 
Scientific, Waltham, MA), 2 mmol/L L-glutamine (Gibco Life Technologies, Grand Island, 
NY) and 0.5 ng/ml interleukin (IL)-6 (R&D Systems, Minneapolis, MN).  Cells were split 
every 3 days and maintained at concentrations between 2-5x106 cells/mL.  In some 
experiments, live cells were isolated by Ficoll-Hypaque (GE Healthcare, Piscataway, NJ) 
prior to analysis. 
   Bortezomib (Bz) (Millennium Pharmaceuticals, Inc., Cambridge, MA) was 
dissolved in serum-free RPMI 1640, and lipopolysacharide (LPS) (E-Coli 0111:B4, 
Sigma-Aldrich) was dissolved in PBS.  Bz and LPS were added to the media at the 
concentration and for the time indicated.  
Cytotoxicity assay.  Cells were cultured at 4x105 cells/mL and treated with indicated 
concentrations of Bz for 48 hours.  Cells were subjected to CellTiter-Glo® Luminescent 
cell viability assay according to manufacturer’s instructions (Promega, Madison, WI).  
Values were normalized to untreated controls.  Numbers of total live cells were 
determined by trypan blue exclusion and counting in triplicate using a hemacytometer. 
Fluorescence analysis and sorting.  Cells were stained with the following anti-mouse 
antibodies: CD69 FITC (clone H1.2F3), CD93 APC (clone AA4.1), CD138/syndecan-1 
PE (clone 281-2), B220 APC (clone RA3-6B2) (all from BD Biosciences, Franklin Lakes, 
NJ), CD38 PE (BioLegend, San Diego, CA) and analyzed using the FACSCalibur (BD 
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Biosciences, Franklin Lakes, NJ).  For fluorescence activated cell sorting experiments, at 
least 2x107 cells were used, stained as described above using anti-mouse CD93 APC 
(clone AA4.1) and sorted using a FACSAria (BD Biosciences).  To detect both 
intracellular and cell-surface CXCR4 expression, cells were first stained with anti-mouse 
CD184/CXCR4-PE (clone 2B11, eBioscience) antibody or Rat IgG2b kappa-PE isotype 
control (eBiosccience) and then fixed using the Cytofix/Cytoperm 
Fixation/Permeabilization kit (BD Biosciences), blocked in buffer containing 30% FBS, 
0.1% Saponin and 20 mM HEPES, and stained a second time with the same antibodies.  
Samples were analyzed using the FACSCalibur and FlowJo Software (Tree Star, 
Ashland, OR). 
Enzyme linked immunosorbant assay (ELISA).  Cells (4 × 105 cells/ml) were plated in 
murine PC media for 48 hours.  Supernatants were harvested and cells were lysed using 
buffer containing 10 mM Tris (pH 7.8), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40.  Ig 
kappa ELISA (Thermo Fisher Scientific) was performed according to the manufacturer’s 
instructions, and Ig kappa levels were determined by subtracting the value from medium 
alone or lysis buffer control and normalized according to CellTiter-Glo® Luminescent 
values.  
Array-comparative genomic hybridization.  Genomic DNA was extracted from 
10x10^6 cells in log phase growth for each cell line in the absence of drug selection 
using the PerfectPure DNA Blood Kit (5 PRIME Inc., Gaithersburg, MD). DNA was heat 
fragmented and DNA from BzR lines was labeled with fluorochrome Cyanine-5 using 
random primers and exo-Klenow fragment DNA polymerase.  Control DNA from parental 
lines was labeled concurrently in Cyanine-3.  The sample and control DNA were 
combined and array-based comparative genomic hybridization (a-CGH) was performed 
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with a microarray constructed by Agilent Technologies that contains approximately 
170,000 distinct biological oligonucleotides spaced at an average interval of 10.9 kb. 
The ratio of sample to control DNA for each oligo was calculated using Feature 
Extraction software 10.5 (Agilent Technologies, Santa Clara, CA).   The abnormal 
threshold was applied using Genomics Workbench 7.0 (Agilent Technologies).  A 
combination of several statistical algorithms were applied.  A minimum of three 
oligonucleotides that have a minimum absolute ratio value of 0.1 [based on a log(2) 
ratio] is required for reporting of a copy number loss or gain. 
Extraction of RNA and RT-PCR.  RNA was extracted using QIAshredder and RNeasy 
RNA purification columns (Qiagen, Valencia, CA). RNA was reverse transcribed using 
the Transcriptor First Strand cDNA Synthesis Kit (Roche, San Francisco, CA). 
Quantitative RT-PCR was performed in triplicate using the LightCycler 480 and Probes 
Master (Roche) using 45 cycles of 95C for 10 sec and 55C for 30 sec (single 
acquisition).  The primers used are presented in supplemental materials. Data were 
analyzed using LightCycler 480 software (Roche), and relative fold changes were 
calculated using the 2− ΔΔCt method with the GAPD reference gene for normalization. 
   The ratio of spliced to unspliced Xbp1 was determined by endpoint PCR using 
GeneAmp PCR System 9700 (Applied Biosystems, Carlsbad, CA) and GoTaq Green 
DNA polymerase (Promega) using 35 cycles of 95C for 30 sec, 50C for 30 sec and 72 
C for 1 min. The XBP1 primers used were as previously described (47) and have been 
included in the supplemental methods: PCR products were resolved on a 2.5% agarose 
gel (BioExpress, Kaysville, UT), visualized using the ChemiDocTM XRS+ Imager (Bio-
Rad, Hercules, CA), and quantified by Image Lab Software. 
Quantitative RT-PCR primers.  The following primers were used:  Cd93, 5’-
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TGAAATAGACGCCCTGAAAAC-3’ (5’ primer), 5’-AATCAAAGCCTGGGTTTAGGA-3’ (3’ 
primer); Cd69, 5’-GGAAAATAGCTCTTCACATCTGG-3’ (5’primer), 5’-
TGATGCTTCTCAAAATGTATACTGG-3’ (3’ primer); Irf4, 5’-
ACAGCACCTTATGGCTCTCTG-3’ (5’ primer), 5’-ATGGGGTGGCATCATGTAGT-3’ (3’ 
primer); Blimp-1, 5’-TGCGGAGAGGCTCCACTA-3’ (5’ primer), 5’-
TGGGTTGCTTTCCGTTTG-3’ (3’ primer); Chop, 5’-GCGACAGAGCCAGAATAACA-3’ 
(5’ primer), 5’-GATGCACTTCCTTCTGGAACA-3’ (3’ primer);  Cxcr4, 5’- 
TGGAACCGATCAGTGTGAGT-3' (5’ primer), 5’- GGGCAGGAAGATCCTATTGA-3’ (3’ 
primer).  The primers included in the Universal ProbeLibrary Mouse Gapd Gene Assay 
(Roche) were used as the reference gene.  
Xbp1 primers.  Xbp1, 5’-ACACGCTTGGGAATGGACAC-3’ (5’ primer), 5’-
CCATGGGAAGATGTTCTGGG-3’ (3’ primer). 
Cell lines and culture.  CH12F3-2 (CH12) and MPC11 were kindly provided by 
Matthew Scharff (Albert Einstein College of Medicine, Bronx, NY).  CH12 cells were 
maintained in RPM -mercaptoethanol 
and 5% NCTC (BioWhittaker, Walkersville, MD), and MPC11 cells were cultured in 
murine PC media described above without IL-6. 
Human gene expression profiling analysis.  Plasma cell purifications and gene 
expression profiling, using the Affymetrix U133Plus2.0 microarray (Affymetrix, Santa 
Clara, CA), were performed as previously described (390).  GEP of CD138+ bone 
marrow plasma cells from 214 MM patients were used from this study.  Signal intensities 
were pre-processed and normalized by GCOS1.1 software (Affymetrix). We performed 
permutation analyses to correlate CXCR4 expression with patient survival in the total 
therapy 3 trial (TT3, n=214); the presented p value was based on the best cut-off (50% 
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patients in high- or low-CXCR4 group) between these 2 parameters. All statistical 
analyses were performed with the use of the statistical software R (Version 2.6.2) 
(http://www.r-project.org). 
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RESULTS 
Acquired bortezomib resistance is associated with immunophenotypic changes. 
   To identify immunophenotypic biomarkers in Bz-resistant PCs, we utilized the 
previously described in vitro double transgenic Bcl-XL/Myc mouse cell lines (124, 242, 
418).  In a previous study, Bz-sensitive (BzS) mouse cell lines were dose escalated with 
bortezomib in vitro to create Bz-resistant (BzR) daughter cell lines which were further 
characterized using gene expression profiling (GEP) (418).  We selected the most Bz-
resistant of these pairs, 589 (4.4-fold increase in IC50) and 595 (4.9-fold increase in 
IC50), for further immunophenotypic characterization.  Both the 595 and 589 BzS and 
BzR lines were characterized by flow cytometry and found to be CD38+CD138+ 
(Supplemental Figure S1) and CD20-CD27- (data not shown) compared to isotype 
controls (Supplemental Figure S2A), characteristic of early plasma cells (439).  These 
cells also express mature B cells markers such as B220, most strongly in the 595 BzS 
line (Supplemental Figure S1).   
   Three cell-surface markers CD93, CD69 and CXCR4 had consistently reduced 
expression in the BzR compared to the BzS cell lines (Figure 1A).  Using quantitative 
RT-PCR, we validated the reduced expression of these genes in all cell lines tested 
(Figure 1B).  The differences in the cell surface mean fluorescence intensity between 
BzS and BzR cells were most well-defined by CD93 and CD69 protein and mRNA 
expression (Figure 1A-B); BzS cells were CD93+CD69+ (double positive) and BzR cells 
were CD93-CD69- (double negative) (Figure 1C). 
Innate and acquired bortezomib resistant cells have similar immunophenotypes. 
   CD93 and CD69 most clearly distinguished mouse BzS from BzR cells. Because 
MM cultures are known to be heterogeneous, we asked whether Bz-resistant CD93-
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CD69- cells are present within drug naïve, BzS cultures. While the majority of BzS 
cultures stained double positive for CD93 and CD69, approximately 0.1% of 595 and 
12% of 589 BzS cells were double negative for CD93 and CD69 (Figure 1C, left panels).  
Characterization of 4 other BzS cell lines derived from the same double transgenic 
mouse model displayed 2-6% CD93/CD69 double negative cells (data not shown). 
   To further characterize this potentially “innate” Bz-resistant population, we 
isolated CD93-CD69- cells from the 589 BzS culture, which displayed the highest 
percentage of double negative cells, by flow sorting and performed Bz dose response 
assays, quantitative RT-PCR and flow cytometry for the immunophenotyic markers 
above.  Dose response assays using Bz revealed that this drug naïve, CD93-CD69- 
sorted population (I-BzR) had an IC50 (Figure 2A) and growth rate (Supplemental Figure 
S2B) comparable to the 589 BzR cell line.  As expected, I-BzR cells expressed reduced 
levels of CD93 and CD69 protein (Figure 2B) and mRNA (Figure 2C).  Moreover, the I-
BzR cells displayed a moderate reduction in the expression of CXCR4 (Figure 2B) 
similar to BzR cells (Figure 1A).  Interestingly, this “innate” Bz-resistant, 
immunophenotype was persistent as long as 1 year post-sort (data not shown), 
characteristic of primary refractory disease seen in MM patients.  These results 
demonstrate that “innate” Bz-resistant cells (I-BzR) isolated from a drug naïve, 
heterogeneous culture display similar immunophenotypic characteristics to cells with an 
acquired (drug-selected) resistance to Bz.  
Bz promotes loss of CD93 and CD69. 
   To characterize the emergence of the CD93-CD69- double negative Bz-resistant 
population, BzS cells were treated with drug to determine whether the loss of CD93 and 
CD69 expression is selected for and/or modulated by Bz treatment.  As expected, BzS 
 128 
 
cells treated with a high-dose of Bz resulted in approximately 95% (595BzS, data not 
shown) and 80% (589BzS, Figure 2A) death.  After gating on live cells, we observed 
reduced expression of CD93 and CD69 by flow cytometry compared to untreated 
controls (Figure 3A). Shifts in CD93 and CD69 cell surface expression were more 
pronounced in the 589 BzS line, the remaining live cells displaying a BzR cell 
immunophenotype (Figure 3A, Supplemental Figure S2C). The maintenance of these 
double negative cells is not likely due to variable growth rates as CD93 and CD69 
double positive and double negative populations divide at similar rates (0.8-0.9 cell 
divisions/day, Supplemental Figure S2B).  Quantitative RT-PCR analysis of BzS cells 
following sub-lethal Bz treatment, a condition not associated with substantial cell death 
(Supplemental Figure S2D), resulted in significantly reduced expression of Cd93 in both 
the 595 and 589 BzS lines and Cd69 in the 595 BzS line (Figure 3B).  These results 
demonstrate that Bz treatment may both select for the CD93 and CD69 double negative 
population as well as induce the loss of these cell-surface markers at the level of mRNA 
regulation. 
Low CXCR4 expression may be of diagnostic value in predicting human Bz-
resistant MM.     
   The data described above define a strong role for CD93, CD69, and CXCR4 as 
biomarkers of both “innate” and “acquired” Bz-resistance in our mouse plasma cell in 
vitro system.  Using a publicly available MM dataset, we sought to determine whether 
these markers were associated with survival in patients treated with Bz.  The total 
therapy 3 (MMTT3) drug trial reported by Shaughnessy, et al. provides GEP data in MM 
patients prior to and following a single, 48 hour test-dose of Bz.   Following this Bz 
treatment, patients were placed on drug cocktail regimens and survival was reported 
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(390).  High expression of both CD93 and CD69 has not been described in human MM.  
Indeed we find that the expression of these markers is very low in patient samples (data 
not shown).  However, CXCR4 is highly expressed in human MM (440).  In fact, as a 
single biomarker, low CXCR4 expression was able to significantly distinguish those MM 
patients with poorer event free (EFS; p = 0.013) and overall (OS; p = 0.010) survival in 
this clinical trial (Supplemental Figure S3A-B).  Therefore, although the consistent 
reduction in CXCR4 that we observe in our mouse cell lines is moderate, CXCR4 may 
be a viable diagnostic target associated with clinical outcome in MM patients being 
treated with Bz. 
The Bz-resistant immunophenotype implicates a role for B cell differentiation.  
   Given our analysis of human MM GEP data, there appears to be utility in the 
immunophenotypic characterization of the mouse BzS and BzR cell lines for identifying 
biomarkers of Bz-resistance; however, whether these biomarkers play a role in the 
mechanism of Bz-resistance remains ill-defined.  In the mouse, we have identified that 
low CD93/CD69/CXCR4 expression best define Bz-resistant cells (Figure 1 & 2).  We 
have also observed minimal losses in other cell-surface markers including CD38 in these 
populations (data not shown).  Mouse PCs are known to express higher levels of Cd93, 
Cxcr4 and Cd38 mRNA relative to germinal center (GC) B cells (441).  In addition, high 
CD93 expression has been shown to be necessary for the maintenance of normal, long-
lived plasma cells in mice (442).  Loss of these markers in both the BzR and I-BzR 
populations led us to hypothesize that, besides their roles as biomarkers, the loss of 
CD93, CD69, CXCR4 and CD38 in Bz-resistant cells is associated with a loss of PC 
maturation markers in MM. 
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   Using a human MM clinical trial reported by Mulligan, et al. where GEP was 
performed on patients prior to treatment with either high-dose dexamethasone or Bz as 
a single agent (APEX drug trial) (403), we compared the expression profiles for genes 
known to be highly involved in PC maturation between Bz responders and 
nonresponders.  A combination of these data and the available mouse GEP data (418) 
showed that there indeed appeared to be reduced expression in some of the genes 
known to be “master regulators” of PC differentiation, XBP1 and PRDM1 (BLIMP-1) in 
Bz nonresponders (data not shown).  These markers were further validated in vitro 
where we found reduced Xbp1 splicing in the Ig-secreting mouse 595 BzR cell line 
relative to its BzS counterpart but not in the 589 line which lacks heavy chain expression 
(Supplemental Figure S4A).  A lack of spliced XBP1 was also present in PCs isolated 
from human Bz-resistant MM patients (Rodger Tiedemann, personal communication).  
Taken together, these data suggest a certain plasticity in the PC commitment of Bz-
resistant cells which may be induced by Bz selection.   
Lipopolysaccharide treatment re-sensitizes Bz-resistant cells to Bz. 
Because the Bz-resistant cells in our model system display features of lost PC 
commitment, we next determined whether we could therapeutically target this process 
by promoting PC differentiation of BzR cells to restore the immunophenotype of the BzS 
population and re-sensitize cells to Bz-induced death.  The toll like receptor (TLR)-4 
ligand, bacterial lipopolysaccharide (LPS), is a known inducer of B cell differentiation 
(443-445). Previous studies have shown that differentiation of B cells to CD138+, 
immunoglobulin-secreting PCs requires the coordinated induction of the transcription 
factor IRF4 (24) and its downstream transcriptional target, BLIMP-1 (30) (Figure 4A). 
Consistent with these studies, LPS treatment of 589 cells for 72 hours resulted in a 6-
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fold increase in Irf4 in both BzR lines (Figure 4B, top panel) and a 3-fold (I-BzR) to 6-fold 
(BzR) increase in Blimp-1 (Figure 4B, bottom panel) mRNA levels.  Interestingly, 
increased expression of Irf4 and Blimp-1 were only observed in BzR cells as these 
transcription factors did not increase in the LPS-treated BzS culture (Figure 4B) 
suggesting that the BzS population is insensitive to further LPS-mediated PC 
differentiation despite similar expression of Tlr4 mRNA (data not shown).  
   BLIMP-1 is required for XBP1 induction and activation of the physiological 
unfolded protein response (UPR) pathway in preparation for immunoglobulin secretion 
(30, 43, 47).  This UPR pathway is responsible for further processing of XBP1 mRNA 
into its spliced form with the assistance of IRE1α (47) (Figure 4A).  Consistent with LPS-
induced PC differentiation, we observed increased Xbp1 splicing in the BzR cells but not 
in the BzS population (Figure 4C).  Xbp1 splicing corresponded to increased Ig kappa 
secretion only in the I-BzR population (Figure 4D). This lack of Ig kappa secretion 
(Figure 4D) and undetectable intracellular Ig kappa in the BzR cells (Supplemental 
Figure S4B) correlated with a deletion within the kappa gene locus as evidenced by 
array comparative genomic hybridization (Supplemental Figure S4C).  Increased BLIMP-
1 has also been associated with CHOP expression (24) (Figure 4A).  Consistent with 
this, we observed increased CHOP in BzR cells (Figure 4B) as well as increased 
sensitivity to LPS treatment (data not shown). 
We next asked whether LPS stimulation promoted the re-expression of CD93, 
CD69 and CXCR4 in BzR populations.  We observed a modest increase in Cd93 mRNA 
(Supplemental Figure S5A) and cell surface expression (Supplemental Figure S5B) only 
in the I-BzR population consistent with the modest increase in Ig kappa secretion (Figure 
4D) demonstrating a positive correlation between CD93 expression and Ig secretion, 
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which has been previously reported (442).  LPS stimulation resulted in increased Cd69 
and Cxcr4 mRNA (Figure 4E) and CD69 cell-surface expression (Figure 4F) in both BzR 
lines.  
Finally we asked whether this re-commitment of an PC immunophenotype 
restores Bz sensitivity in BzR cells.  Following LPS pre-treatment, live cells were re-
plated for Bz treatment. Consistent with our previous findings, we observed reduced 
viability of the non-LPS treated BzS population and little death in BzR cells following Bz 
treatment (Figure 5).  However, LPS pre-treatment prior to Bz treatment significantly 
reduced the viability in all cultures including the previously Bz-resistant populations (BzR 
and I-BzR) (Figure 5).    
Taken together, we have identified an immunophenotype that can segregate Bz-
sensitive and -resistant mouse PC lines in vitro.  Furthermore, these distinguishing 
markers suggest that BzR cells represent a population with reduced PC commitment 
which is perhaps both selected and induced by Bz treatment.  This lack of commitment 
may prove to be a therapeutic target in Bz refractory MM. 
 
 
 
 
 
 
 
 
 
 
 133 
 
DISCUSSION 
In this study we utilized tumor lines derived from the Bcl-XL/Myc transgenic 
mouse model of PC malignancy to immunophenotypically characterize neoplastic Bz-
sensitive and -resistant PCs in order to identify biomarkers associated with acquired and 
innate Bz resistance.  Although these pairs of cell lines shared many common markers 
of PC expression, we found that Bz-sensitive cells are predominately CD93/CD69 (88-
99.9%) double positive cells (6 independently derived transgenic mouse lines analyzed), 
whereas BzR cells display a striking reduction in the expression of both of these 
markers.  In fact, CD93 and CD69 are the two cell-surface proteins that best 
distinguished Bz-sensitive from -resistant, both “innate” and “acquired”, cells.  While 
CD93 is expressed during early B cell development, this expression is lost in GC B cells 
and is again induced as B cells differentiate into PCs (442).  CD93/CD138 expression 
has been shown to be restricted to antibody-producing cells and is required for the 
maintenance of long-lived plasma cells in the bone marrow in mice (442).  Expression of 
CD93 and CD138 on Bz-sensitive cells is consistent with their PC differentiation stage 
and Ig secretion; however, we see a loss of CD93 in Bz-resistant cells.  Stessman, et al. 
reported that a GEP analysis of the BzS and BzR lines in the absence of drug showed 
enrichment for downstream targets of the transcription factors, XBP1 and BLIMP-1, both 
of which are involved in PC commitment (418).  These findings, as well as our use of the 
APEX clinical trial to further analyze the expression of PC markers in Bz-refractory MM 
patients, suggest that there is an association between Bz-resistance and a loss of PC 
commitment.   
LPS stimulation induced the re-expression of CD93 in about 27% of I-BzR cells 
which is positively correlated with a 30% increase in Ig secretion, suggesting that these 
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two events are likely occurring together within the CD93+ population. Since LPS pre-
treatment did not uniformly increase CD93 expression, re-sensitization of BzR cells may 
not always correlate with CD93 expression.  However, expression of the activation 
marker CD69 increased uniformly following LPS treatment suggesting that CD69 may in 
fact be a better marker for predicting Bz sensitivity although little is known about the 
function of this protein during PC differentiation (441).  Future studies are required to 
determine the precise role of CD69 in Bz sensitivity, specifically, whether this is simply a 
biomarker or perhaps playing a larger mechanistic role in resistance.   
While BzR cells maintain some features of PCs, still others are reduced; 
however, BzR cells do not share a complete shift by GEP to a GC B cell stage (441) 
(data not shown).  It is possible and, based on our data, in fact likely that the loss of PC 
commitment may serve as not only a biomarker of Bz resistance but as a direct 
therapeutic target in refractory MM.  The loss of PC commitment may confer a selective 
advantage for evading Bz-mediated death via the reduction of the unfolded protein 
response (UPR).  GC B cells, which express and secrete fewer immunoglobulin 
molecules than PCs, are less sensitive to endoplasmic reticulum stress and display a 
reduced UPR (45, 47).  We demonstrate that BzR cells secrete reduced immunoglobulin 
proteins compared to BzS cells, consistent with the observation that BzR cells have lost 
some of their PC commitment. This raises the possibility that BzR cells are resistant 
because of reduced antibody production suggested previously by others (446). While 
LPS stimulation re-sensitized both BzR and I-BzR cells to Bz, re-sensitization correlated 
minimally with increased Ig secretion in I-BzR cells arguing, at least in this context, that 
Bz sensitivity does not always require Ig synthesis and secretion. On the other hand, 
LPS stimulation increased XBP1 splicing and CHOP expression, two components 
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necessary for the UPR, suggesting that Bz sensitivity may require the initiation of the 
UPR signaling cascade which may occur independently of Ig synthesis.  
Although low CD93 and CD69 best distinguish our Bz-resistant mouse cell lines, 
these markers are not highly expressed on human PCs.  However, using this model 
system we have demonstrated that an immunophenotype may exist that could be used 
diagnostically to identify Bz-sensitive and -resistant patients prior to treatment.  In fact, 
reduced expression of CXCR4 and CD38 were also identified as components of our Bz-
resistant immunophenotype and are expressed on human MM cells.  Reduced 
expression of CXCR4 is thought to play a role in PC homing to the bone marrow (447), 
and, when injected back into syngeneic mice, BzR cells fail to home to the marrow 
compared to their BzS counterparts (418).  These data suggest that reduced CXCR4 
expression correlates with increased disease severity. This is consistent with our 
analysis of the MMTT3 trial (390) which showed that low CXCR4 expression was 
significantly associated with reduced event free and overall survival compared to 
patients with high CXCR4 expression treated with Bz.  These data suggest that Bz 
selection may promote the loss of CXCR4 which in turn may decrease the reliance of the 
MM cells on the bone marrow microenvironment promoting extramedullary disease.  
The re-sensitization of previously Bz-resistant cells to Bz following LPS 
pretreatment supports the hypothesis that BzR cells have lost some of their PC 
commitment distinct from Bz-sensitive cells. While LPS promoted PC differentiation of 
BzR cells, BzS cells were unaffected by LPS stimulation similar to in vitro adapted 
plasmacytoma tumors (448).  Re-sensitization of Bz-resistant MM lines following PC 
differentiation using 2-methoxyestrodiol or all-trans-retinoic acid was recently described 
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(353).  Combined, these studies argue that augmentation of PC differentiation may be a 
logical chemotherapeutic approach in Bz-refractory MM.  
These studies outline the immunophenotypic characterization of Bz-sensitive and            
-resistant PCs using a mouse model which has identified the loss of PC commitment in 
Bz-resistant cells compared to Bz-sensitive cells.  By therapeutically forcing Bz-resistant 
cells to differentiate back into PCs, we have shown that we can re-sensitize these cells 
to Bz treatment.  Of the Bz-resistant markers identified, low CXCR4 best correlates with 
poor MM patient clinical outcomes suggesting that this could be a useful biomarker for 
developing a diagnostic test to identify Bz resistance. The positive impact of such a 
diagnostic tool in patient care could mean the early detection of Bz resistance and 
improved overall survival through individualized medical treatment.  In addition, if in fact 
these immunophenotypic biomarkers are involved in the drug-resistant mechanism, this 
may provide novel drug targets for the synthesis of new compounds aimed at reversing 
resistance by promoting PC differentiation prior to Bz treatment.  This highlights a unique 
therapeutic option for the treatment of relapsed and primary refractory MM patients.  
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Figure 1. Immunophenotypic characterization of acquired bortezomib resistant 
lines.   
A.  Fluorescence-activated cell sorting analysis of BzS (solid black line) and BzR (dark 
grey histogram) cells stained with indicated antibodies.  B.  Quantitative RT-PCR 
analysis of Cd93 and Cd69 relative mRNA expression in 595 and 589 BzS and BzR 
lines. Values were normalized to Gapd mRNA and error bars represent PCR triplicates.  
Significance was determined using a one-tailed Student’s t-test (* p < 0.05; ** p < 0.01; 
**** p < 0.0001).  C.  Fluorescence-activated cell sorting dot plot analysis of BzS and 
BzR cells double stained with CD93 and CD69 antibodies.   
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Figure 2. Establishment and characterization of innate bortezomib resistant lines.   
A. 589 BzS, BzR, and I-BzR lines were cultured in the presence of indicated 
concentrations of Bz for 48 hours and percentage of live cells determined by CellTiter-
Glo® values normalized to untreated controls. Error bars represent three independent 
CellTiter-Glo® readings. B.  Fluorescence-activated cell sorting analysis of BzS (solid 
black line) and I-BzR (light grey histogram) stained with indicated antibodies.  C.  
Quantitative RT-PCR analysis of Cd93 and Cd69 relative mRNA expression in 589 BzS 
and I-BzR lines. Values were normalized to Gapd mRNA and error bars represent PCR 
triplicates.  Significance was determined using a one-tailed Student’s t-test (** p < 0.01; 
**** p < 0.0001).    
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Figure 3.  Bortezomib promotes loss of CD93 and CD69.   
A. Fluorescence-activated cell sorting analysis of live untreated BzS cells (solid black 
line), BzS cells treated with 64 nM Bz for 48 hours (dotted black line) and untreated BzR 
cells (dark grey histogram) stained with CD93 and CD69 antibodies.  Live cells were 
gated using forward and side scatter.  B. Quantitative RT-PCR analysis of Cd93 and 
Cd69 mRNA in 595 and 589 lines. Values were normalized to Gapd mRNA and error 
bars represent PCR triplicates.  Significance was determined using a one-tailed 
Student’s t-test (** p < 0.01; *** p < 0.001; **** p < 0.0001). 
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Figure 4.  LPS induces plasma cell differentiation in Bz-resistant cells.  
A.  Schematic of genes normally expressed highly at the plasma cell (PC) 
developmental stage shown relative to germinal center (GC) and 
plasmablast/intermediate plasma cell (iPC) stages.  B. Quantitative RT-PCR analysis of 
Irf4, Blimp1, and CHOP mRNA in 589 untreated cells and 72 hour LPS-treated cells. 
Values were normalized to Gapd mRNA, and error bars represent PCR triplicates.  C. 
Densitometry values representing the percentage of spliced/unspliced Xbp1 in 589 BzS, 
BzR and I-BzR cells untreated or treated with LPS for 72 hours. D.  ELISA of Ig kappa 
light chain secreted into the media following 72 hour LPS treatment, cells were ficolled 
and incubated for an additional 24 hours.  The error bars represent three independent 
ELISA readings, and values were normalized to total live cells determined by CellTiter-
Glo®. E.  Quantitative RT-PCR analysis of Cd69 and Cxcr4 mRNA in 589 untreated cells 
and 72 hour LPS-treated cells. Values were normalized to Gapd mRNA and error bars 
represent PCR triplicates.  Significance was determined using a one-tailed Student’s t-
test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).  F.  Fluorescence-activated 
cell sorting analysis of untreated BzS (solid black line), BzR (dark grey line), or I-BzR 
(light grey line) and LPS-treated (dotted lines) stained with CD69.    
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Figure 5.  LPS re-sensitizes Bz-resistant cells to bortezomib treatment. 
72 hour LPS-treated or untreated BzS and BzR lines were ficolled and re-plated in the 
presence or absence of 60 nM Bz for 48 hours.  The percentage of live cells determined 
by CellTiter-Glo® values normalized to untreated controls (i.e. In the absence of Bz, 
LPS-treated were normalized to non-LPS-treated cells, and following LPS treatment, Bz-
treated were normalized to non-Bz-treated cells) are shown.  Error bars represent three 
independent CellTiter-Glo® readings. 
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Supplemental Figure S1.   
Fluorescence-activated cell sorting analysis of 595 BzS (solid black line) and 589 BzS 
(dotted black line) cells compared to GC B cell, CH12 (dark grey histogram), and 
plasmacytoma, MPC11 (light grey histogram), reference cell lines stained with indicated 
antibodies.  
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Supplemental Figure S2.   
A. Fluorescence-activated cell sorting analysis of 589 BzS and BzR cells either 
unstained (top panel) or stained with isotype control antibodies (lower panels).  B.  Total 
live 589 BzS, BzR, and I-BzR cells were determined by trypan blue exclusion by three 
independent cell counts.  C.  Fluorescence-activated cell sorting analysis of 589 BzS 
cells in the presence or absence of 64 nM (high dose) Bz for 48 hours double stained 
with CD93 and CD69.  Live cells were gated based on FSC and SSC.  The gated 
populations are reflected in dot plots below.  D.  595 and 589 BzS and BzR lines were 
incubated in the presence or absence of 33 nM (low dose) Bz for 24 hours. The 
percentage of live cells determined by CellTiter-Glo® values were normalized to 
untreated controls. Error bars represent three independent CellTiter-Glo® readings. 
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Supplemental Figure S3.   
A.  Event-free (EFS) and B. overall survival (OS) analysis of high and low CXCR4 
expressing MM patient groups taken from the total therapy 3 (TT3) drug trial (390).  The 
p value represents significant difference by one-way ANOVA.  The number of cases 
analyzed is indicated.  
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Supplemental Figure S4.   
A.  End-point RT-PCR analysis of Xbp1 mRNA.  Xbp1s (spliced) is represented by a 26 
bp smaller spliced product compared to unspliced, Xbp1u.  B.  ELISA of intracellular Ig 
kappa light chain from lysates prepared following 72 hour LPS treatment. Cells were 
ficolled and incubated for an additional 24 hours. C. Array comparative genomic 
hybridization analysis highlighting the loss of light chain in the 589 BzR line. 
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Supplemental Figure S5.   
A.  Quantitative RT-PCR analysis of Cd93 mRNA in 589 untreated cells and 72 hour 
LPS-treated cells. Values were normalized to Gapd mRNA and error bars represent 
PCR triplicates.  Significance was determined using a one-tailed Student’s t-test (*** p < 
0.001).  B.  Fluorescence-activated cell sorting analysis of untreated BzS (top panel), 
BzR (middle panel) and I-BzR (bottom panel) and LPS-treated cells stained with CD93 
and CD38.   
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ABSTRACT 
  Activation induced cytidine deaminase (AID) is a DNA-mutating enzyme that can 
promote the deamination of cytosine bases within single-stranded DNA, a function that is 
necessary for successful class switch recombination and somatic hypermutation but has 
been linked with acquired drug resistance in B cell malignancy.  Burkitt lymphoma (BL), 
a type of non-Hodgkin lymphoma, shares many characteristics with germinal center B 
cells including the expression of AID.  Previous work suggests that inhibition of the 
proteasome prevents AID degradation within BL cells.  With the advent of proteasome 
inhibitors as a successful treatment for other B cell malignancies, the cellular 
consequences of AID stabilization by such compounds in BL may contribute to off-target 
mutations, potentially resulting in drug resistance.  Here, we utilize a well-described, 
human BL cell line to show that short-term stabilization of AID protein does occur 
following treatment with a clinically relevant proteasome inhibitor, bortezomib (Bz).  
However, we find less on-target AID activity and no off-target mutations at the Bz active 
site following long-term Bz treatment.  These results suggest that although AID is 
stabilized in the short-term by Bz, AID activity may be selected against by Bz and does 
not likely contribute to reduced Bz sensitivity in this case. 
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LETTER TO THE EDITOR 
  Burkitt lymphoma (BL) is a form of non-Hodgkin B cell lymphoma (NHL) that 
primarily affects children and is especially prevalent in endemic areas.  Sporadic BL, the 
primary form of BL found in North America, accounts for 30-40% of all childhood NHL 
cases in the United States (449).  A highly proliferative, clonal, B cell neoplasm, BL has 
characteristics of germinal center (GC) B cells including the expression of Bcl-6, CD10, 
IgM, and the DNA-mutating enzyme, activation induced cytidine deaminase (AID) (449).  
AID promotes mutagenesis by deamination of cytidine residues to uridines within single-
stranded regions of DNA. The resultant G:U mismatch can be processed via replication, 
base excision repair, or mismatch repair in an error-prone manner.  
  On-target AID-induced mutations within the immunoglobulin (Ig) locus are 
necessary for the generation of a highly diverse antibody repertoire.  AID induces a high 
rate of mutation both within the rearranged Ig variable region resulting in somatic 
hypermutation (SHM) and within switch regions enabling class switch recombination 
(CSR) (450).  While it is known that AID prefers WRC/GYW hot spot motifs (showing the 
top and bottom strands where W=A/T, R=A/G, Y=C/T), the complete AID targeting 
mechanism remains unclear.  Mistargeting of AID can promote mutations in off-target 
(non-Ig) genes such as proto-oncogenes and contribute to chromosomal translocations 
like those involving c-myc/IgH frequently associated with BL as well as other B cell 
malignancies (451, 452).  Due to the mutagenic activity of AID, its expression is normally 
restricted to GC B cells.  However, aberrant AID expression has been identified in 
malignant non-GC B cells and solid tumors (453).  Approximately 85% of NHLs are 
thought to be a result of AID-induced mutations (454), and recently, multiple lines of 
evidence have suggested that aberrant expression of AID in cancer may contribute to 
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drug resistance.  For example, in chronic myeloid leukemia, AID promotes imatinib 
mesylate/GLEEVEC® resistance through off-target mutagenesis within the BCR-ABL-1 
target gene (455) demonstrating the important role that AID mistargeting plays in 
promoting B cell tumorigenesis and the acquisition of drug resistance, further 
underscoring the importance of its strict regulation. 
The proteasome plays an essential role in regulating the nuclear abundance of 
AID by degrading excess AID protein (456, 457).  This is especially important given that 
the dose of AID has been correlated with its level of mutagenic activity, particularly its 
ability to transform lymphocytes (458).  Chemical inhibition of the 26S proteasome 
complex has been shown to stabilize AID protein (457).  However, because the 
proteasome is also necessary for the degradation of regulatory proteins required for 
cellular homeostasis, targeting this complex has become a viable chemotherapeutic 
approach for cancer treatment. The boronic acid dipeptide, bortezomib/VELCADE® (Bz), 
was the first clinically approved reversible, specific inhibitor of the  proteasome (459).  
Since its discovery, Bz has been primarily used in the treatment of multiple myeloma and 
relapsed mantle cell lymphoma but has also been tested for efficacy in other B cell 
malignancies including BL.   
While Bz promotes cell cycle arrest and apoptosis by preventing the proteasomal 
degradation of cellular proteins, the specific mode of action for Bz toxicity remains 
unclear (459). Furthermore, patients treated with Bz eventually relapse due to drug 
resistance (459). Thus, it is critical that the cellular consequences of Bz treatment be 
deciphered in order to understand its mode of action and to develop novel approaches to 
combat drug resistance. Mutations have been identified within the active site of the 
proteasomal subunit PSMB5, the target of Bz, in in vitro models of Bz resistance (202) 
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suggesting that this could be a molecular mechanism for acquired resistance.  The most 
common of these mutations, which result in substitutions of Ala49 and Ala50 within the 
PSMB5 protein occurs within AID hotspots (Supplemental Figure 1).  Therefore, we 
hypothesize that the stabilization of AID protein upon Bz treatment may promote off-
target mutations that contribute to acquired Bz resistance.  
  Here, we have utilized a previously published subclone of the AID-expressing, 
human BL cell line, Ramos 6 (Ramos), as a model system for this study (460).  This cell 
line contains a nonsense mutation within the variable region of the Ig heavy chain gene, 
and can be used to monitor AID on-target activity by reversion of the mutation detected 
by surface IgM expression. As predicted, Ramos cells were highly sensitive to Bz-
induced apoptosis in vitro (IC50=11 nM) (Supplemental Figure 2A). 
Because AID is degraded by the proteasome (456) we asked whether Bz 
treatment results in stabilization of AID protein.  Ramos cells were treated with the 
indicated concentrations of Bz for 24 hours, and only viable cells were gated and 
analyzed for intracellular AID protein by flow cytometry.  Bz treatment increased AID 
levels above the untreated control up to 2-fold in the 20 nM Bz treated samples (Figure 
1A).  Western blotting of the 0 and 10 nM treated cells, (Supplemental Figure 2A), also 
showed an approximate 2-fold increase in intracellular AID following Bz treatment 
(Figure 1B).  The 20 nM Bz treated sample was eliminated from the Western analysis 
due to large-scale cell death.  Cellular protein fractionation of the cytoplasmic and 
nuclear compartments showed that increased AID expression was present in both 
locations (data not shown).  Quantitative RT-PCR did not show increased AID transcript 
following Bz treatment (data not shown), indicating that short-term proteasome inhibition 
 163 
 
by Bz results in the stabilization of AID protein independent of transcriptional expression 
changes. 
To analyze whether chronic long-term Bz treatment influences AID activity, 
Ramos cells were pulsed with 15 nM Bz, allowed to grow for one week, and the cycle 
was repeated for a total of ten weeks. Subsequently, IgM reversion (surface IgM- to 
IgM+) was measured as a marker of AID on-target activity (460).  Because IgM- and IgM+ 
Ramos cells display similar Bz IC50 values (data not shown), differences in IgM reversion 
suggest alterations in AID activity.  As expected, untreated Ramos cells showed 
increased surface IgM expression as a result of AID-dependent reversion of the 
nonsense mutation within the variable region of the heavy chain gene.  Surprisingly, no 
reversion was observed in chronic Bz-treated (BzR) cells compared to untreated controls 
(Figure 1C) despite increases in AID levels during short-term Bz treatment (Figure 1B).  
Consistent with these results, when variable regions from the total cell pool were 
amplified, sequenced and scored for unique V region mutations (460), BzR cells had 
significantly fewer point mutations at the on-target IgM locus than their untreated Ramos 
counterparts (Figure 1D).  In addition, BzR cells had reduced sensitivity to Bz compared 
to untreated controls with a 2.3-fold increase in the IC50 (Table I, Supplemental Figure 
2B), yet displayed growth characteristics similar to the parental Ramos line 
(Supplemental Figure 2C).  In this model system, reduced sensitivity to Bz also 
conferred a general reduced sensitivity to other proteasome inhibitors 
(carfilzomib/KYPROLIS®, MLN2238, and epoxomicin; Table I), while maintaining 
sensitivity to other classes of chemotherapeutic agents (data not shown).  Array 
comparative genomic hybridization of these Bz-sensitive and BzR cells indicated the 
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presence of many copy number variations (data not shown), suggesting that genetic 
alterations had occurred or had been selected for as a result of Bz treatment.   
To determine whether stabilization of AID by long-term Bz selection results in 
increased mutation frequency of PSMB5, we sequenced this off-target gene that when 
mutated confers reduced sensitivity to Bz.  Despite the presence of AID hotspots, we 
identified no mutations within the off-target PSMB5 gene in BzR cells (data not shown) 
that could explain their reduced Bz sensitivity.  These data suggest that although there is 
ongoing genomic instability in chronically treated AID expressing Ramos BzR cells, AID 
stabilization by proteasome inhibition does not promote IgM or PSMB5 mutations.  
The data presented here show that proteasome inhibition of Ramos cells using 
Bz increases the abundance of intracellular AID.  This AID is expressed both in the 
cytoplasmic but most importantly in the nuclear compartment where AID-induced 
damage is known to occur (450).  However, this stabilization is likely short-term, as long-
term chronically Bz treated cells do not express higher baseline levels of AID protein 
(data not shown) and lack increased AID activity at the on-target IgM locus.  These 
results indicate that an interesting paradigm may be emerging where ongoing AID-
induced DNA damage may be selected against under the pressure of Bz treatment.  
Indeed, AID expression has been shown to render B cells sensitive to apoptosis [(461)], 
thus it is possible that the AID-high, mutated Ramos cells were selectively eliminated 
from our chronically treated Ramos pool. 
Bz is most commonly used to treat the B cell malignancy multiple myeloma (459), 
a plasma cell tumor of differentiated B cells that normally do not retain expression of 
AID, which is generally restricted to GC B cells (451). However, AID is a member of a 
larger superfamily of enzymes called cytidine deaminases which include the APOBEC 
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family of proteins.  Having similar function to AID, the expression of APOBECs has been 
identified in a variety of solid tumors (462).  Therefore, with current clinical trials aiming 
to utilize Bz for the treatment of a variety of tumors (459), determining what role, if any, 
APOBECs play in acquired Bz resistance may be an important future aim. 
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Table I. IC50 table comparing Bz-sensitive and -selected Ramos 6 cell lines. 
 
Drug Fold increase in IC50 
(Bz selected/sensitive) 
Bortezomib 2.3 
Carfilzomib 3.0 
MLN2238 2.0 
Epoxomicin 3.3 
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Figure 1. Bz treatment results in AID protein stabilization but lower mutation 
frequency over long-term selection.  A) Flow cytometry of intracellular AID protein 
following 24 hour Bz treatment with 0 (black line), 10 (dark gray line), or 20 (light gray 
line) nM Bz.  All samples were normalized to an isotype control (filled gray peak) and 
quantified using FlowJo software (shown to the right).  B) Western blotting of the 0 and 
10 nM treated whole-cell lysates for AID normalized to β-actin expression at each Bz 
concentration quantified using Image Lab software (shown below).  C) Surface IgM 
protein detected by flow cytometry on Ramos cells at weeks 0, 2, 10 and 17 over the 
course of weekly, 15 nM Bz treatments (total of ten weeks) compared to an untreated 
control.  D) AID mutation frequency (number of mutations per total number of bases 
sequenced) within the variable region of the heavy chain locus between Ramos and 
RamosBzR cell lines.  A total of 9522 bases were sequenced from untreated Ramos and 
9108 bases were sequenced from chronically treated RamosBzR cells.   Significance 
was determined using Pearson’s chi-squared test where a p-value<0.05 was considered 
significant. 
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Supplemental Figure S1.  Mutations identified in PSMB5 lie within predicted AID 
hotspots.  Mutations identified previously (202) within the PSMB5 gene target of Bz-
selected cells.  GCA and GCG code for Ala49 and Ala50, respectively, and are important 
for the chymotrypsin-like activity of PSMB5.  The single mutations G322A and C323T as 
well as the combination of both mutations (highlighted in gray) identified lie in AID 
hotspots (460) (underlined), and, therefore, could be the result of off-target AID activity. 
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Supplemental Figure S2.  Bz is cytotoxic to Ramos cells.  A) Annexin V/propidium 
iodide (PI) analysis of Ramos cells treated with the indicated doses (left) of Bz for 48 
hours.  Analyses of cell cycle percentages (left panels) and percentages of cells that are 
Annexin V+/PI+ (right panels) at each concentration were performed using FlowJo 
software.  B) Kill curve analysis of Ramos (filled circles) and RamosBzR (open circles) 
cell lines using the indicated doses of Bz over the course of 48 hours.  All experiments 
were performed in triplicate and are shown as relative to an untreated control using 
GraphPad Prism software.  C) PI analysis of Ramos and RamosBzR cells in the 
absence of Bz selection.  Analysis of cell cycle percentages was performed using 
FlowJo software.     
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Supplemental Methods and Methods 
 
Protein extractions 
 Cellular protein fractionation was performed as a protocol adapted from the 
CellLytic NuCLEAR Extraction protocol (Sigma).  Briefly, 5 x 106 cells were centrifuged 
at 450 x g for 5 minutes and washed twice with PBS.  The pellet was resuspended in five 
times volume of isotonic lysis buffer (10 mM Tris-HCl, pH 7.5, 2 mM MgCl2, 3 mM CaCl2, 
and 0.3 M sucrose).  The cells were lysed by the addition of 10% NP40 to 0.4%.  
Samples were centrifuged at 9000 x g for 30 seconds.  Supernatants (cytoplasmic 
contents) were stored at -80° C.  The remaining pellet was resuspended in nuclear 
extraction buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.6 M NaCl, 0.2 mM EDTA, 
25% (w/v) glycerol, 10 mM DTT) supplemented with protease inhibitors.  Samples were 
agitated on ice for 15 minutes and spun at 20,000 x g for 5 minutes at 4° C.  
Supernatants (nuclear contents) were stored at -80° C. 
Whole-cell lysates were prepared by incubating cells in buffer containing 300 mM 
NaCl, 20 mM HEPES, 1 mM MgCl2, 0.2% Nonidet P-40, 2.5 M glycerol, 1 mM DTT and 
complete protease inhibitor tablets.   
AID expression 
The following primers were used: AID, 5’-TCCTGCTCACTGGACTTCG-3’ (5’ 
primer), 5’-GCGTAGGAACAACAATTCCAC-3’ (3’ primer); Sybr green (Qiagen).  The 
primers included in the Universal Human GAPD Gene Assay (Roche) were used as the 
reference gene. Data were analyzed using LightCycler 480 software (Roche) and 
relative fold changes were calculated using the 2− ΔΔCt method with the GAPDH 
reference gene for normalization.  
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PCR Amplification, cloning and sequencing 
The V region from Ramos cells were amplified using Pfu Turbo Cx Hotstart 
polymerase from genomic DNA by using 30 cycles of 95C for 30 sec, 60C for 30 sec 
and 72 C for 1 min.  Primers for the V region were 5’-
TGTCTTCAGATCAGCAGCCTAAAG-3’ (5’ primer) and 5’-
CATTCTTACCTGAGGAGACGGTG-3’ (3’ primer).  PCR products were modified by A-
tailing using Taq polymerase and cloned using the pGEM-T vector system. Minipreps 
were prepared and sequenced using the following V region primer: 5’-
GCACAAGAACATGAAACACC-3’. 
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CHAPTER 7 
DISCUSSION AND FUTURE AIMS 
Cancer is a multi-faceted disease whose cure still remains elusive for the 
majority of cases.  Although cancer-related deaths have decreased significantly over the 
past decade (463), there is still much that we do not understand about cancer, 
particularly how to eliminate minimal residual disease (MRD) that in most cases 
contributes to relapse and death.  Of the cancer deaths that have been predicted for 
2013, over 5% will likely be derived from a B cell of origin, of which, one-third will be MM 
patients (463).  The elimination of MRD is particularly problematic in MM because these 
cells lack distinguishing and unique druggable targets compared to their normal PC 
counterparts (such as the Philadelphia chromosome in chronic myelogenous leukemia 
(464)).  Therefore, further characterization of sensitivity and resistance to 
chemotherapeutic agents in MM is desperately needed for better personalized medicine 
approaches like those that are currently being used in some solid tumor types (e.g. 
Oncotype DX) (465).  We believe that the culmination of these works specifically 
address this need and will contribute to the growing body of literature that will drive the 
utilization of new clinical approaches for the treatment of MM and other types of cancer. 
For the majority of these studies, we have utilized a well-described mouse model 
of plasma cell malignancy to create a pipeline for secondary drug discovery which we 
present in Chapters 2 and 3.  We have shown that we can isolate primary malignant 
mouse plasma cell lines in culture that can be further characterized and manipulated and 
injected back into syngeneic mice for in vivo validation of secondary therapies in the 
case of acquired Bz resistance.  Importantly, this in vivo validation can be performed in 
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the presence of an active immune system.  We currently have the only MM mouse 
model that harnesses this type of pipeline approach.    
However, no model system is without limitations.  For example, our mouse model 
likely only represents a subset of patients with aggressive disease and, therefore, does 
not allow us to study the entire genetic spectrum of MM patients.  In addition, a current 
class of drugs that are being used regularly in the treatment of MM patients, the IMiDs, 
cannot be used in mice which lack the proper hepatic enzymes for drug activation.  This 
further underscores the fact that homology is not 100% conserved between mice and 
humans meaning that we may identify genes that contribute to drug resistance in mice 
but not humans and perhaps some disease subsets but not others.  However, the use of 
primary patient samples is also not trivial.  Besides the rarity of MM patients, the process 
by which PCs are obtained from patients (e.g. bone marrow biopsy) involves a painful 
procedure that can produce sometimes only miniscule numbers of PCs.  Furthermore, 
some have theorized that small “pockets” of clonal MM cells may reside at multiple 
independent sites within the bone marrow compartment (54, 110).  Current reports 
regarding clonal evolution and the existence of potentially multiple MM clones within the 
same patient may further complicate the use of primary patient samples.  We believe 
that given the advantages and disadvantages of both systems that the use of the mouse 
model provides the strongest tool for secondary drug discovery but that these new drugs 
must be further validated using patient data. 
Within this mouse in vitro cell culture system, we use GEP to characterize how 
Bz-sensitive and -resistant cells respond differently to Bz treatment and use those data 
to predict secondary therapies that may be especially effective in combating refractory 
disease.  Using CMAP we identified three distinct patterns of prediction: 1) drugs with 
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consistent correlation to the Bz-induced signature, 2) drugs with consistent anti-
correlation to the Bz-induced signature, and 3) drugs with unique predictions in certain 
cell lines but not others to the unique Bz-induced signatures.  Those drugs with 
consistent correlation within this study provided a nice proof-of-principle for the 
mechanism of Bz action.  Indeed in Chapter 4, the investigation of the mode of action for 
the unknown compound VRC2 using correlating signatures from CMAP is proving 
particularly useful.  Because the anti-correlated signatures are less well-described in the 
literature, we chose to investigate the utility of these predictions further in Chapter 4.  
Interestingly, the overlap of Topo inhibitors predicted by the CMAP approach and a high-
throughput drug screening approach suggest that anti-correlated signatures might also 
have utility as secondary therapies in Bz-refractory MM.  However, these studies are 
ongoing and need to be further validated using human MM cell lines and patient 
samples. 
In Chapter 3, we show that perhaps those correlations with the most predictive 
power may be those with clear and conserved patterns of prediction in some but not all 
samples.  In this study we highlighted a unique HDAC inhibitor correlation as predictive 
of an advantageous response to these drugs as secondary therapies in some but not all 
Bz-refractory disease.  The optimization of this pipeline could have tremendous pre-
clinical impact.  However, one current limitation of this approach is a lack of MM 
specificity within the CMAP database.  Currently, this database is populated with 
transcriptional responses to many drugs using four, well-described solid tumor cell lines.  
MM, apart from not being a solid tumor, is a unique and complex disease that currently 
is not represented in CMAP.  We propose, as a future aim of these studies, to create a 
MM CMAP database to refine the predictive power of this approach using a combination 
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of clinical trial and HMCL data that is publicly available (Figure 1).  However, in this 
current climate of exponential genome technology advancement, the combination of 
these available data into a database may be increasingly difficult.  As array technology 
becomes an approach of the past making way for RNA-seq and exome sequencing, our 
best approach may be to focus on recreating some of these data using these newer 
approaches which will require both money and time.  However, we believe that these 
costs may provide a much larger benefit to the clinical community by providing a 
database that can continually be annotated with new patient data providing stronger 
predictive power. 
 We also identify that in the absence of drug treatment that Bz-sensitive and -
resistant cells have different homing properties in vivo in Chapter 3.  Where the Bz-
sensitive cells created the characteristic bone marrow “hot spots” by PET imaging, the 
Bz-resistant cells were more dispersed and infiltrated the extramedullary tissues.  This is 
particularly interesting given that extramedullary disease has been observed in Bz 
relapse in MM patients (187, 466).  When we queried our GEP for differences that might 
explain changes in cell homing, we identified that Cxcr4 expression was differentially 
expressed between Bz-sensitive and -resistant cells.  In Chapter 5, we show that based 
on CXCR4 expression alone we can predict significant differences in survival in MM 
patients on a Bz-only drug regimen.  Another cell type within MM cell patients that has 
shown decreased sensitivity to Bz and extramedullary homing properties is the 
clonotypic B cell-like population that some have proposed may serve as the MM CSC 
population.  These cells are thought to express cell markers that are representative of a 
more GC B-cell-like origin including decreased expression of CXCR4 which, when 
expressed, aids in migration to the bone marrow compartment (447).   
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 We show that decreased expression of CXCR4 is associated with both the loss 
of plasma cell maturation markers as well as an increase in TFs known to regulate the 
GC B-cell phenotype within our mouse model system.  However, whether the starting 
population is heterogeneous and these cells are simply selected for or whether Bz itself 
is inducing such changes remains unknown.  Perhaps in some cases, as is the case with 
the loss of CD93, both scenarios may contribute to the loss of this marker in Bz-resistant 
cells.  We show that CD93 status, in the mouse system, can be used to isolate primary 
Bz-refractory cells.  These innate resistant cells also show a loss of PC maturation 
markers and an increase in a GC B-cell-like immunophenotype, similar to acquired Bz-
resistant cells.  However, little work has been done comparing primary refractory disease 
(PRD) and refractory disease following drug treatment.  If in fact these cell types are 
similar, our characterization of refractory disease may further inform the treatment of 
drug naïve patients that may be identified in advance as having PRD guiding clinicians 
toward alternative therapies.  Regardless to whether PRD and refractory disease are 
similar or dissimilar, further characterization of these cells is needed to create diagnostic 
tests with the utility to distinguish both. 
 Additional studies have associated Bz resistance with changes in B-cell 
differentiation.  Interestingly, in models of MCL, a pre-GC disease, the Bz-resistant 
phenotype was associated with the upregulation of the plasmacytic differentiation 
markers IRF4, CD38 and CD138, but this was not accompanied by a corresponding 
increase in Ig secretion (354).  These data in combination with our own observations 
suggest that Bz-resistance may intersect at a GC-B cell-like stage of differentiation that 
can be reached by forward differentiation (in the case of MCL) or by reversion (in the 
case of MM).  This phenotype may be similar to the proposed CSC, although how similar 
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has yet to be defined.  However, if there is a Bz-resistant immunophenotype common to 
both MCL and MM, the further characterization of these cells may reveal unique 
druggable targets for the elimination of the CSC population and MRD. 
    Although Chapters 3 through 5 focused on the characterization of Bz-
resistance and -sensitivity with the goal of identifying secondary therapies, Chapter 6 
explores one potential mechanism by which Bz-resistance may be acquired in an 
additional type of B cell malignancy, BL.  In this particular cell type, malignant cells retain 
the expression of the DNA mutator, AID, normally responsible for SHM and CSR in the 
GC B cell of origin.  The expression of AID in BL has been associated with acquired 
Gleevec resistance due to off-target activity (455).  We find that AID protein is stabilized 
by Bz treatment, but that AID activity may in fact be downregulated in those cells that 
survive long-term drug selection.  In addition, even though AID hotspots were identified 
in the Bz active site, mutations at these sites did not contribute to reduced Bz sensitivity 
following long-term selection.  It is, therefore, unlikely that AID contributes to Bz-
resistance in NHLs where it is expressed.  However, there have been recent reports of 
aberrant expression of AID in MM (467).  The expression of AID in this case may be 
mediated by simulation from neighboring dendritic cells within the bone marrow niche.  
This increased expression of AID in MM cells has been shown to increase the amount of 
DSBs in both HMCLs and primary MM patient samples.  Furthermore, related DNA-
damaging enzymes, the APOBEC family, have been reported in many types of cancer 
and may contribute genomic instability that leads to drug resistance (468-470).  These 
reports suggest that a more comprehensive study of the expression of AID and 
APOBEC proteins with regard to their potential contributions to acquired drug resistance 
and disease progression in MM is warranted. 
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The next decade of research, which will likely merge genomics with novel drug 
modeling, will surely provide exponentially greater amounts of information that may be 
utilized for more personalized clinical approaches.  Already, researchers are collecting 
exome and copy number information in serial relapse samples from diagnosis to plasma 
cell leukemic stages in MM patients (356).  However, the number of these samples 
remains small likely due to a lack of bioinformatic support which will be required to 
process the terabytes of information that may be collected for each patient.  However, 
this is an obstacle that must be overcome given that the availability of genome 
sequencing to the general public is on the horizon and approaching quickly.  Indeed, 
new approaches have shown that copy number variation can now be imputed from 
exome sequencing data (471), and new technologies may also allow methylation 
patterns to be detected during real-time sequencing (472).  Implementation of these 
approaches may mean that RNA-seq experiments will provide exome sequencing, gene 
expression, copy number, and epigenetic information all in one run making each sample 
a gold mine of information.  By combining these patient data into publicly available 
databases together with clinical treatment information, we will be able to identify 
signatures related to drug sensitivity and resistance (Figure 1).  We might also glean 
information that helps us to better understand clonal evolution and how this might 
contribute to drug sensitivity in MM.  However, tremendous foresight and planning will be 
required to organize and collect such data.  Common platforms and techniques must be 
adopted.  Also, we must consider carefully which reference sequence we will use for 
analyzing these data.  For example, a comparison of each patient’s tumor sample to 
their germline sequence may eliminate genetic factors that contribute to primary 
refractory disease.  The potential of these combined approaches, although complex, will 
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provide a larger picture of the tumor genome that will inform the future treatment of MM 
patients, perhaps even providing, in some cases, a cure. 
The culmination of the studies presented in this thesis would not have been 
possible without a team approach.  Although I designed and organized these interactive 
projects, our in vivo mouse studies would not have been feasible without Dr. Siegfried 
Janz and our other colleagues at the University of Iowa, Carver College of Medicine.  
Similarly, the combined in silico and high-throughput drug screening approaches were 
made possible through collaborating laboratories within the University of Minnesota 
Computer Science and Engineering Department and at Penn State Hershey Medical 
Center.  In creating this MM working group, we have utilized multiple areas of expertise 
to contribute preclinical data toward individualized medicine approaches in MM. 
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Figure 1. Proposed pipeline approach for therapy prediction in MM patients.  A 
diagram depicting the potential application of the combined approaches used in this 
thesis for individualized medicine approaches for MM patients.  All patients will receive a 
bone marrow (BM) biopsy at diagnosis (or relapse) from which plasma cells (PCs) will be 
isolated and analyzed by in silico (MM CMAP = Myeloma-specific Connectivity Map 
database) and high-throughput drug screening methodologies for combined signatures 
and predictions of effective therapeutic options.  The serial collection of patient samples 
from diagnosis through each relapse will provide individualized therapeutic data for each 
patient while helping to populate the MM CMAP database creating greater predictive 
power with each enrolled patient. 
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